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1  Summary 
 
Tumour cells that exhibit aberrant outgrowth have evolved various ways to 
escape detection by the immune system. In addition to modifications in the 
surface  repertoire  of  its  individual  cells  to  avoid  immune  surveillance,  the 
tumour exhibits alterations in its microenvironment. These are among others 
altered oxygen levels in the tumour core or shedding of biochemical factors by 
tumour cells that in turn modify the functions of phagocytes such as Dendritic 
cells (DC). DC are professional antigen-presenting cells, which play mutiple 
roles in immunity, achieved by specialization into different functional subsets. 
Myeloid  DC  (mDC)  are  efficient  in  antigen  presentation,  thereby  activating 
immunity, whereas plasmacytoid DC (pDC) act as rheostats of the immune 
system.  PDC  activate  natural  killer  cells and  cause activation  of  bystander 
mDC,  but  also  interact  with  T  cells  to  induce  tolerance.  This  ambiguity 
positions pDC at the centre of inflammatory diseases such as cancer, arthritis 
and autoimmune diseases.  
 
Protocols to generate human mDC ex vivo made it possible to engineer these 
cells  to  suit  therapeutic  needs.  Unfortunately,  a  similar  easily  accessible 
system to generate human pDC was not available. A first goal of this study 
was therefore to develop a method to generate human pDC equivalents ex 
vivo  from  peripheral  blood  monocytes,  termed  mo-pDC  (monocyte-derived 
pDC), using Fms-related tyrosine kinase 3 ligand (Flt3-L). Mo-pDC showed a 
characteristic pDC surface protein marker profile, as well as a low capacity to 
induce  autologous  lymphocyte  proliferation  and  to  phagocytose  apoptotic 
debris  in  comparison  to  mDC. Furthermore,  mo-pDC  upregulated  the  pDC 
lineage-determining  transcription  factor  E2-2  during  differentiation  and 
expressed the E2-2 target gene BDCA2. Importantly, mo-pDC produced high 
levels of interferon-α  (IFN-α),  the  main  functional  parameter  of  pDC,  when 
pre-treated with tumour necrosis factor-α (TNF-α) and/or when differentiated 
additionally  with  vitamin  D3  or  all-trans  retinoic  acid.  When  differentiated 
under hypoxia, E2-2 and its target gene BDCA2 were downregulated in mo-
pDC.  Furthermore,  mo-pDC  differentiated  under  hypoxia  did  not  secrete  Summary      2 
IFN-α, but produced high levels of other inflammatory cytokines. Hence, mo-
pDC can be used to study differentiation and function of human pDC.  
 
Strikingly,  hypoxia  also  blocked  differentiation  of  mouse  pDC  from  bone 
marrow  precursors.  Hypoxia-inducible  factor  1  (HIF-1α)-dependent 
repression  of  E2-2  via  its  transcriptional  counterpart  ID2  seemed  to  be  a 
crucial  factor  in  disturbing  the  differentiation  of  precursors  into  pDC,  since 
pDC  differentiation  was  normal  when  culturing  HIF-1
fl/fl  LysM-Cre  bone 
marrow under hypoxia. In addition, the differentiation of mouse pDC under 
hypoxia  followed  a  similar  transcription  factor  regulation  pattern  compared 
with human mo-pDC.  
 
Hypoxia plays an important role in the pathogenesis of pulmonary disease, 
stroke, heart  disease  and  cancer.  In  cancer,  hypoxia  is  one  of  the tumour 
stress factors that topple anti-tumour immunity. Intrinsic immunosuppression 
is a major obstacle for successful therapy of tumours. Despite some progress, 
mechanisms  how  immunosuppression  is  induced  and  regulated  in  cancer 
patients  are  ill-defined.  Besides  hypoxia,  a  microenvironmental  component 
that might prevent anti-tumour immunity is the presence of dying tumour cells. 
Apoptosis of tumour cells is abundant in tumour under steady-state conditions 
and is largely increased following conventional cancer ablation methods such 
as chemo- or radiotherapy. Shedding of apoptotic debris and/or secretion of 
factors  to  the  tumour  bed  or draining lymph  nodes  might  have  a  profound 
impact  on  professional  phagocytes  such  as  dendritic  cells  (DC)  and  the 
subsequent  priming  of  lymphocyte  responses.  To  clarify  this,  we  exposed 
human  myeloid  DC  to  supernatants  of  living,  apoptotic  or  necrotic  human 
breast cancer cell supernatants, followed by their co-culture with autologous T 
cells.  Priming  with  apoptotic  debris  prevented  DC  from  establishing 
cytotoxicity towards living human tumour cells by inducing a regulatory T cell 
(Treg)  population,  defined  by  co-expression  of  CD39  and  CD69. 
Immunosuppression  via  Treg  was  transferable  to  viable tumour  cell-primed 
co-cultures and required the bioactive lipid sphingosine-1-phosphate (S1P), 
present in apoptotic cell supernatants and acting via S1P receptor 4 on DC to Summary      3 
induce  IL-27  secretion. We  propose  that  CD69-expression  on  CD39
+  Treg 
enables  them  to  interact  with  CD73-expressing  CD8
+  T  cells  to  generate 
adenosine,  which  acts  via  adenosine  receptor  A2a  on  cytotoxic  T  cells  to 
suppress their function. These findings might aid the understanding how dying 
tumour  cells limit  anti-tumour  immunity  and  might  provide  cues  to improve 
anti-tumour immunotherapy. In conclusion, the findings described here identify 
mechanisms  how  tumour  microenvironmental  factors  influence  human  DC 
subtype function. Understanding these mechanisms can give valuable hints 
for choosing functional immunotherapy targets or chemotherapy regimens for 
the treatment of cancer.  
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2  Zusammenfassung 
 
Um  aberrant  auswachsen  zu  können  müssen  Tumorzellen  in  vielfältiger 
Weise  evolutive  Prozesse  durchlaufen,  die  es  Ihnen  ermöglichen  der 
Erkennung durch das körpereigene Immunsystem zu entkommen. Zusätzlich 
zur  Modifikation  der  Oberflächensignatur  einzelner  Tumorzellen,  zur 
Vermeidung  einer  effizienten  Immun-Überwachung,  weisen  Tumore  eine 
Modifikation  ihrer  Mikroumgebung  auf.  Diese  Veränderungen  entstehen 
einerseits  passiv,  z.B.  durch  veränderte  Sauerstoffkonzentrationen 
überwiegend  im  Tumorkern,  aber  andererseits  auch  aktiv,  durch  die 
Freisetzung biochemischer Faktoren aus Tumorzellen. Diese Faktoren sind in 
der  Lage  die  Funktion  von  Tumor-assoziierten  Phagozyten,  wie  z.B. 
Dendritischen  Zellen  (DC)  zu  modifizieren.  Solcherart  durch  die 
Tumormikroumgebung polarisierte Immunzellen fördern das Tumorwachstum 
in vielfältiger Weise.  
 
Bei DC handelt es sich um professionelle Antigen-präsentierende Zellen, die 
ihre  vielfältigen  Rollen  im  Immunsystem  durch  Spezialisierung  in 
verschiedene  funktionale  Subtypen  sicherstellen.  Beispielsweise  sind 
myeloische DC (mDC) besonders effizient in Hinsicht auf die Präsentation von 
Antigenen, wohingegen plasmazytoide DC (pDC) eher regulatorisch auf das 
Immunsystem  einwirken.  Sie  sind  in  der  Lage  natürliche  Killerzellen  oder 
benachbarte  mDC  zu  aktivieren,  interagieren  aber  auch  mit  T  Zellen  um 
Immuntoleranz zu erzeugen. Diese doppelsinnige Funktionsweise positioniert 
pDC im Zentrum der Regulation inflammatorischer Erkrankungen zu denen 
u.a.  die  Karzinogenese,  aber  auch  Arthritis  und  Autoimmunerkrankungen 
gehören. 
 
Auch mDC spielen eine wichtige Rolle bei der Karzinogenese. Weiterhin wird 
Ihnen  ein  großes  Potential  zur  Initiation  einer  Anti-Tumor-Immunreaktion 
zugeschrieben.  Humane  mDC  können  ex  vivo  aus  Monozyten  hergestellt 
werden.  Folgerichtig  werden  aus  Monozyten  hergestellte,  funktionell 
maßgeschneiderte  humane  mDC  schon  heute  zur  Therapie  von  Tumoren Zusammenfassung      5 
klinisch erprobt. In Mausmodellen wird das Anti-Tumor-Potential von ex vivo 
generierten  mDC  durch  pDC  extrem  verstärkt.  Leider  war  es  bisher  nicht 
möglich  humane  pDC  in  ausreichender  Menge  für  therapeutische 
Applikationen, in Analogie zur Generierung von mDC, herzustellen.  
 
Aus  diesem  Grund  war  ein  erstes  Ziel  dieser  Arbeit  eine  Methode  zur 
Generierung  von  humanen  pDC,  oder  zumindest  Zellen  mit  äquivalenter 
Funktion, aus Vorläuferzellen zu entwickeln. In Analogie zur Herstellung von 
mDC  wurden  Monozyten  peripherem  Humanblut  als  Vorläuferzellen 
eingesetzt. Diese wurden mittels des Wachstumsfaktors Fms-related tyrosine 
kinase  3  ligand  (Flt3-L)  zu  pDC-Äquivalenten  differenziert,  welche  als 
monocyte-derived pDC (mo-pDC) bezeichnet wurden. In der Tat zeigten mo-
pDC  ein  für  humane  pDC  charakteristisches  Oberflächenmarkerprofil,  u.a. 
eine  hohe  Expression  des  Interleukin  3  (IL-3)  Rezeptors  CD123  und  des 
blood  dendritic  cell  antigen  4  (BDCA4).  Weiterhin  zeigten  mo-pDC  eine 
geringe Expression des kostimulatorischen Moleküls CD86 und des toll-like 
receptor  4  (TLR4)  welche  für  mDC  charakteristisch  sind.  Auch  funktional 
waren mo-pDC klar von mDC zu unterscheiden. Sie wiesen, im Vergleich zu 
mDC, eine geringe Kapazität zur Induktion der Proliferation autologer T Zellen 
auf. Auch die Phagozytose apoptotischer Zellen war in mo-pDC in Vergleich 
zu mDC verringert. Die Flt3-L-vermittelte Differenzierung von Monozyten zu 
pDC-Äquivalenten  war  auch  auf  der  Ebene  der  Expression 
populationsspezifischer Transkriptionsfaktoren ersichtlich. Mo-pDC erwarben 
im  Verlauf  ihrer  Differenzierung  aus  Monozyten  eine  kontinuierlich  erhöhte 
Expression des pDC-spezifischen Transkriptionfaktors E2-2 und exprimierten 
erhöhte Mengen des pDC-spezifischen Oberflächenmarkers BDCA2, welcher 
unter der transkriptionellen Kontrolle von E2-2 steht. Die wichtigste Funktion 
von pDC ist die Produktion großer Mengen von Interferon-α (IFN-α) in Antwort 
auf eine Virusinfektion oder Agonisten der Rezeptoren TLR7 und TLR9. Mo-
pDC  waren  ebenfalls in  der  Lage  große  Mengen  an  IFN-α  zu  sekretieren, 
allerdings nur nach vorheriger Aktivierung mit Tumornekrosefaktor-α (TNF-α) 
und/oder wenn zu ihrer Differenzierung neben Flt3-L auch Vitamin D3 oder 
all-trans-Retinolsäure  verwendet  wurde.  Nach der  erfolgreichen  Etablierung 
eines  Protokolls  zur  Generierung  von  funktionalen  pDC-Äquivalenten  aus Zusammenfassung      6 
humanen Monozyten war es das Ziel den Phänotyp dieser Zellen unter dem 
Einfluss  eines  Faktors  der  Tumormikroumgebung,  in  diesem  Fall  geringe 
Sauerkonzentrationen  (Hypoxie),  zu  untersuchen.  Die  Differenzierung  von 
Monozyten  mittels  Flt3-L  unter  Hypoxie  veränderte  die  Differenzierung  zu 
pDC in drastisch. Die Expression des spezifischen Transkriptionsfaktors E2-2 
war stark vermindert, wie auch die Expression von BDCA2, CD86 und des 
Haupthistokompatibilitätskomplexes I (MHCI). Mo-pDC welche unter Hypoxie 
generiert  wurden  waren  weiterhin  nicht  in  der  Lage IFN-α  zu  produzieren, 
sekretierten jedoch als Antwort auf eine Stimulation des TLR9 hohe Mengen 
anderer inflammatorischer Zytokine. Diese Daten zeigten zunächst, dass mo-
pDC  für  das  Studium  von  Differenzierung  und  Funktion  humaner  pDC 
eingesetzt  werden  können.  Weiterhin  lieferten  sie  Hinweise  auf  eine 
veränderte Differenzierung humaner pDC unter Hypoxie.  
 
In  einem  nächsten  Schritt  wurde  folglich  untersucht,  ob  Hypoxie  die 
Differenzierung von pDC auch aus deren physiologischen Vorläufern aus dem 
Knochenmark beeinflusst. Für diese Studien wurde ein gut etabliertes System 
unter  Verwendung  von  Knochenmarkszellen  der  Maus  eingesetzt.  Diese 
wurden mit Flt3-L unter Normoxie oder Hypoxie zu pDC differenziert. In der 
Tat  war  die  Differenzierung  von  Knochenmarkstammzellen  zu  pDC  unter 
Hypoxie  unterdrückt,  was  sich  auch  in  der  Expression  von  E2-2 
widerspiegelte. Hypoxie aktiviert u.a. spezifische Transkriptionsfaktoren, die 
sogenannten Hypoxie-induzierten Faktoren (HIF). HIF-1 kann die Expression 
des  funktionell  antagonistischen  Transkriptionsfaktors  zu  E2-2,  inhibitor  of 
DNA binding 2 (ID2), induzieren. Interessanterweise war die Expression von 
ID2  in  Knochenmarkskulturen  unter  Hypoxie  induziert.  Wurden  jedoch 
Knochenmarksstammzellen von HIF-1
fl/fl LysM-Cre Mäusen, bei denen die 
Expression  von  HIF-1  in  pDC-Vorläuferzellen  ausgeschaltet  ist,  mit  Flt3-L 
unter Hypoxie generiert, so war die Differenzierung zu pDC wiederhergestellt, 
die Expression von E2-2 normalisiert und die Induktion von ID2 unterdrückt. 
Zusammenfassend  kann  also  gesagt  werden,  dass  die  Hypoxie-induzierte 
Aktivierung  von  HIF-1  die  Differenzierung  von  pDC  unterdrückt, 
wahrscheinlich  in  Abhängigkeit  von  ID2,  was  die  Expression  des  pDC-Zusammenfassung      7 
spezifischen Transkriptionsfaktors E2-2 verhindert. Hypoxie ist ein wichtiger 
Faktor der Mikroumgebung vieler pathologischer Zustände/Erkrankungen wie 
z.B. Schlaganfall, Herzinfarkt und Krebs. In Tumoren ist Hypoxie einer der 
Tumor-induzierten Stressfaktoren, die die Anti-Tumor-Immunantwort negativ 
beeinflussen.  Da  pDC  eine  potente  Anti-Tumor-Immunantwort  bewirken 
können,  diese  jedoch  in  vivo  oft  unterbleibt,  könnte  der  hier  aufgezeigte 
Mechanismus für das Verständnis der Hypoxie-induzierten Immunsuppression 
hilfreich sein und zur Entwicklung neuer innovativer Immuntherapien gegen 
Tumore beitragen.  
 
Neben  Hypoxie  tragen  viele  andere  Faktoren  zur  Immunsuppression  in 
Tumoren  bei.  Diese  intrinsische  Immunsuppression  ist  eines  der  größten 
Hindernisse für die erfolgreiche Therapie von Tumoren, vor allem von soliden 
Tumoren. So wird z.B. der Erfolg einer Immuntherapie mit ex vivo-aktivierten 
DC  oder  T  Zellen  durch  immunsuppressive  Faktoren  der 
Tumormikroumgebung gemindert. Obwohl es in den letzten 10 Jahren einige 
Fortschritte gegeben hat, sind die Mechanismen wie die Immunsuppression in 
Krebspatienten  induziert  und  reguliert  wird  weiterhin  weitestgehend  unklar. 
Eine  Komponente  der  Mikroumgebung  in  Tumoren  ist  das  Vorhandensein 
sterbender  Tumorzellen.  Besonders  physiologischer  Zelltod,  Apoptose,  von 
Tumorzellen  findet,  im  Kontrast  zur  generellen  Sicht  von  Tumoren  als 
Apoptose-resistente Entitäten, im Überfluss statt. Die Präsenz von sterbenden 
Tumorzellen  kann  dann  durch  konventionelle  Tumortherapien  wie  Chemo- 
oder  Radiotherapie  noch  stark  erhöht  werden.  Apoptotische  körpereigene 
Zellen unterdrücken unter physiologischen Bedingungen das Immunsystem. 
Deshalb  könnte  das  Freisetzen  von  apoptotischem  Material  oder  die 
Sekretion von Faktoren aus sterbenden Tumorzellen in den Tumor selbst oder 
in  assoziierte  Lymphknoten  einen  starken  Einfluss  auf  die  Funktion  von 
professionellen  Phagozyten  wie  z.B.  DC  und  die  damit  verbundene 
Aktivierung von tumoriziden Lymphozyten haben.  
 
Zweites  Ziel  der  vorliegenden  Arbeit  war  es,  den  möglichen 
immunsuppressiven Einfluss von apoptotischen Tumorzellen auf die Funktion 
humaner mDC zu untersuchen. Humane, aus Monozyten hergestellte mDC Zusammenfassung      8 
wurden  zu  diesem  Zweck  mit  Überständen  lebender,  apoptotischer  oder 
nekrotischer humaner Brustkrebszellen inkubiert, welche sowohl Fragmente 
apoptotischer Zellen (AC) als auch von AC freigesetzte Mediatoren enthalten. 
Solcherart  aktivierte  mDC  wurden  im  Anschluß  mit  autologen  T  Zellen  ko-
kultiviert.  Danach  wurde  das  Potential  der  ko-kultivierten  T  Zellen  zum 
Abtöten  lebender  Tumorzellen  analysiert.  Interessanterweise  stattete  die 
Aktivierung  mit  Überständen  lebender  Tumorzellen  humane  mDC  mit  der 
Fähigkeit aus tumorizide T Zellen zu induzieren, wohingegen die Aktivierung 
mit  Überständen  apoptotischer  Tumorzellen  diese  Fähigkeit  stark 
unterdrückte.  Ko-Kultur  von  AC-aktivierten  mDC  mit  autologen  T  Zellen 
resultierte  in der  Ausbildung  einer  Population  von  regulatorischen  T  Zellen 
(Treg), die durch die gleichzeitige Expression der Oberflächenmoleküle CD39 
und  CD69  charakterisiert  war.  Diese  Treg  Zellen  waren  kritisch  für  die 
Unterdrückung der Aktivierung von zytotoxischen T Zellen. Dies wurde durch 
Depletions- und Transferexperimente belegt. Depletion der CD39- und CD69-
exprimierenden Treg Zellen aus AC-aktivierten Ko-Kulturen resultierte in der 
Aktivierung von T Zellen, welche effizient lebende Tumorzellen lysierten, und 
Zugabe  der  Treg  Zellen  zu  Ko-Kulturen  von  mit  lebenden  Tumorzellen 
aktivierten mDC und autologen T Zellen unterdrückte die sonst ausgeprägte 
Generierung zytotoxischer T Zellen.  
 
Die  Ausprägung  der  CD39-und  CD69-exprimierenden  Treg  Zell-Population 
war  abhängig  von  der  Freisetzung  des  bioaktiven  Lipids  Sphingosin-1-
Phosphat  (S1P),  welches  den  S1P-Rezeptor  4  auf  mDC  aktivierte.  Nach 
S1PR4 Aktivierung setzten mDC das immunregulatorische Zytokin IL-27 frei. 
Neutralisierung von IL-27 in AC-aktivierten Ko-Kulturen von mDC und T Zellen 
blockierte die Generierung von CD39- und CD69-exprimierenden Treg Zellen 
und  resultierte  deshalb  in  der  Aktivierung  zytotoxischer  T  Zellen.  In  einem 
nächsten Schritt wurde der Mechanismus der Treg Zell-induzierten Hemmung 
zytotoxischer  T  Zellen  untersucht.  Die  Bildung  von  Adenosin  in  den  Ko-
Kulturen  und  die  Aktivierung  des  Adenosin-Rezeptors  A2a,  potentiell  auf 
zytotoxischen T Zellen, waren hierfür vonnöten. Erste Experimente lieferten 
Hinweise auf eine direkte Interaktion von CD69- und CD39-exprimierenden 
Treg Zellen mit CD73-exprimierenden zytotoxischen T Zellen. Da CD39 und Zusammenfassung      9 
CD73  für  die  Bildung  von  Adenosin  aus  ATP  benötigt  werden,  könnte  die 
Interaktion  von  Treg  Zellen  und  zytotoxischen  T  Zellen  diese  erst 
ermöglichen,  was  in  der  Folge  in  der  Hemmung  zytotoxischer  T  Zellen 
resultiert. Diese Beobachtungen können dem Verständnis von Mechanismen 
der Immunsuppression dienlich sein und könnten Hinweise zur Unterstützung 
einer effektiven Tumor-Immuntherapie liefern.  
 
Zusammenfassend zeigen die hier präsentierten Ergebnisse wie Faktoren der 
Tumormikroumgebung die Funktion von humanen DC Subtypen beeinflussen 
können. Ein Verständnis der zugrundeliegenden Mechanismen kann wertvolle 
Informationen für die Wahl effektiver Immuntherapien oder Chemotherapien 
liefern und so die Therapie humaner Tumore unterstützen. 
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3  Introduction 
3.1  The inflammatory tumor microenvironment 
 
A growing tumour is constantly challenged by the immune system. Tumour 
cells exhibit certain unique alterations in surface antigens, metabolic output 
and release of peptide or lipid factors. Such factors released by tumour cells 
are shed into the tumour microenvironment or dumped into the draining lymph 
nodes. Ideally, these biochemical messages are used by immune cells to start 
and synchronise a tumour elimination network that include antigen-presenting 
and effector cells.  
 
 
 
 
Figure 1: Tumour microenviromental stress factors. A growing tumour exhibits stress factors 
such as: left an area with oxygen content as low as 1 mmHg at its core. Hypoxic tumour cells 
thus formed secrete various chemokines and cytokines that influence immunity; right Dying 
tumour cells are generated due to the tumour growth process or due to cancer-eradication 
treatments such as chemo- or radiotherapy. These tumour cells may undergo necrotic or 
apoptotic cell death thereby releasing respective immunomodulatory factors into the tumour 
microenvironment and the circulation. 
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However,  in  order  to  avoid  their  eradication,  tumour  cells  have  evolved 
strategies, which are largely dictated by their microenvironmental status. In 
this regard, stress factors that are most abundant in the tumour bed are the 
presence of 1) hypoxia and 2) dying tumour cells. Under these specialized 
conditions, the tumour sheds many factors that recruit immune cells from the 
bone marrow or from the circulation (Figure 1).  
 
A growing tumour may secrete soluble interleukins, cytokines and chemokines 
(Figure 2). Factors such as monocyte chemotactic protein-1 (MCP-1), colony 
stimulating factor-1 (CSF-1), vascular endothelial growth factor-A (VEGF-A), 
TNFα,  and  stromal  cell  derived  factor-1  alpha  (SDF-1α)  are  secreted  by 
hypoxic tumour cells to attract myeloid cells in general. Specifically, regulated 
upon activation, normal T-cell expressed and secreted (RANTES) and MCP-1 
attract  macrophages,  β-defensin  attracts  mDC,  IL-8  attracts  mainly 
monocytes, chemokine (C-X-C motif) ligand 5 (CXCL5) recruits granulocytes 
[1] and CXCL12 attracts pDC [2]. Lymphocytes (NK cells, T cells, B cells) are 
also recruited by the tumour. For instance, tumour-secreted ligands binding to 
C-C chemokine receptor type 5 (CCR5) (chemoattractants MCP-2, MIP-1α/ß, 
RANTES) or CXCR3 (chemoattractants CCL9/10) on T cells recruits them to 
the tumour microenvironment [3]. In addition, a tumour under hypoxic stress 
releases VEGF, which promotes neo-angiogenesis during which, recruitment 
and  proliferation  of  endothelial  cells  secures  blood  supply  to  the  growing 
tumour.  
 
Of all the immune cells that infiltrate tumour tissues or lymph nodes of tumour-
bearing  animals/patients,  antigen  presenting  cells  (APC)  such  as  DC  are 
crucial in modulating immunity. DC are phagocytes that fullfil various tasks in 
immunity. They shape the tumour immunity towards anti-tumour inflammation 
or  tolerance,  depending  on  the  microenvironmental  factors  that  they  are 
exposed to.  
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Figure 2: Immune cells infiltrating the tumour microenvironment. From top left: Tumour shed 
cytokines  and  chemokines  which  attract  various  immune  cell  populations  from  the  bone 
marrow or bloodstream. These immune cells include lymphocytes such as NK, T and B cells 
and myeloid cells such as granulocytes, monocytes, macrophages or mDC. In addition, pDC 
and  fibroblasts  are  also  recruited  to  the  tumour  bed.  The  tumour  needs  to  develop 
vasculature  to  support  the  newly  proliferating  tissue.  For  this  purpose,  the  tumour  sheds 
factors that attract endothelial cells.  
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3.2  Dendritic cells 
 
The  interaction  pattern  of  living  organisms  amongst  each  other  extends 
beyond a predator-prey relationship to include an internal ‘sensing-reacting’ 
relationship. This interaction is brought about by a highly evolved network of 
immune  cells.  Higher  organisms  are  constantly  confronted  with  externally-
derived antigens that can be microbial or viral, or self-antigens that are e.g. 
tumoural in nature. For eradication of the invaders, the cells of the immune 
system  have  evolved  a  repertoire of  receptors  to  ‘sense’  the  antigens  and 
engulf  them  through  sophisticated  antigen  uptake  machinery.  Afterwhich, 
these cells aptly termed APC, train the effector immune cells to ‘react’ and 
mount  an  immune  response  against  the  antigen-bearing  invaders.  This 
ultimately  leads  to  the  eradication  of  the  latter.  Antigen  sensing  and 
presentation are the two key functions of these specialized cells that include 
macrophages and DC. DC are the professional APC of the immune system 
that link the innate and adaptive immunity. DC display a wide array of antigen-
capturing molecules on their surface and in intracellular compartments. For 
instance,  molecules  such  as  TLR4  on  the surface  of  DC  serve  to  capture 
microbial antigens such as lipopolysaccharide (LPS) or intracellular molecules 
like  TLR7/9  recognize  CpG  sequences  in  bacterial  genomes  or  viral 
DNA/RNA. In addition to capturing antigens and presenting them to effector T 
cells of the adaptive immunity, DC are also important for B cell activation, 
proliferation and antibody production [4]. 
 
3.3  DC subtypes and their role in immunity 
 
DC are highly plastic cells that appear in the ‘twilight zone’ of the immune 
system,  under  more  than  one  classification  of  immunity.  1)  DC  bridge  the 
interface between peripheral tissues and lymphoid tissues, 2) depending on 
the  environment  that  foster  them,  they  can  be  immunostimulatory  or 
tolerogenic  in  nature.  DC  exert  multiple  roles  in  immunity  (Figure  3)  that 
include  activation  of  innate  immune  cells,  antigen-presentation  to  T  cells, 
mounting immunological tolerance and anti-viral responses.  Introduction      14 
The  varied  functions  performed  by  DC  are  possible  due  to  the  division  of 
labour between cellular DC subsets which are specialized to perform distinct 
functions. Myeloid DC (mDC) are key players in immunity against bacteria or 
tumours.  They  produce  pro-inflammatory  cytokines  and  perform  antigen 
presentation [5]. In contrast, plasmacytoid DC (pDC) are the producers of type 
I interferons (IFN-α/β) in response to viral infection. On the one hand, pDC 
maintain the immune system by activation of NK cells, influencing the primary 
antibody response [6] and by causing bystander mDC activation [7]. On the 
other hand, pDC are less efficient in priming antigen specific T cells compared 
to mDC [8] and favour the generation of regulatory T cells (Tregs) [9].  
 
 
 
 
 
Figure 3: DC play multiple roles in immunity. These functions are shared between the DC 
subsets. Myeloid DC (yellow) have important functions (depicted as yellow-lined boxes) in 
cellular immunity, humoral immunity, allergy, tissue repair and tolerance. Plasmacytoid DC 
(red) play a role (depicted as red-lined boxes) principally in anti-viral defence but also aid in 
innate immune cell activation as well as humoral cell and effector T cell expansion. 
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3.4  Role of mDC in effector immunity 
 
mDC play a plethora of roles in immunity that makes them the professional 
antigen-presenting cells that ideally participate in anti-tumour immunity. Most 
importantly, they are committed to all facets of effector immunity including T 
cell and B cell function (Figure 4).  
 
 
 
 
 
Figure 4: Role of mDC in effector Th immunity: The function of mDC in effector Th immunity 
can be outlined as follows. Clockwise from top: A) mDC particpate in T cell immunity as 
follows: by means of MHC class II molecule interactions with T cells and CD80 molecules 
activated Th1 cells to produce IFN-γ. The IL-12/IL-18 produced by the mDC aids in activating 
the Th1 cells; B) mDC activate TH17 cells by means of Ox40L-Ox40 interactions and by 
means of IL-1/6/23 production. Th17 cells thus activated participate in tissue repair, pathogen 
defence  and  inflammation;  C)  mDC  encourage  differentiation  of  antigen-specific  Treg;  D) 
mDC  produced  IL-33  helps  in  differentiation  of  IL-4  producing  Th2  cells.  These  T  cells 
participate in mounting allergic reponses; E) In addition to the role in T cell immunity, mDC 
also participates in humoral or B-cell immunity. mDC in co-operation with IFN-γ producing 
Th1 cells, induce antibody-production in B cells. 
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3.4.1  mDC in tumour tolerance induction 
 
According to the theory of immunosurveillance, new cancer cells arise and 
these  ‘altered’  cells  are  destroyed  by  the  immune  system,  preventing  the 
tumour outgrowth. To escape its elimination, a growing tumour activates the 
immune system in ways to ensure its own survival and further on, encourage 
its invasion to other areas of the body. Polarization to a tumour-supportive 
state can be principally observed for every immune cell population, including 
APC  of  the  innate immune  system  such  as  macrophages [39]  or  DC [40]. 
These  phagocytes  program  the  cells  of  the  adaptive  immunity  [41]  to 
selectively induce immunosuppression and thereby dampen the inflammatory 
anti-tumour attack. This principle is exemplified for Treg cells in this study. 
 
3.4.2  mDC and T cell interaction 
 
DC undergo maturation, in order to be functionally active. Such mature DC 
present antigen to effector cells and produce cytokines to activate immune 
cells such as NK cells. Initially DC exist in an immature state in peripheral 
tissues. These immature DC have a capacity to phagocytose bacteria, viruses 
or tumour antigens or exosomes through pattern recognition receptors present 
on their surface. Once having phagocytosed, the DC undergo maturation. The 
maturation process is linked to changes in costimulatory molecules, cytokine 
production, changes in cytoskeleton, shutting down of the cell cycle and up-
regulation of chemokine molecules [42]. During maturation, the changes in the 
cytoskeleton and chemokine receptor profiles induce DC to migrate to lymph 
node where they present antigens to T cells.  
 
T cells are thymus-derived white blood cells that play a major role in effector 
immunity. They exhibit a specialized receptor called the T cell receptor (TCR) 
that allows them to communicate with phagocytes. Through the TCR, T cells 
establish contact with the major histocompatibility complex (MHC) molecules 
on DC. Antigens bound to MHC molecules are then recognized by T cells. 
Based on their functions T cells can be divided into several subtypes. The Introduction      17 
helper T cells (Th) and cytotoxic T cells (Tc) recognize antigens presented by 
the DC through MHC II [43] or MHC I molecules [44] respectively. Th cells can 
be subdivided into Th1, Th2, Th17 and Treg depending on their functional 
profile  [45].  They  are  also  called  CD4
+  T  cells  since  they  express  CD4 
molecule on their surface, which is needed as a co-receptor in the TCR-MHC 
II complex. Th cells can produce cytokines that modulate the immune milieu 
but cannot kill pathogen-infected cells or aberrantly growing cancer cells. Th1 
cells produce cytokines such as IFN-γ that facilitates cellular immunity [46] by 
activating other immune cells such as NK cells, cytotoxic CD8
+ T-cells and 
macrophages.  IFN-γ  promotes  antigen  presentation  in  macrophages  and 
increases expression of MHC molecules, leukocyte migration and expression 
of  intrinsic  anti-viral  defense  factors.  Th2  cells  participate  in  allergy  and 
antibody  production.  Th2  cells  produce  IL-4  which  activates  B-cell  class 
switching  to  IgE  and  induce  their  auto-proliferation.  IFN-γ  and  IL-4  are 
cytokines that participate in T cell immunity by tilting the Th1/Th2 balance [47, 
48]. Besides promoting Th1 immunity as described above, IFN-γ suppresses 
Th2  differentiation  which  would  cause  a humoral  (antibody)  response.  IL-4 
contributes  to  anti-inflammatory  response  by  decreasing  the  production  of 
macrophage and dendritic cell-derived IL-12. Th17 cells are another subtype 
of Th cells that mainly produce IL-17 and contribute to chronic inflammation 
and tissue repair. They cause autoimmune responses and in addition, Th17 
cells produce IL-22 which is important for defence against pathogens such as 
Candida [49]. Regulatory T cells (Treg) are another subtype of Th cells that 
are  central  mediators  of  immune  tolerance.  Treg  produce  TGF-ß  or  IL-10 
which keep hyperinflammation in check [50]. Tc or cytotoxic T cells have the 
capacity  to  kill  pathogen  or  viral  infested  cells  and  cancer  cells.  They  are 
called CD8
+ T cells since they express CD8 molecule on their surface, which 
is  a  co-receptor  in  the  TCR-MHC  I  complex.  Tc  cells  produce  various 
molecules  such  as  granzyme  or  perforin  which  cause  lysis  of  pathogen-
infected or tumour cells [51]. 
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3.4.3  DC-Treg interaction in tumour-bearers 
 
DC dampen anti-tumour immunity among other mechanisms, by generating 
tumour-specific Treg cells. The Treg cells have been demonstrated to be a 
major obstacle for anti-tumour immunity [52] due to their role in suppressing 
anti-tumour immunity. Treg can be primed and activated predominantly in the 
tumour-adjacent  draining  lymph  nodes  (TDLN),  by  factors  shed  from  the 
tumour  [53]  or  within  the  tumour  bed  itself  [54].  Evidently  Treg  are  often 
detected in the sentinel/regional lymph nodes (LNs) of tumour-bearing hosts 
that exhibit poor clinical prognosis [55]. Once primed in the TDLN, Treg travel 
to the tumour site, where they prevent effector T cells from eradicating the 
tumour and furthermore stimulate metastasis of tumour cells [56]. The aim of 
adoptive  cellular  immunotherapy  against  tumours  is  to  generate  tumour-
directed cytotoxic T cells. However, the TDLN-derived suppressive Treg can 
potentially curb the benefit of an adoptive immunotherapy by suppressing the 
function  of  transferred  or  endogenous  cytotoxic  T  cells.  In  addition, 
conventional cytotoxic therapy would need an active immune system to keep 
the residual tumour masses in check, which might be prevented by Treg [57]. 
Hence,  the  mechanisms  of  Treg  generation  within  the  TDLN  have  to  be 
defined in order to design effective therapeutic strategies.  
 
3.4.4  Different states of immunosuppressive DC in tumour-bearing animals 
 
Generation/priming  of  tumour-specfic  Treg,  requires  antigen  uptake  and 
presentation by professional APC, i.e, DC. To exhibit their regulatory function, 
DC probably undergo tumour-dependent phenotypical alterations that enables 
them to foster immune escape [40, 58]. Initially, DC were thought to promote 
T cell tolerance due to being trapped in an immature state in tumour-bearing 
animals.  However,  it  emerges  that  depending  on  the  tumour 
microenvironment  they  are exposed  to,  DC may  exist in  different  states  of 
maturation, activation, i.e immunostimulatory capacity [59, 60]. Thus, even DC 
within the tumour  might be capable of presenting tumour-derived antigens. 
Tumour-derived antigens are acquired by DC directly at the tumour site [61], Introduction      19 
from  metastasing  tumour  cells  [60],  or  through  tumour-released 
exosomes/microvesicles [62, 63], which are primarily drained to the TDLN.  
 
3.4.5  Uptake of dying tumour cell-derived factors by DC  
 
In addition to antigens, DC receive other tumour-derived signals that shape 
their phenotype and the subsequent profiling of T cells. A prominent source of 
such signals are dying tumour or stromal cells that are continuously produced 
during tumour growth [64] or by conventional cancer-ablation methods such 
as chemotherapy or radiotherapy. With regard to the immunological outcome, 
the two extremes are: 1) effective antigen cross-presentation and induction of 
an  inflammatory  response  elicited  by  DC  that  eventually  prepares  immune 
effectors to eradicate malfunctioning cells or 2) tolerance to dampen an over-
activated immune reaction [65, 66]. The decision towards inflammation versus 
tolerance depends on the surface protein/lipid signatures as well as immune-
modulating factors released by dying cells, which are primarily determined by 
the mode of cell death [67].  
 
3.4.6  Types of cell death  
 
There  are  two  broad  classifications  of  how  cells  may  undergo  death.  This 
includes:  1)  necrosis,  which  occurs  when  a  cell  is  exposed  to  extreme 
physiological conditions such as hypoxia/anoxia or hypothermia that leads to 
rupture of the plasma membrane and release of contents that elicit an immune 
response; or 2) apoptosis, which occurs under normal physiological conditions 
ensuring cell turnover and tissue homeostasis (Figure 5). Introduction      20 
 
 
 
 
Figure 5: Modes of cell death and the factors released: Cell death can occur in two modes. 1) 
On left: Necrosis refers to cell death following the introduction of an intense physiological 
stressor such as hypoxia or hypothermia. Following this the cells undergo necrotic cell death. 
The characteristic feature of necrotic cell death includes swelling of cells, rupture of plasma 
membrane, rupture of internal organelles and the release of the cellular contents. Factors 
released during necrotic cell death may include molecules classified as danger-associated 
molecular patterns (DAMP) among them heat shock proteins (HSP) or high-mobility group 
protein B1 (HMGB) or large amounts of ATP. On the other hand cells might also undergo 
‘physiological’  apoptotic  cell  death  as  a  part  of  maintaining  cell  turnover  and  tissue 
homeostasis. 2) On right: In this case cells do not swell, but rather shrink. Further the cell 
blebs, forming apoptotic bodies. The cell undergoes changes in the genetic material such as 
chromatin condensation, DNA degradation and nuclear fragmentation through activation of 
specific proteases. This further results in release of lipids such as lysophosphatidylcholine 
(LPC)  or  sphingosine-1-phosphate  (S1P),  anti-inflammatory  proteins  such  as  transforming 
growth factor (TGF)-β as well as nucleotides such as UTP/ATP. 
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3.4.7  Cell death-induced immune responses 
 
Necrosis  induces  shedding  of  danger-associated  molecular  patterns 
(DAMPs),  which  activate  corresponding  TLRs  on  DC.  For  example  high-
mobility group box 1 (HMGB1) is recognized by TLR2, TLR4 or the receptor 
for advanced glycation end products (RAGE) on the surface of APC [68]. In 
contrast,  heat  shock  proteins  (HSP)  are  taken  up  through  scavenger 
receptors. For apoptosis, the immunological outcome is ambiguous, because 
of  the  varying  nature  of  the  apoptotic  cell  surface  proteome.  These  may 
include  ligand-receptor  interactions  such  as  phosphatidylserine  (PtdSer)-
MER/BAI1/ T-cell immunoglobulin- and mucin-domain-containing molecule-4 
(TIM-4), intercellular adhesion molecule-3 (ICAM-3)-CD14 or milk fat globule-
EGF  factor  8  (MFG-E8)-lipid  rafts  between  apoptotic  cells  and  phagocytes 
respectively.  In  addition,  apoptotic  cells  shed  lipids,  nucleotides  and  other 
immunomodulating factors that interact with the DC by means of appropriate 
receptors  [69].  Apoptosis  can  be  immunogenic  as  demonstrated  by  an 
increase in antigen-cross-presentation and the induction of cytotoxic T cells 
upon priming with AC in vivo [70]. On the other hand, triggering of multiple 
immunosuppressive  pathways  upon  priming  with  AC  has  been  recognized 
[71].  In  case  of  cancer-ablation  treatments  such  as  chemotherapy,  the 
decision towards generating an anti-tumour response or tolerance might be 
determined by the drug being used, as recent evidence suggests that certain 
chemotherapeutic drugs such as oxaliplatin trigger immunogenic cancer cell 
death  [72].  However,  cross-presentation  of  AC-derived  antigens  after 
chemotherapy does not necessarily culminate in anti-tumour immunity [73]. 
Interestingly,  forced  expression  of  (heat  shock  proteins)  HSP,  which  are 
usually present on necrotic cells, can render AC immunogenic [74].            
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Figure 6: Exposure of phagocytes to NC or AC-derived signals. Left: The signals released 
from necrotic cells (NC) are usually factors such as HSP, HMGB1 or DAMP those are sensed 
by DC. Right: Apoptotic cells expose ligands such as PtdSer, ICAM-3, MFG-E8, between 
which interact with receptors TIM-4, CD14 or rafts on the surface phagocytes. In addition 
apoptotic cells may shed soluble factors such as lipids LPC or S1P that are taken up by the 
phagocytes. 
 
Studies have focused on immunogenicity of surface alterations on dying cells. 
However,  the  signalling  molecules  secreted  from  dying  cells  that  drain  the 
adjacent lymph nodes together with tumour antigens may also be important 
for  inducing  tolerance  and  possibly  favour  relapse  [53].  AC  secrete 
immunomodulators  in  a  regulated  manner,  among  them  lipids  such  as 
lysophosphatidylcholine  (LPC)  or  sphingosine-1-phosphate  (S1P),  anti-
inflammatory proteins such as transforming growth factor (TGF)-β as well as 
nucleotides, which have the capacity to modify DC-dependent immunity [67] 
(Figure 6). 
 
3.5  pDC roles in immunotherapy 
 
Myeloid DC have been widely used in immunotherapy against cancer at least 
in model systems [10]. Furthermore, the use of the viral mimetic CpG that 
activates pDC or using pDC themselves along with mDC in cancer therapy 
resulted in favourable outcomes [11, 12]. In addition, IFN-α production by pDC 
was required to cause tumour rejection by the immune system [13]. On the 
other  hand,  pDC  might  also have  a  tumour-inducing  capacity,  which  could Introduction      23 
offset promising therapeutic implications [14]. On the contrary, the ‘tolerance-
inducing’ properties of pDC (Figure 7) were harnessed for therapy in diseases 
such as allograft rejection [15] or rheumatoid arthritis [16].  
 
 
 
Figure 7: pDC roles in immunity: The functions of pDC in modulating immunity can be viewed 
in detail as follows: (clockwise from left) A) pDC are the vital immune cells in the body that are 
involved  in  anti-viral  defence.  Upon  virus  instigated  TLR-9  activation,  pDC  drive  IFN-α-
dependent  inflammation.  pDC  are  the  principal  producers  of  IFN-α  and  together  with 
production of IL-12 they activate Th1 immunity; B) pDC produce TGF-β or retinoic acid which 
help  in  differentiation  of  FoxP3-expressing  regulatory-T  cells  (Treg).  These  Treg  in  turn 
produce immunosuppressive IL-10 thereby encouraging tolerance; C) The IFN-α produced by 
pDC can activate CD8
+ T cells and likewise Th1 cells to produce IFN-γ. Thus pDC play a vital 
role  in  expanding  and/or,  activating  T  cells;  D)  In  addition  pDC-produced  IFN-α  helps  in 
differentiation of antibody-secreting plasma cells from precursor plasmablasts; E) finally pDC 
are crucial for innate immune cell activation. pDC encourage IL-12 production by mDC and 
enhance the cytotoxic function of NK cells. 
 
 
The  importance  of  pDC in  research  and  therapy  necessitates  a  system  to 
generate  pDC  equivalents  from  easily  available  sources  in  humans.  In Introduction      24 
addition,  these  cells  are  rare  in  human  blood  forming  up  to  0.32%  of  all 
immune cells in peripheral blood [17]. In addition, if such pDC-like cells could 
be manipulated during their development, they might be engineered according 
to specific therapeutic needs. 
 
3.6  DC development 
3.6.1  Precursors involved in DC subset development  
 
In  order  to  understand  DC  function  or  to  generate  functional  subsets  for 
cellular  therapy  in  vitro,  it  is  necessary  to  understand  the  biology  and 
classification  of  DC  precursor  development.  Hematopoeisis  is  the  process 
responsible for generation of the various cells that make up the blood. The 
principal precursors are called hematopoietic stem cells (HSC). They have an 
innate capacity to give rise to different progenitor cells which include common 
myeloid  progenitors  (CMP)  or  common  lymphoid  progenitors  (CLP).  These 
ultimately  give  rise  to  the  different  immune  cell  populations.  For  example 
downstream  of  CMP,  1)  erythropoiesis  gives  rise  to  reticulocytes  and 
erythrocytes, 2) thrombopoiesis gives rise to thrombocytes, 3) granulopoiesis 
gives rise to basophils, neutrophils and eosinophils, 4) Mast cells form directly 
from CMP and 5) monocytopoiesis gives rise to monocytes and myeloid DC. 
Downstream  of  CLP,  lymphopoiesis  takes  place  giving  rise  to:  1)  B 
lymphocytes or plasma cells, 2) T lymphocytes and 3) lymphoid DC. Thus, DC 
precursors are also formed as a result of hematopoiesis in the bone marrow.  
 
Classically,  the  development  of  DC  subsets  was  assumed  to  result  from 
radically  different  precursor  sources.  mDC  were  reported  to  develop  from 
myeloid precursors and the development of pDC was assumed to be entirely 
lymphoid.  However,  recently  common  progenitors  were  identified  for  both 
mDC  and  pDC.  Whereas  HSC-derived  multipotent  progenitors  give  rise  to 
either CMP or CLP, both these progenitors were able to generate pDC [18]. 
Interestingly,  at  least  in  the  mouse,  the  functions  of  common  myeloid 
progenitor  (CMP)-derived  and  common  lymphoid  progenitor  (CLP)-derived Introduction      25 
pDC were found to be distinct. Whereas CLP were prone to pDC generation, 
thus yielding higher numbers of pDC, MP developed faster into pDC which 
also produced higher levels of IFN-α [19]. In addition following another, more 
recent hypothesis, the common precursor of DC subtypes can be a myeloid 
progenitor-monocyte/DC  progenitor  (MP-MDP)  or  yet  another  unidentified 
progenitor further downstream of MP-MDP. Following the current perception, 
the MP-MDP then give rise to respective mDC or pDC precursors [20] (Figure 
8). To add further complicaction to the whole scenario, the above described 
theories may be true for DC development only in mice. DC development in 
humans  may  operate  independently  of  conventional  myeloid  or  lymphoid 
pathways [21].  
 
 
 
 
Figure 8: DC subset development theories: (Left) Distinct precursor theory: This classical 
theory suggests that the DC subsets arise from distinct precursors. Hematopoietic stem cells 
(HSC) give rise to multipotent progenitor (MPP) which forks into two distinct precursors - the 
common myeloid precursor (CMP) and the common lymphoid precursor (CLP). The CMP 
gives rise to Langerhans DC, interstitial DC or cDC through a series of steps involving one or 
two precursors. In detail, cDC arise from pre-DC1 or monocytes under the CMP precursor 
pathway. PDC arise from the CLP arm through a pre-DC2 precursor. (Middle) The common 
precursor theory suggests that a common precursor downstream of the HSC-MPP pathway 
differentiates to either CMP or CLP. cDC arise from CMP, whereas pDC arise from both CMP 
and CLP. (Right) The common DC precursor theory suggests that a common DC progenitor 
(CDP)  differentiating  along  the  myeloid  progenitor-monocyte/DC  progenitor  (MP)-(MDP) 
pathway is reponsible for cDC or pDC differentiation from respective precursors.  
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3.6.2  Cytokines  that  shape  pDC  development  and  the  myeloid  progenitor 
hypothesis 
 
A crucial determinant for pDC generation is the Fms-related tyrosine kinase 3 
ligand (Flt3-L). Flt3-L overexpressing transgenic mice had increased numbers 
of  pDC,  whereas  Flt3-L  deficient  mice  had  less  [18].  Importantly,  the 
administration  of  Flt3-L  to  humans  led  to  increased  numbers  of  peripheral 
pDC [22]. Common precursors for mDC and pDC were identified as common 
pro-DCs  in  the  mouse  bone  marrow  [18].  Also,  Flt3
high  and  Flt3
low  CD34
+ 
progenitor cells, isolated from human bone marrow, were described. CD14
+ 
monocytes  were  the  major  cell  type  generated  from  Flt3
high  cells,  whereas 
cells generated from Flt3
low cells were mainly erythroid cells [23]. Furthermore, 
Flt3 was detected on a subset on CD34
+ CD14
+ CD64
+ monocytic precursors 
in addition to being detected on a subset of CD34
+ CD38
- bone marrow cells 
and CD34
+ CD19
+ B lymphoid progenitors. Thus, it is tempting to speculate 
that administration of Flt3-L to humans results in high pDC numbers which are 
mobilized to differentiate along the myeloid lineage. Interestingly, monocytes 
are  easily  available  myeloid-derived  cells  in  human  peripheral  blood.  This 
opens the possibility to employ them for pDC generation. Besides Flt3-L, GM-
CSF might be important for pDC generation. PDC progenitors were less in 
Flt3-L-deficient  mice  as  compared  to  GM-CSF-deficient  mice,  and 
interestingly the latter had less pDC progenitors than wildtype mice [24].  
 
3.6.3  Transcriptional machinery involved in pDC development 
 
The basic helix-loop-helix transcription factor E2-2 was recently defined as the 
critical pDC lineage-determining transcription factor in humans and mice [25]. 
E2-2 haploinsufficiency in humans leads to the development of a condition 
called  the  Pitt-Hopkins  syndrome  characterized  by  cranio-facial/neural 
abnormalities,  mental  retardation  and  motor  dysfunction.  In  addition,  such 
individuals exhibit a reduced capacity to fight viral diseases due to decreased 
number  of  pDCs  and  an impaired  type  I IFN  production/response  of  these Introduction      27 
cells  [25].  E2-2  is  inhibited  by  ID  proteins  (inhibitor  of  differentiation/DNA 
binding) [26]. Of this protein family, ID2 was found to be essential for mDC 
development, but loss of ID2 did not affect pDC development [27]. In addition, 
genes  that  are  enriched in  pDC  such  as  SpiB,  Irf7  and  Irf8  are  under  the 
transcriptional control of E2-2 [25] (Figure 9). SpiB, which was considered to 
be  the  crucial  pDC  determining  factor,  serves  to  suppress  ID  proteins  and 
additionally requires E2-2 to determine pDC development [28]. Importantly, 
E2-2 is also required to maintain the function of pDC after they are generated 
[29].  
 
 
Figure  9:  Transcription  factors  (TF)  involved  in  pDC  development.  A)  TF  profile  in  DC 
subsets: mDC express high levels of ID2 and do not express E2-2. This is in contrast to pDC 
which express high levels of E2-2 but a low ID2; B) E2-2 is a TF that is crucial for pDC 
development. The TF is active as a dimer. An active E2-2 dimer binds to E-Box element in 
genes such  as Irf-7/8, Spi-B and activates their transcription;  C) In the presence of E2-2 
inhibiting protein ID2, E2-2 monomers are not able to dimerize, which is required to initiate 
transcription. In this case the E-Box is not occupied by the E2-2 dimer and gene expression is 
switched off. Therefore in the presence of high levels of ID2, the E2-2 dependent transcription 
of pDC-defining genes is shut down, thereby inhibiting pDC function and differentiation. 
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3.6.4  Hypoxia as a microenvironmental factor in hematopoiesis 
 
In  addition  to  its  effects  regarding  angiogeneis  and  modulation  of  immune 
responses,  hypoxia  may  also  participate  in  hematopoiesis  in  the  bone 
marrow. The oxygen content (O2) in the bone marrow may range from close to 
anoxia (0%) to 6% as opposed to a well oxygenated tissue such as the blood, 
where O2 levels range from 4% to 14% [30, 31]. The O2-gradient within the 
bone marrow is a determining factor for either keeping hematopoietic stem 
cells (HSC) in a low-replicating pluripotent state or to induce differentiation 
along the hematopoietic lineage. HSC are located in an extremely hypoxic 
niche  as  demonstrated  by  dye-perfusion  and  engraftment  studies  [32,  33]. 
The  primary  hypoxia-induced  transcription  factors,  the  hypoxia-inducible 
factors  (HIF)-1  to  3  are  stabilized  under  low  O2  concentrations.  They  are 
heterodimers  consisting  of  a  variable  O2-sensitive    subunit  and  a  stable 
common  β  subunit,  also  known  as  aryl  hydrocarbon  receptor  nuclear 
translocator (ARNT) [34]. Both HIF-1 and HIF-2 were recently connected to 
HSC biology. HIF-1 is needed for HSC quiescence in their hypoxic niche [35], 
whereas HIF-2 is activated downstream of STAT5 in HSC to maintain their 
self-renewing capacity [36]. Beside HSC maintenance, HIF-1 plays a major 
role  in  hematopoiesis  in  embryos  [37]  and  in  the  adult  organism  [38]. 
However,  whether  HIFs  affect  myeloid  cell  development  in  the  adult  bone 
marrow of mammals was unknown.  
 
 
 
 
 
 
 
 
 
 
 Introduction      29 
3.7  Aims of this study 
 
Tumour  antigens  are  recognized  by  APC,  which  take  up  and  present  the 
antigens  to  effector  cells.  These  effector  cells  then  ideally  eradicate  the 
tumour. In patients that develop a clinically detectable tumour, the immune 
status is dysregulated. Most often they exhibit increased levels of alternatively 
activated APC such as DC and regulatory T cells. These together suppress 
anti-tumour immunity. 
 
Dendritic cells act as professional APC that are central in regulating various 
immune processes including tumour immunity. The ability of DC to perform 
opposing  functions  spans  across  the  whole  immune  spectrum,  including 
antigen presentation and immune cell activation, anti-viral immunity, tolerance 
induction or tissue repair. These functions are met by at least two distinct DC 
subsets.  The  unique  property  of  mDC  to  activate  effector  T  cells  towards 
tumour killing made them likely candidates for use in cancer immunotherapy. 
Whereas  the  generation  of  mDC  generation  in  vitro  has  been  long 
established, a similar protocol to generate pDC was lacking. Hence, the first 
part of the thesis, addresses the aim of establishing a protocol to generate 
pDC equivalents from an easily and abundantly available source, so that they 
might  be  studied under  the influence of  tumour  microenvironmental  factors 
such as hypoxia or dying tumour cells. Since monocytes meet the criteria for 
the latter,  we  asked  if  they  could  be harnessed  for  generation  of  pDC-like 
cells. Further on, the mo-pDC thus generated had to be characterized in detail 
to identify similarities to their physiological counterparts or to check in which 
features these cells behaved differently to primary pDC. Therefore, mo-pDC 
were  characterized  along  these  levels:  1)  lineage-determining  transcription 
factor profile, 2) specific surface markers and 3) functional profile. The mo-
pDC differentiation was also studied under the tumour stress factor hypoxia. 
Interestingly, the bone marrow exhibits a low-oxygen environment as opposed 
to other tissues. Therefore, we also asked for the impact of hypoxia on pDC 
generation from mouse bone marrow precursors to support findings in from 
the studies with human cells as outlined above. Of particular interest was the Introduction      30 
impact  of  the  hypoxia-induced  transcription  factor  HIF-1,  which  we 
investigated by using bone marrow from conditional HIF-1α-deficient mice.  
 
In order to keep immune hyperinflammation in check, the immune system has 
evolved a regulatory network that shuts down its over-activation. This includes 
the APC that produce regulatory cytokines such as IL-10 or TGF-β to limit 
inflammation. In addition, these alternatively activated APC modulate effector 
immunity to mount tolerance. By way of producing tolerance-inducing factors, 
cancer cells use this APC-effector regulatory network to their benefit. At the 
top  of  the  trigger  of  this  regulatory  network  lie  tumour  microenvironmental 
stress factors such as hypoxia or the presence of dying cells. Therefore, in the 
second part of the thesis we focused on elucidating the influence of apoptotic 
tumour cells on the mDC phenotype with a focus on their ability to shape T 
cell responses. Since tumour cells are thought to evade immunity by shedding 
certain factors that mount tolerance, we specifically asked if supernatant of 
apoptotic  tumour  cells  can  prime  DC  to  trigger  T  cell  differentiation  that 
borders  along  tolerance.  T  cells  were  characterized  along  these  levels:  1) 
cytotoxic function, 2) surface marker profile and 3) secreted cytokines. Indeed, 
apoptotic  tumour  cells  induced  tolerogenic  DC  that  expanded  a  certain 
subpopulation of Treg cells. Hence, we investigated the factor released from 
apoptotic tumour cells that was responsible for this shift in the T cell profile. 
Also we checked mechanisms how DC achieved Treg generation. Last, we 
wanted to know how the specific Treg in our system suppressed CD8
+ T cells 
from  eradicating  tumour  cells.  The  impact  of  adenosine  generation  was 
investigated as  a  candidate  responsible  for the  suppression of  cytotoxicity. Materials      31 
4  Materials  
4.1  Chemicals and Reagents 
The  commercially purchased  chemicals  used  were  of  the  highest  grade  of 
purity: 
 
β-mercaptoethanol  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
40% Acrylamide/Bis-acrylamide 
(37.5% : 1.0% w/v)  
Roth GmbH, Karlsruhe 
Accutase  PAA Laboratories GmbH, Cölbe 
Acrylamide/Bis-acrylamide  Bio-Rad Laboratories GmbH, 
München 
Ammonium chloride (NH4Cl)  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Ammonium persulfate (APS)  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Brefeldin A  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Blocking buffer  Rockland Immunochemicals Inc, 
Gilbertsville (USA) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Bromophenol blue  Fluka GmbH, Buchs 
Caspase-3 substrate (Ac-DEVD-
AMC) 
Alexis Biochemicals, Grünberg 
Chloroform  Merk Eurolab GmbH, Darmstadt 
Collagenase IA  Sigma, Steinheim, Germany 
Dimethylsulfoxide (DMSO)   Roth GmbH, Karlsruhe 
Disodium hydrogen phosphate  
(Na2HPO4)  
Merck EuroLab GmbH, Darmstadt 
Dithiothreitole (DTT)   Roth GmbH, Karlsruhe 
DNAse I  Promega, Mannheim Germany Materials      32 
Ethanol   Roth GmbH, Karlsruhe 
Ethylenediaminetetraacetic acid 
(EDTA)  
Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
HEPES   Roth GmbH, Karlsruhe 
Isopropanol   Merck EuroLab GmbH, Darmstadt 
L-glutamine   PAA Laboratories GmbH, Cölbe 
Lymphocyte separation medium 
(Ficoll) 
PAA Laboratories GmbH, Cölbe 
Magnesium chloride (MgCl2)  Roth GmbH, Karlsruhe 
Magnesium sulfate (MgSO4)  Roth GmbH, Karlsruhe 
Methanol (MeOH)   Roth GmbH, Karlsruhe 
1-Methyl-tryptophan (L/D-1MT)  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Milk powder  Merck EuroLab GmbH, Darmstadt 
Monopottasium phosphate 
KH2PO4 
Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Neomycin (G 418)  PAA Laboratories GmbH, Cölbe 
Nonidet P-40  Sigma, Steinheim, Germany 
Oxaliplatin  Sigma, Steinheim, Germany 
Paraformaldehyde (PFA)  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Phenylmethanesulfonylfluoride 
(PMSF) 
Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Potassium bicarbonate (KHCO3) 
 
Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Potassium chloride (KCl)   Merck EuroLab GmbH, Darmstadt 
Protease inhibitor mix   Roche Diagnostics GmbH, 
Mannheim 
Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Tris  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Tris buffered saline (TBS)  Sigma-Aldrich Chemie GmbH, Materials      33 
Deisenhofen 
Triton X-100  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Trypsin  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Tween 20  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Sodium chloride (NaCl)   Merck EuroLab GmbH, Darmstadt 
Tetraethylendiamine (TEMED)   Roth GmbH, Karlsruhe 
Tris-HCl   Roth GmbH, Karlsruhe 
Triton X-100   Roth GmbH, Karlsruhe 
Tryptone  Sigma-Aldrich Chemie GmbH, 
Deisenhofen 
Tween 20   Roth GmbH, Karlsruhe 
Yeast extract   Life Technologies, Scotland 
 
4.2  Buffers and Solutions 
 
Rinsing buffer: (for cell separation) (in PBS) 
EDTA           0.5 M 
 
Running buffer: (for cell separation) (in PBS) 
BSA            0.5% 
EDTA           0.5 M 
 
FACS wash buffer (in PBS) 
BSA            0.2% 
 
Antibody solution 
TBS             50% (v/v) 
Blocking Buffer        50% (v/v) 
Tween 20           0.06% (v/v) 
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Blocking solution (in PBS) 
Triton X-100         0.1% 
BSA            3% 
 
10 x blotting buffer (pH 7.4) (in PBS) 
Tris-HCl           250 mM 
Glycine           1.9 M 
pH             8.3 
NaCl            137 mM 
KCl             2.7 mM 
Na2HPO4           8.1 mM 
KH2PO4           1.5 mM 
 
Potassium phosphate buffer (pH 8.5) 
KH2PO4          1 M 
 
Lower Tris Buffer (pH 8.8) 
Tris/HCl           1.5 M  
 
HIF lysis buffer (pH 8.0) 
Tris/HCl           50 mM 
EDTA           5 mM 
NaCl            150 mM 
Nonidet P-40         150 mM 
PMSF           0.5 mM 
DTT             1 mM 
Protease inhibitor mix       1 x 
 
4 x SDS-PAGE sample buffer (pH 6.9) 
Tris/HCl           125 mM 
10% SDS           2% (v/v) 
Glycerol           20% (v/v) 
Bromophenol blue        0.002% (w/v) 
DTT             5 mM Materials      35 
 
SDS separating gel (10%) 
H20 distilled          4.9 ml 
Lower Tris buffer        2.5 ml 
40% Acrylamide/Bis-acrylamide    2.5 ml  
(37.5% : 1.0% w/v) 
SDS 10% (w/v)        100 µl 
Ammonium persulfate 10% (w/v)   50 µl 
TEMED          5 µl   
 
SDS stacking gel (4%) (pH 7.1) 
H20 distilled          6.4 ml 
Upper Tris buffer        2.5 ml 
40% Acrylamide/Bis-acrylamide    1 ml   
(37.5% : 1.0% w/v) 
SDS 10% (w/v)        100 µl 
Ammonium persulfate 10% (w/v)   50 µl 
TEMED          5 µl   
10 x SDS running buffer: 
Tris/HCl           250 mM 
Glycine           1.9 M 
SDS             7 mM 
 
10 x TBS (pH 7.4) 
Tris/HCl           500 mM 
NaCl            1.5 M 
 
TE (Trypsin/EDTA in PBS) 
Trypsin           0.5 g/l 
EDTA           0.2 g/l 
 
1 x TTBS 
TBS             1 x 
Tween 20           0.06% (v/v) Materials      36 
 
Upper Tris Buffer pH 6.8 
Tris/HCl           0.5 M  
 
 
Erythrocyte lysis buffer (in 1L distilled H2O) 
NH4Cl                                                         8.26g 
KHCO3                                                        1 g           
EDTA                                                          0.037 g 
 
4.3  Pre-made Buffers 
 
autoMACS running buffer  Miltenyi  Biotec,  Bergisch  Gladbach, 
Germany 
BD Cytofix/Cytoperm Buffer  BD Pharmingen, San Jose, CA USA 
BD perm/wash buffer  BD Pharmingen, San Jose, CA USA 
FACS wash buffer  Miltenyi  Biotec,  Bergisch  Gladbach, 
Germany 
FoxP3 buffer set  BD Biosciences, Heidelberg 
 
4.4  Dye and beads 
 
CFSE  (carboxyfluorescein 
succinimidyl ester) 
Molecular  probes,  Invitrogen, 
Karlsruhe, Germany 
CMAC  (CellTracker  Blue  -
amino-4-chloromethylcoumarin) 
Invitrogen, CA, USA 
CompBeads  BD Biosciences, Heidelberg 
Cytometer  Setup  and  Tracking 
(CST) beads 
BD Biosciences, Heidelberg 
Flow-Count Fluorospheres   Beckman-Coulter, Krefeld, Germany 
Propidium iodide (PI)  Sigma-Aldrich  Chemie  GmbH, 
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4.5  Kits 
 
4.6  Antibodies 
4.6.1  Human FACS antibodies:  
 
anti-IFN-α-PE  BD Pharmingen, San Jose, CA USA 
anti-CD14-APC  Immunotools, Friesoythe, Germany 
anti-CD45RA-APC  Immunotools, Friesoythe, Germany 
anti-CD123-APC  Immunotools, Friesoythe, Germany 
anti-CD86-FITC  Immunotools, Friesoythe, Germany 
anti-CD135-FITC  Immunotools, Friesoythe, Germany 
anti-CD1a-FITC  Immunotools, Friesoythe, Germany 
anti-BDCA2-PE  Miltenyi  Biotec,  Bergisch  Gladbach, 
Germany 
anti-CD11b-APC  Miltenyi  Biotec,  Bergisch  Gladbach, 
Germany 
anti-HLA-ABC (MHC I)-FITC  Miltenyi  Biotec,  Bergisch  Gladbach, 
Germany 
anti-HLA-DR (MHC II)-PE-Cy7  BD  Biosciences,  Heidelberg, 
Annexin V-FITC/PI Apoptosis Kit  Coulter-Immunotech GmbH, Hamburg 
BD  Cytometric  Bead  Array 
Human Inflammation Kit 
BD Biosciences, Heidelberg 
BD Human Th1/TH2/TH17 kit  BD Biosciences, Heidelberg 
iLite human IFN-α kit  PBL  InterferonSource,  Piscataway, 
NJ, USA 
Peq Gold  Peqlab, Erlangen, Germany 
RNeasy micro kit  Qiagen, Hilden, Germany 
Sensiscript RT kits  Qiagen, Hilden, Germany 
Standard DC Protein Assay Kit  Bio-Rad Laboratories GmbH, Munich 
VeriKine ELISA kit  PBL  InterferonSource,  Piscataway, 
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Germany 
Anti-TLR4-PE  Imgenex, San Diego, CA, USA 
Human  Fc  Receptor  Binding 
Inhibitor 
eBioscience, San Diego, CA USA 
Anti-CD3-V450  BD  Biosciences,  Heidelberg, 
Germany 
Anti-CD4-V500  BD  Biosciences,  Heidelberg, 
Germany 
Anti-CD8-APC-H7  BD  Biosciences,  Heidelberg, 
Germany 
Anti-CD25-PE-Cy7  BD  Biosciences,  Heidelberg, 
Germany 
Anti-CD69-AlexaFlour 700  BD  Biosciences,  Heidelberg, 
Germany 
Anti-CD73-PE  BD  Biosciences,  Heidelberg, 
Germany 
Anti-CD39-FITC  Miltenyi  Biotec,  Bergisch  Gladbach, 
Germany 
Anti-CD19-Qdot 655  Invitrogen, Carlsbad, CA, USA 
Anti-FoxP3-APC  BD  Biosciences,  Heidelberg, 
Germany 
Anti-TGF-β1-PE  IQ products, Groningen, Netherlands 
Anti-CD80-PE  Biolegend, Fell, Germany 
Anti-CD83-APC  Biolegend, Fell, Germany 
Anti-CD40-FITC  Biolegend, Fell, Germany 
 
4.6.2  Human Neutralizing antibodies 
 
IL-27 neutralizing antibody  R&D  Systems,  Wiesbaden-
Nordernstadt, Germany 
IgG1 isotype control  R&D  Systems,  Wiesbaden-
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TGF-ß neutralizing antibody   R&D  Systems,  Wiesbaden-
Nordernstadt, Germany 
 
4.6.3  Murine FACS antibodies 
 
CD19-APC-Cy7-PE  BD Biosciences, Heidelberg, 
 Germany 
CD115-PE  BD Biosciences, Heidelberg,  
Germany 
CD45-V450  BD Biosciences, Heidelberg,  
Germany 
B220-V450  BD Biosciences, Heidelberg,  
Germany 
CD11c-AlexaFluor700  BD Biosciences, Heidelberg,  
Germany 
Ly6C-PerCP-Cy5.5  BD Biosciences, Heidelberg,  
Germany 
CD11b-eFluor605  ebioscience, San Diego,  
CA, USA 
CD8-eFluor650  ebioscience, San Diego,  
CA, USA 
HLA-DR-APC  Miltenyi,  Bergisch  Gladbach, 
Germany 
CD11b-APC  Miltenyi,  Bergisch  Gladbach, 
Germany 
SiglecH-PerCP-Cy5.5  Biolegend, Fell, Germany 
CD317/120G8  Dendritics, Lyon, France 
Mouse BD Fc Block  BD Biosciences, Heidelberg,  
Germany 
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4.6.4  Primary human antibodies: 
 
Anti-E2-2  (rabbit polyclonal)  ABCAM, Cambridge, UK 
Anti-IDO  (mouse monoclonal)  ABCAM, Cambridge, UK 
 
4.6.5  Secondary human antibodies: 
 
IRDye680-labelled anti-rabbit   Li-COR  Biosciences  GmbH,  Bad 
Homburg 
IRDye800-labelled anti-rabbit   Li-COR  Biosciences  GmbH,  Bad 
Homburg 
 
4.7  Microbeads: 
 
Human CD14 microbeads    Miltenyi,  Bergisch  Gladbach, 
Germany 
Human  CD4
+  CD25
+  regulatory 
T cell isolation kit  
Miltenyi,  Bergisch  Gladbach, 
Germany 
Anti-FITC microbeads  Miltenyi,  Bergisch  Gladbach, 
Germany 
 
4.8   Media and reagents for cell culture 
 
Bovine insulin  Sigma-Aldrich  Chemie  GmbH, 
Deisenhofen 
Dulbecco’s  Modified  Eagle 
Medium (DMEM) 
PAA Laboratories GmbH, Cölbe 
FCS  PAA Laboratories GmbH, Cölbe 
L-glutamine  PAA Laboratories GmbH, Cölbe 
Lymphocyte separation medium  PAA Laboratories GmbH, Cölbe 
Non essential amino acids  PAA Laboratories GmbH, Cölbe Materials      41 
PBS (Instamed 9.55 g/ml)   Biochrom AG, Berlin 
Penicillin/Streptomycin   PAA Laboratories GmbH, Cölbe 
Roswell  Park  Memorial  Institute   
(RPMI) 1640 
PAA Laboratories GmbH, Cölbe 
Sodium pyruvate  PAA Laboratories GmbH, Cölbe 
 
4.9  Cytokines 
 
 
4.10 ELISA  
 
 
4.11 Stimulators and Inhibitors 
 
APCP  (CD73  inhibitor  5′-[αβ-
methylene] diphosphate)  
Sigma, Steinheim, Germany 
ARL67156  Sigma, Steinheim, Germany 
all-trans retinoic acid (ATRA)   Sigma-Aldrich, St. Louis,
 MO, USA 
1x Brefeldin A (BFA)  BD fastimmune, San Jose, CA USA 
CpG-A  (2336)  oligonucleotides  InvivoGen, San Diego, CA, USA 
Human Flt3-L  Immunotools, Friesoythe, Germany 
Murine Flt3-L  PeproTech, London, UK 
Human GM-CSF  Miltenyi,  Bergisch  Gladbach, 
Germany 
Human IL-2  Immunotools, Friesoythe, Germany 
Human IL-4  Immunotools, Friesoythe, Germany 
Human TNF-α  Peprotech Inc. NJ, USA 
IL-27 sandwich ELISA  Biolegend, San Diego, CA USA 
VeriKine
TM  Mouse  Interferon-
Alpha ELISA Kit 
PBL interferon source, NJ, USA Materials      42 
(ODN)  
CSC  (Adenosine  receptor  A2a 
antagonist  8  (3-chlorostyryl) 
caffeine)  
Sigma, Steinheim, Germany 
CYM50358  Courtesy:  E.  Roberts,  The  Scripps 
Institute, La Jolla, CA, USA 
CYM50374   Courtesy:  E.  Roberts,  The  Scripps 
Institute, La Jolla, CA, USA 
JTE-013  Biomol, Hamburg Germany 
Lipopolysaccharide   Sigma, Steinheim, Germany, 
Staurosporine   Sigma, Steinheim, Germany 
Vitamin D3   Fluka,  Biochemica,  St.  Louis,
  MO, 
USA 
VPC23019  Avanti  Polar  Lipids,  Alabaster,  AL, 
USA 
 
4.12 Oligonucleotides 
 
The below given oligonucleotides were from biomers.net GmbH (Ulm): 
 p35:  sense  5’-AGATAAAACCAGCACAGT-GGAGGC-3’,  antisense:  5’-
GCCAGGCAACTCCCATTAGTTAT-3';  
p28  sense:  5’-AGGA-GCTGCGGAGGGAGTT-3’,  antisense:  5’-
AGGGGCAGGAGGTACAGGTTC-3’;  
IL-10  sense:  5’-AAGCCTGACCACGCTTTCTA3-’,  antisense:  5’-
TAGCAGTTAGGAAGCCCC-AA-3’.  
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Human  E2-2  (QT00031829),  human  ID2  (QT00210637),  human  IFN-α1 
(QT00201964),  IFN-α2  (QT00212527),  IFN-α16  (QT00202671),  and  human 
IRF7 (QT00210595). Actin (QT01680476) and 18S (QF00530467) served as 
the internal controls. 
 
4.13 Cells and cell lines  
 
Primary  human  monocytes:  Primary  human  monocytes  were  isolated  from 
Buffy  Coats,  which  were  obtained  from  DRK-Blutspendedienst  Baden-
Württemberg-Hessen, Frankfurt. 
 
MCF-7  cells:  MCF-7  human  breast adenocarcinoma  cells  were  established 
from the pleural effusion of a 69-year-old Caucasian woman with metastatic 
mammary carcinoma (after radio- and hormone therapy) in 1970 [75]. 
 
Mouse pDC: Mouse bone marrow cells were used as a precursor source for 
generating pDC. Bone marrow cells were obtained from hindlimbs of HIF-1
fl/fl 
LysM-Cre  mice  under  sterile  conditions  followed  by  erythrocyte  lysis.  The 
bone  marrow  cells  were  cultured  in  low  adhesion  plates  with  appropriate 
cytokines such as murine FLT3-L to obtain mouse pDC. 
 
4.14 Instruments  
 
Autoclave HV 85   BPW GmbH, Süssen 
autoMACS™ Separator   (Miltenyi  Biotec,  Bergisch  Gladbach, 
Germany) 
AxioScope  fluorescence 
microscope  
Carl  Zeiss  MicroImaging,  Jena, 
Germany 
B250 Sonifier   Branson Ultrasonics, Danbury (USA) 
Bioanalyzer   Agilent , Böblingen, Germany 
CASY®   Schärfe System, Reutlingen 
Centrifuge 5415 R   Eppendorf GmbH, Hamburg Materials      44 
Centrifuge CR 3.22   Jouan GmbH, Unterhaching 
Centrifuge MR 23i   Jouan GmbH, Unterhaching 
Centrifuge ZK380   Hermle GmbH, Wehingen 
FACSCanto flow cytometer  BD Biosciences GmbH, Heidelberg 
Fluorescence  microscope 
Axiovert 200M  
Carl  Zeiss  MicroImaging  Inc, 
Göttingen 
Holten LaminAir clean bench   Jouan GmbH, Unterhaching 
Hypoxia workstation incubator  In vivo 400, Ruskin Technology, UK 
IG 150 (cell culture incubator)   Jouan GmbH, Unterhaching 
LabLine Orbit Shaker   Uniequip GmbH, Martinsried 
LSRII/Fortessa flow cytometer  BD Biosciences 
Magnetic stirrer Combimag RCH  IKA  Labortechnik  GmbH  &  Co.  KG, 
Staufen 
Mastercycler Thermocycler   Eppendorf GmbH, Hamburg 
MediMachine  BD Biosciences GmbH, Heidelberg 
Mini-PROTEAN 3 System (SDS-
PAGE)  
Bio-Rad  Laboratories  GmbH, 
München 
Mithras LB940 multimode reader  Berthold Technologies, Bad Wildbad 
NanoDrop spectrophotometer  NanoDrop, Wilmington, USA 
Odyssey  infrared  imaging 
system 
Li-COR  Biosciences  GmbH,  Bad 
Homburg 
Pure water system Purelab Plus   ELGA LabWater GmbH, Siershahn 
Sub-Cell®  GT  electrophoresis 
system  
Bio-Rad  Laboratories  GmbH, 
München 
Thermomixer 5436   Eppendorf GmbH, Hamburg 
Ultra-Sonifier   MSE, Loughborough (England) 
UV-Transilluminator  gel 
documentation system  
Raytest GmbH, Straubenhardt 
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4.15 Plastic material 
 
12-well  Ultra-Low  attachment 
plates 
Corning, Amsterdam, Netherlands 
Nylon mesh  BD Biosciences GmbH, Heidelberg 
Pipettes (10 µl, 100 µl, 1.000 µl)   Eppendorf GmbH, Hamburg 
Cell culture dishes)   Greiner  Bio-One  GmbH, 
Frickenhausen 
 
4.16 Software 
 
Aida Image Analyzer v 3.11   Raytest GmbH, Straubenhardt 
AxioVision Software   Carl  Zeiss  MicroImaging  Inc, 
Göttingen 
BD FACSDiva
TM Software   BD Biosciences GmbH, Heidelberg 
FCAP software  BD Biosciences, San Jose, CA USA 
FlowJo software 7.6.1  Treestar, Ashland, OR, USA 
Gene Expression Macro  Bio-Rad, München, Germany 
GraphPad Prism 5.0   GraphPad Software, San Diego, CA, 
USA 
MikroWin 2000     Berthold Technologies Bad Wildbad  
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5  Methods  
5.1  Cell culture 
MCF-7 breast carcinoma cells were maintained in RPMI 1640 supplemented 
with 5 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% 
heat-inactivated  FCS  supplemented  with  1mM  sodium  pyruvate,  1  x  non 
essential  amino  acids  and  10  µg/ml  bovine  insulin.  Cells  were  kept  in  a 
humidified atmosphere of 5% CO2 in air at 37°C and were transferred twice a 
week. 
   
5.2  Primary human immune cell isolation and expansion 
Primary  human  blood  cells  were  obtained  from  Buffy  Coats  (DRK-
Blutspendedienst  Baden-Württemberg-Hessen,  Institut  für 
Transfusionsmedizin  und  Immunhämatologie,  Frankfurt,  Germany)  using 
Ficoll-Hypaque  gradients.  For  isolation  of  CD14
+  human  monocytes,  total 
Buffy Coats were layered on a Ficoll-Isopaque gradients (P=1077
 g/ml) and 
the interphase containing PBMC  was obtained by centrifugation (440 g, 35 
min).  PBMC  were  washed  with  PBS/2  mM  EDTA/0.5%  BSA  and  CD14
+ 
monocytes  were  isolated  by  magnetic  cell  sorting  using  human  CD14 
microbeads in the autoMACS™ Separator. The negative fraction consisting of 
CD14
- PBMC was used for T cell enrichment. Therefore, cells were cultured in 
T cell medium [76] containing IL-2 (100 U/ml) for 6 days. Every two days, cells 
adhering to the culture flask were depleted and expanding lymphocytes were 
split  1:2.  Or  using  a  similar  protocol,  the  negative  fraction  was  used  to 
separate  CD3
+  lymphocytes  from  the  same  donor  using  human  CD3 
microbeads. CD3
+ T lymphocytes were cultured with IL-2 (100 U/ml) for up to 
6 days [77]. 
 
5.3  Animals 
Animal handling followed the guidelines of the Hessian animal care and use 
committee. Mice carrying loxP-flanked alleles of HIF-1 [78] were bred with Methods      47 
LysM-Cre  transgenic  mice  [79]  in  the  C57BL/6  background.  Age-matched 
C57BL/6 wildtype mice were controls.  
 
5.4  Generation and maturation of plasmacytoid and myeloid DC 
Human primary monocytes were cultured in 12 well cell culture plates in RPMI 
1640 containing 10% FCS for 5 days with GM-CSF (100 ng/ml) and IL-4 (5 
ng/ml) to generate myeloid DCs and Flt3-L (100 ng/ml) to generate mo-pDC. 
On day 5, Lipopolysaccharide (LPS) (1 µg/ml) was added to mDC cultures 
and 5 µg/ml CpG-A (2336) oligonucleotides (ODN) were added to mo-pDC 
cultures to induce maturation. In some experiments immature mo-pDC were 
used or mo-pDC were allowed to differentiate for 10 days. To investigate the 
impact of vitamins on mo-pDC development, monocytes were cultured with 
Flt3-L in combination with 3 nM all-trans retinoic acid (ATRA) or 3 µM Vitamin 
D3. In some experiments mo-pDC were prestimulated overnight with 10 ng/ml 
TNF-α  prior  to  addition  of  CpG-A  oligonucleotides.  Also,  human  peripheral 
CD14
+ human monocytes were differentiated with Flt3-L under hypoxia (1% 
O2,  5%  CO2)  in  a  hypoxia  workstation  incubator.  The  resulting  mo-pDC 
cultured under hypoxia were then compared with mo-pDC differentiated under 
normoxia (20% O2, 5% CO2). Morphology of mo-pDC and mDC was routinely 
analyzed using an AxioScope fluorescence microscope at room temperature, 
using a charge-coupled device camera and the AxioVision Software. 
 
5.5  Isolation of primary pDC 
Primary  untouched  pDC  were  isolated  from  human  PBMC  using  a 
Plasmacytoid  DC  Isolation  Kit  that  employs  an  indirect  magnetic  labeling 
system.  
 
5.6  Murine pDC generation from bone marriow and hypoxic culture 
pDC were differentiated from bone marrow as described [80]. Briefly, mouse 
bone marrow cells were obtained from the  hindlimbs after disinfection with 
70% ethanol. The limb was dissected at the knee to obtain upper and lower Methods      48 
limb.  A  26-gauge  needle  filled  with  PBS  was  used  to  flush  out  the  bone 
marrow  contents.  The  elution  was  passed  through  a  76µM  nylon  mesh  in 
order to obtain a single cell suspension.  Cells were centrifuged at 500xg for 5 
minutes. Erythrocyte lysis was performed on the pellet using an hypotonous 
solution.  The  resulting  erythrocyte-free  cell  suspension  was  seeded  in  a 
concentration  of  2  x  10
6  total  bone  marrow  cells/ml  in  RPMI1640 
supplemented with 10% FCS and 200 ng/ml recombinant murine Flt3-L were 
seeded to 12-well Ultra-Low attachment plates. Culture was maintained for up 
to 9 d, with medium change every 3
rd day. Cells were cultured either under 
high (20%) or low (1-5%) O2 levels as indicated using a InVivo2 400 hypoxia 
workstation. 
 
5.7  Preparation of tumour cell supernatants 
MCF-7 human breast carcinoma cells were grown in RPMI 1640 medium plus 
10% FCS. Generation of supernatants of living (VCM), apoptotic (ACM) or 
necrotic  (NCM)  MCF-7  cells  was  performed  essentially  as  described    To 
produce apoptotic cell conditioned medium (ACM), cells were exposed to 1 
µg/ml staurosporine (Sts) 1 h to induce apoptosis). Cells were washed twice 
with  PBS  subsequent  to  apoptosis-induction,  followed  by  an  incubation  for 
another  4  h  in  appropriate  medium  (1.2.1).  Alternatively, [81].  MCF-7
  cells 
remained untreated (living), or 30 µM oxaliplatin for 16 h (immunogenic cell 
death) or were incubated at 56°C for 30 min (necrosis), followed by washing 
and further incubating for at least another 5 h in full medium. The resulting 
conditioned  medium  were  called  viable  condition  medium  (VCM)  or 
Oxaliplatin-ACM  (OXA-ACM)  or  necrotic  condition  medium  (NCM) 
respectively Thereafter, conditioned
 media were harvested by centrifugation 
(13.000  x  g,  5  min)  and  filtration  through  0.2  µm  pore  filters,  to  remove 
apoptotic bodies (incase of ACM or OXA-ACM) [82], [83] or residual cellular 
particles (in case of NCM or VCM).  
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5.8  DC-T cell co-culture 
Tumour cell supernatants were added to 2 x 10
5 human monocyte-derived DC 
at  ratios  of  1:1  for  16  h,  followed  by  washing.  Afterwards  2  x  10
6  T  cell-
enriched PBMC were added and co-cultures were maintained for another 3 
days without changing media.  
 
5.9  Treg isolation and CD39
+ cell isolation 
Treg  were  isolated  from  DC-T  cell  co-cultures  using  the  CD4
+CD25
+ 
Regulatory  T  Cell  isolation  Kit  by  magnetic  separation.  Treg-depleted 
populations  were  added  back  to  the  respective  co-cultures.  Isolated  Treg 
(controlled via FACS, Figure 26) were either used for RNA isolation or were 
interchanged between ACM and VCM groups at ratios reconstituting mean 
FoxP3-expressing cells (0.5%) to monitor their specific suppressive potential. 
CD39-expressing T cells from IL-2 enriched T cell cultures were removed by 
staining with CD39-FITC antibody and magnetic separation using anti-FITC 
microbeads. The CD39-depleted populations were then used for co-cultures.  
 
5.10 Stimulation of human monocyte-derived DC 
S1P and the S1PR1/3 inhibitor VPC23019 (1 µM) were dissolved according to 
the  manufacturer’s  instructions.  The  S1PR2/4  antagonist  JTE-013  (15  µM) 
and the S1PR4 antagonists CYM50358 and CYM50374 (each 200 nM) [84] 
were dissolved in DMSO. These reagents were pre-incubated for 30 min with 
DC  prior  to  addition  of  tumour  cell  supernatants.  The  indolamine-2,3-
dioxygenase (IDO) inhibitors L-1MT or D-1MT (1 mM) [85] were added to DC 
2 h prior to T cell addition. IL-27 neutralizing pab and the isotype control were 
added at 1 µg/ml to DC 30 min before addition of T cells. The CD39 inhibitor 
ARL67156  (250  µM),  the  CD73  inhibitor  5′-[αβ-methylene]  diphosphate 
(APCP) [86] (100 µM) dissolved in ddH2O and the adenosine receptor A2a 
antagonist 8 (3-chlorostyryl) caffeine (CSC) [87] (10 mM) dissolved in DMSO 
as  well  as  the  CD69  antibody,  TGF-ß  neutralizing  antibody  [88]  and  the 
respective isotype controls were added to DC-T cell co-cultures at day 2.  
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5.11 Cytotoxicity assay 
Cytotoxicity  was  quantified  using  a  slightly modified  established assay [89] 
(Figure 10). The T cells from DC-T cell coculture was harvested into FACS 
tubes.  These  were  pelleted  at  500  xg  for  5  minutes.  The  pellet  was 
resuspended  in  500µl  FACS  buffer  (PBS  +  0.2%  BSA).  20µl  of  this 
suspension was pipetted into FACS tubes along with 80µl FACS buffer. These 
cells were stained with propidium iodide (PI) for 10 min. 
 
 
                   
 
 
Figure 10: Cytotoxicity assay was performed as depicted: 1. DC were cocultured for 3 days 
with T cell-enriched PBMC, here depicted as DC-T cell coculture; 2. Live MCF-7 cells were 
stained with Cell Tracker Blue (CMAC) dye for 45 minutes. The resulting cells were called 
CMAC-MCF-7 cells. 3. T cells were stained with flourospheres and absolute cell counting was 
done using flow cytometry; 4. T cells were added to CMAC-MCF-7 cells at different ratios and 
cocultured  for  4h;  5.  The  CMAC-MCF-7-T  cell  coculture  was  stained  with  PI  and 
flourospheres. The number of living MCF-7 cells and their absolute count was determined by 
comparing PI and flourocount flouresence respectively with that of the non co-cultured MCF-7 
control. 
 
 
Directly  before  sample  acquisition,  Flow-Count  Fluorospheres  (Beckman-
Coulter, Krefeld, Germany) were added as an internal cell counting standard. 
10
3 events of living lymphocytes were recorded. The value of flourospheres 
required to attain the number was used to calculate the absolute number of 
lymphocytes. Human breast carcinoma cells (MCF-7 and T47D), 2 x 10
6 each Methods      51 
were  suspended  in  FACS  buffer.  The  cells  were  stained  with  100  µM 
CellTracker Blue (7-amino-4-chloromethylcoumarin, CMAC) (Invitrogen, CA, 
USA) according to manufacturer’s instructions for 45 min. This was followed 
by washing with FACS buffer and the cells were centrifuged at 500 xg for 5 
minutes. Afterwards, 5 x 10
4 breast cancer cells were seeded in FACS tubes 
together with T cells from DC co-cultures in ratios as indicated for 4 h. The 
reaction mix was then stained with propidium iodide (PI) for 10 min. Directly 
before  sample  acquisition,  Flow-Count  Fluorospheres  (Beckman-Coulter, 
Krefeld, Germany) were added as an internal cell counting standard and 2 x 
10
3 living (PI
-, CMAC
+, FSC
high) breast cancer cells were recorded for each 
sample in comparison to unstimulated breast cancer cells. Cytotoxicity was 
calculated as described [89]. In some experiments, blocking of CD8 in T cells 
was triggered using CD8 antibody [90] or the respective isotype control (BD 
Biosciences) 1 h before performing cytotoxicity experiments. 
 
5.12  Flow cytometry of human DC 
Antibodies used for mo-pDC staining in comparison to mDC; monocytes or 
primary  pDC  were  APC-labelled  CD14,  CD45RA,  CD123,  FITC-labelled 
CD86, CD1a, Alexa 488-labelled CXCR3, PE-labelled CD135, BDCA2, APC-
labelled BDCA4 and CD11b, HLA-ABC (MHC I)-FITC, FITC-labelled TLR7, 
PE-labelled TLR9 and TLR4 and respective isotype controls. For analysis of 
surface marker expression, monocytes or DC were detached from the dishes 
by treatment with accutase [91] and washed with ice-cold PBS. Cells were 
then  stained  with  respective  antibodies,  incubated  on  ice  for  30  min  and 
analyzed  by  flow  cytometry.  Appropriate  isotype  controls  or  monocytes 
stained with respective antibodies were used as controls.  
 
For analysis of DC maturation, DC were detached from the wells by treatment 
with accutase [91] (PAA), washed with ice-cold PBS/0.2% BSA and incubated 
on ice for 20 min with CD86-FITC, HLA-DR (MHC II)-PE-Cy7 or HLA-ABC 
(MHC  I)-FITC  or CD80-PE,  CD83-APC  and  CD40-FITC. For polychromatic 
flow cytometry analysis of T cells from DC co-cultures, cells were harvested 
using a pipette, transferred to FACS tubes and washed with ice-cold PBS. Methods      52 
Next,  non-specific  antibody  binding  to  FC-γ  receptors  was  blocked  using 
Human Fc Receptor Binding Inhibitor for 20 min, cells were resuspended in 
FACS  staining  buffer  and  incubated  with  a  pre-mixed  antibody  cocktail 
consisting  of  CD3-V450,  CD4-V500,  CD8-APC-H7,  CD25-PE-Cy7,  CD69-
AlexaFlour 700 and CD73-PE, CD39-FITC, CD19-Qdot 655  on ice for 30 min. 
Then, cells were fixed and permeabilized using the FoxP3 buffer set from BD 
Biosciences according to manufacturer’s intructions, washed with PBS/0.2% 
BSA and incubated with FoxP3-APC antibody for 60 min at RT. For analysis 
of TGF-β expression, cells were pre-treated with 500 ng/ml Brefeldin A and 
TGF-β1-PE antibody was used alongside with the FoxP3 antibody. Samples 
were  acquired  using  a  LSRII/Fortessa  flow  cytometer  and  analyzed  using 
FlowJo  software  7.6.1.  All  antibodies  were  titrated  to  determine  optimal 
concentrations.  Antibody-capturing  CompBeads  were  used  for  single-color 
compensation to create the multi-color panel compensation matrix. For gating, 
fluorescence minus one (FMO) controls and/or isotype controls were used. 
The instrument calibration was controlled and adjusted daily using Cytometer 
Setup and Tracking (CST) beads. 
 
5.13 Murine Polychromatic flow cytometry 
pDC were identified from in vitro bone marrow cultures, whole bone marrow, 
spleen  or  whole  blood  using  the  following  antibodies:  CD19-APC-Cy7, 
CD115-PE,  CD45-V450,  B220-V450,  CD11c-AlexaFluor700,  (CD11b-
eFluor605,  CD8-eFluor650  ;  HLA-DR-APC,  CD11b-APC;  SiglecH-PerCP-
Cy5.5;  CD317/120G8.  Single  cell  suspensions  were  generated  from  solid 
tissues by digestion with 3 mg/ml Collagenase IA, 1 U/ml DNAse I in 50% 
DMEM for 30 min at 37°C, followed by processing with MediMachine, RBC 
lysis  and  filtering  through  a  70  µm  nylon  mesh.  Cells  were  transferred  to 
FACS tubes, non-specifc antibody binding to FC-γ receptors was blocked with 
Mouse BD Fc Block for 20 min on ice. This was followed by incubation with 
individual antibody cocktails for 30 min on ice. Samples were acquired with a 
LSRII/Fortessa flow cytometer and analyzed using FlowJo software 7.6.1. All 
antibodies  were  titrated  to  determine  optimal  concentrations.  Antibody-
capturing  CompBeads  were  used  for  single-color  compensation  to  create Methods      53 
multi-color compensation matrices. For gating, fluorescence minus one (FMO) 
controls  were  used.  The  instrument  calibration  was  controlled  daily  using 
Cytometer Setup and Tracking beads. 
 
5.14 RNA isolation, cDNA synthesis and qPCR 
RNA  from  mo-pDC  was  extracted  using  peqGold
  RNAPure.  RNA 
concentrations were determined using the NanoDrop spectrophotometer and 
1 µg RNA was used for cDNA synthesis. Total RNA
 (1 µg) was transcribed 
with the iScript cDNA synthesis kit
 .Quantitative
 real-time PCR was performed 
using MyIQ real-time PCR system
 (and Absolute Blue QPCR SYBR Green 
fluorescein
 mix.  The  following  primers  were  used  for  quantitative  real-time-
PCR of mo-pDC:
 human E2-2; human ID2; human IFN alpha 1 , IFN alpha 2, 
IFN  alpha  16,  human  IRF-7.  18S  RNA  levels  were  employed  for 
normalization.
 Real-time PCR results
 were quantified using Gene Expression 
Macro. 
 
RNA from < 10
5 Treg was isolated using the RNeasy micro kit according to 
the manufacturer’s instructions. The resulting RNA was quantitated using the 
Bioanalyzer from Agilent and was transcribed to cDNA using sensiscript RT 
kits. Quantitative PCR was performed as described [92]. Human ebi3, actin 
and 18S rRNA were amplified using QuantiTect Primer Assays. Results were 
analyzed using Gene Expression Macro (Bio-Rad, München, Germany). Actin 
and 18S served as the internal controls. For amplifying murine E2-2/TCF4, 
ID2, CXCL12, actin or TBP, QuantiTect Primer Assays were used. Results 
were analyzed using Gene Expression Macro. Actin and TBP served as the 
internal controls. 
 
5.15 Cytokine quantitation  
The amount of TNF-, IL-10, IL-6, IL-12 in DC supernatants and the cytokines 
IFN-γ, IL-10, IL-4, IL-17, IL-2 from DC/T cell co-cultures were measured using 
Human Inflammatory Cytokine or Human Th1/TH2/TH17 kits according to the 
manufacturer’s  protocol.  TLR  agonists  were  added  to  DC  to  induce Methods      54 
maturation. After 24h, the supernatants were harvested and centrifuged. The 
amount of TNF-α, IL-10, IL-6, IL-1ß in the supernatants of mature DC and the 
amounts  of  TNF-α  in  the  supernatants  from  immature  DC  were  measured 
using  human  inflammation  kits  according  to  manufacturer.  Samples  were 
analyzed  by  FACS  and  processed  with  BD  Biosciences’  FCAP  software. 
Samples  were  acquired  in  the  flow  cytometer  and  processed  with  BD 
Biosciences FCAP software. An IL-27 sandwich ELISA was used to quantify 
IL-27  levels  in  treated  DC  supernatants  following  the  manufacturer’s 
instructions. Measurement of murine IFN- in supernatants of 5 µg/ml CpG-A-
stimulated pDC was performed using VeriKine ELISA kit. 
 
5.16 T lymphocyte proliferation assay 
CD3
+ T lymphocytes were loaded with 0.5 µM carboxyfluorescein succinimidyl 
ester  (CFSE)  according  to  manufacturer’s  protocol.  CFSE  loaded  CD3
+  T 
lymphocytes  were  cocultured  with  autologous  mature  DC  subsets  at  a  5:1 
ratio  for  5  days.  Afterwards,  the  supernatant  from  the  cocultures  was 
harvested. DC were gated from the CD3
+ T lymphocyte population, following 
which,  CFSE-dependent  green  fluorescence  was  quantitated  using  FACS 
analysis. 
 
5.17 Apoptotic cell phagocytosis assay 
Jurkat cells were stained with CFSE according to the manufacturer’s protocol. 
CFSE-labelled Jurkat cells were treated with 1 µg/ml staurosporine for 2.5 h in 
RPMI 1640 without serum. The resulting apoptotic Jurkat cells were added to 
mDC and mo-pDC in a 50:1 ratio and cultures were incubated at 37 
0C for 3.5 
h. Then, the cells were harvested and placed on ice to arrest phagocytosis. 
Cells were incubated for 30 min with APC labelled anti-CD11b antibody and 
the fluorescence was quantitated using FACS analysis. CD11b
+ cells, which 
were double-positive for CFSE were considered to be phagocytic. Apoptotic 
Jurkat cells (only CFSE
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5.18 Western blot analysis 
Generally,  immature  mo-pDC  were  used  for  Western  analysis,  which  was 
performed as described [81]. A Rabbit polyclonal antibody to E2-2 was used. 
Blots were counterstained with IRDye infrared secondary antibodies, which 
were visualized with the Odyssey infrared imaging system. 
 
5.19 IFN-α intracellular staining (ICS) 
DC or PBMC were suspended in 500 µl culture medium. Cells were treated 
with CpG ODN for 2 h and incubated with 10 µl of 1x Brefeldin A (BFA) to 
block  anterograde protein  transport.  After 2  h,  50  µl  of  20  mM  EDTA  was 
added  and  cells  were  incubated  overnight  at  4
C.  Thereafter,  cells  were 
washed with FACS wash buffer) and stained with anti-CD123 or anti-CD45RA 
antibody for 30 min. Subsequently, cells were fixed and permeabilized using 
BD Cytofix/Cytoperm Buffer and washed with BD perm/wash buffer, followed 
by staining for 60 min with anti-IFN-α PE antibody, that is described by the 
manufacturers to react with human IFN-α2b and to lesser extent with IFN-α7. 
After subsequent washing steps, staining was analyzed in FACS.  
 
5.20 IFN-α bioassay 
TLR agonists were added to DC to induce maturation or immature DC were 
used.  Supernatants  were  harvested  24  h  after  stimulation.  In  order  to 
quantitatively  determine  bioactivity  of  IFN-α  in  the  supernatants,  the  iLite 
Human  interferon  alpha  kit  was  used  according  to  the  manufacturer’s 
instructions.  
 
5.21 Statistical analysis 
FlowJo 7.5 software was used for generating FACS traces and for quantifying 
the mean flourescence intensities. p-values were calculated by ANOVA with 
Bonferroni’s correction or paired Student’s t-test. Differences were considered 
significant  at  p  <  0.05.  Data  were  analyzed  using GraphPad  Prism  5.0 for 
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6  Results  
6.1  Ex-vivo mo-pDC generation and study under hypoxia 
 
The  study  of  dendritic  cell  populations  under  the  influence  of  tumour 
microenvironmental factors required easily available cell sources for in vitro 
analysis of their function. Since pDC are rare in human blood and suitable cell 
lines do not exist, we wondered if these cells could be generated in vitro in a 
comparable  manner  as  described  for  mDC  [93].  Therefore,  in  this  study, 
monocytes  present  in  human  peripheral  blood  were  exploited  for  the 
generation of pDC-like cells using Flt3-L. The  mo-pDC thus obtained were 
analyzed  for  expression  of  surface  markers,  which  are  known  to  be 
differentially expressed on pDC compared to mDC. Mo-pDC mimicked pDC 
characteristics  but  retained  some  properties  of  monocytes  from  which  they 
were differentiated. In addition, the functional behaviour of mo-pDC, such as 
the ability to cause autologous lymphocyte proliferation and the capacity of 
mo-pDC to phagocytose apoptotic cells were determined. Mo-pDC expressed 
E2-2 as well as markers, which are under the transcriptional control of E2-2. 
Further, functional human pDC equivalents were generated by standardizing 
appropriate  cytokine  or  agonist  combinations  that  accentuate  IFN-α 
production.  Finally,  the  influence  of  hypoxia  on  pDC  generation  and  the 
resulting mo-pDC phenotype was investigated. 
 
6.1.1  Generation  and  characterization  of  mo-pDC  from  human  monocytes 
using Flt3-L 
 
Though the developmental origin of pDC was long considered to be entirely 
lymphoid, recently common myeloid progenitors were identified for both mDC 
and pDC [18]. Besides, Flt3-L was identified as a vital determinant for pDC 
generation in humans [22] and mice [18]. Therefore, we questioned whether 
pDC equivalents could be generated from monocytes using Flt3-L.  
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First, we checked for the expression of Flt3 to justify an attempt to generate 
pDC  equivalents  using  Flt3-L.  CD14
+  monocytes  isolated  from  human 
peripheral blood were stained with anti-Flt3 antibody and found to be positive 
for Flt3 by using FACS analysis (Figure 11A). 
 
 
 
Figure  11.  Morphology  of  mo-pDC  compared  to  mDC  and  macrophages  (A)  Human 
peripheral blood CD14
+ monocytes were stained with anti-Flt3 (CD135)-PE and its expression 
was quantitated by FACS. Isotype antibody stained monocytes served as a negative control, 
indicated  as  shaded.  (B)  Phase  contrast  images  indicate  the  morphology  of  mo-pDC, 
compared to mDC or macrophages (upper panels: 40x magnification, bars indicate 100 µm; 
lower  panels:  20x  magnification,  bars  indicate  20  µm).  Representative  FACS  traces  are 
shown. Experiments were repeated at least four times using monocytes of different donors.  
   
 
Subsequently, monocytes were cultured in the presence of Flt3-L for 5 days to 
generate  pDC-like  cells.  The  resulting  monocyte-differentiated  cells  were 
called  mo-pDC.  These  immature  mo-pDC  were  matured  with  CpG  ODN, 
which is a viral mimetic TLR9 ligand, while mDC were matured with the TLR4 
ligand  LPS.  The  numbers  of  DC  subsets  obtained  from  monocytes  were 
routinely determined. From 10
6 monocytes, 1.34 ± 0.63 x 10
5 mo-pDC were 
obtained, whereas the number of mDC was 4.18 ± 1.73 x 10
5. Furthermore, 
differences in morphology of mo-pDC versus mDC were routinely monitored 
using phase-contrast microscopy (Figure 11B).  
 
 PDC  were  reported  to  differ  in  their  expression  of  surface  markers  when 
compared to mDC [18, 94]. Immature myeloid CD11c
+ DC express TLR1-4 
and TLR6-8 while pDC express TLR1, TLR6, TLR7, TLR9, and TLR10 [94]. 
Therefore,  we  checked  for  differences  in  expression  of  surface  markers 
between  the  resulting  mo-pDC  and  mDC.  As  a  reference,  we  compared 
expression of important surface markers on mo-pDC with their expression on 
primary pDC isolated from human blood. Results      58 
 
   
Figure  12.  Mo-pDC  differ  in  surface  marker  expression  compared  to  mDC.  (A)  Ex-vivo 
untouched human pDC were isolated from different donors and activated for 24 hours with 
5µg/ml CpG-A 2336. Monocytes were differentiated with GM-CSF (100 ng/ml)/IL-4 (5 ng/ml) 
for 5 days and resulting mDC were matured with LPS. Monocytes were differentiated with 
Flt3-L (100 ng/ml) for 5 days and resulting immature mo-pDC were analyzed (dotted FACS 
traces) or matured with CpG ODN or LPS prior to analysis. The mo-pDC or mDC and primary 
pDC were stained with anti-BDCA4, CD123, CD11c, CD86, MHCI, CD45RA, CD1a, TLR7, 
TLR9, CXCR3 antibodies; (B) For some surface marker analysis mo-pDC were differentiated 
for up to 10 days (long-term mo-pDC). The mo-pDC or mDC, primary pDC and long-term mo-
pDC were stained with anti-TLR4, CD14 (here CD14 stained monocyte served as positive 
control indicated by dashed-line), CD11b antibodies. Expression of the surface markers was 
quantitated by FACS. Isotype antibody-stained mDC or mo-pDC or primary pDC or long-term 
mo-pDC  respectively  served  as  appropriate  negative  controls  (shaded  FACS  traces). 
Representative FACS traces are shown. Experiments were repeated at least four times using 
monocytes of different donors.  
 
   
In human blood and bone marrow, BDCA4 is exclusively expressed on pDC 
[95], while CD123 is also a prominent pDC marker [94]. Indeed BDCA4 and 
CD123  surface  expression  was  higher in  mo-pDC  compared  to  mDC,  and 
similar to primary pDC (Figure 12A). In contrast, CD11c and CD86 which are 
co-stimulatory  molecules  for  T  cell  activation  were  lower  in  mo-pDC  and 
primary  pDC  (Figure  12A).  In  addition  mo-pDC  generated  with  Flt3-L 
expressed MHCI, CD1a and higher CD45RA compared to mDC (Figure 12A).  Results      59 
Table 1: Quantification of surface marker expression  
 
 MFI ± S.D of surface marker expression displayed in Figure 11A, 12A, 12B, 
13D 
 
In  addition  mo-pDC  expressed  CD14,  a  monocytic  marker  and  TLR4,  a 
prominent mDC marker, which were however lost upon long-term culture for 
10 days. Mo-pDC expressed slightly lowered CD11b which was retained even 
through  long-term  culturing  (Figure  12B).  Primary  pDC  are  reported  to 
express TLR7 and TLR9 as opposed to myeloid DC [94]. Mo-pDC expressed 
high TLR7 compared to mDC and similar to primary pDC, whereas TLR9 was 
highly expressed on mo-pDC, but surprisingly also on mDC. Plasmacytoid DC 
Surface 
markers 
Monocytes          
CD135  68±11         
Surface 
markers 
mDC   Immature 
mo-pDC  
Mature  
mo-pDC  
Primary 
pDC  
Long-term 
mo-pDC 
BDCA4  40±9  64±0.4  45±6  51±2   
CD123  28±5  58±4  57±22  77±5   
CD11c  48±9  24±16  5±7  26±10   
CD86  55±14  9±0.7  10±1  4±2   
MHCI  189±45  72±51  113±83  84±3   
CD45RA  66±3  59±8  74±4  88±7   
CD1a  113±22  37±4  39±2     
CD14  165±36  640±74  390±87  77±4  40±15.8 
TLR4  1440±101  341±14  327±19  84±3  5±1.6 
CD11b  80±3  69±13  62±4  5±0.2  41±16.2 
TLR7  9±14  1±2  45±6  99±12   
TLR9  92±3  3±2.5  84±2.2  85±4   
CXCR3  7.2±4  10±1.2  14±1.2  60±6   
BDCA2  37±12.6    51±3.5  79±2   Results      60 
were characterized by CXCR3 expression [96]. Mo-pDC were slightly CXCR3 
positive compared to primary pDC, but CXCR3 was not expressed on mDC 
(Figure 12A). Quantification of the expression data is shown in Table 1.  
 
6.1.2  Expression of pDC developmental transcription factors by mo-pDC 
 
E2-2, a specific transcriptional regulator of the pDC lineage, was shown to be 
absent  in  monocytes,  macrophages  and  CD11c
high  CD11b
+  mDC  [25]. 
Therefore, we compared E2-2 protein expression in monocytes, which were 
frozen directly after isolation vs. mo-pDC generated from monocytes of the 
same donor. 
 
            
 
 
 
Figure  13.  Expression  of  pDC  lineage  determining  transcription  factor  E2-2  and  E2-2-
controlled BDCA2. (A) E2-2 protein expression in monocytes and immature mo-pDC from the 
same  donor  was  analyzed  by  Western  blotting.  Actin  serves  as  a  loading  control.  A 
representative blot of three independent experiments using different donors is shown. (B) E2-
2  mRNA  expression  in  mo-pDC  and  mDC  was  quantitated  by  qPCR.  Asterisks  marks 
statistically significant differences (p < 0.05). (C) ID2 mRNA expression in mo-pDC and mDC 
was quantitated by qPCR. Asterisk marks statistically significant differences (p < 0.05). (D) 
Monocytes were differentiated with Flt3-L or GM-CSF/IL-4 for 5 days and matured with CpG 
ODN or LPS. Resulting mo-pDC or mDC and primary pDC, immature mo-pDC (dotted FACS 
trace) were stained with the anti-BDCA2 antibody. BDCA2 expression was quantitated by 
FACS along with isotype controls. Representative FACS traces are shown. Experiments were 
repeated at least four times using monocytes of different donors.  
 
 
Mo-pDC  showed  strong  E2-2  protein  expression,  while  it  was  absent  in 
monocytes (Figure 13A). Furthermore, on mRNA level, mo-pDC expressed 
significantly  higher  E2-2  compared  to  mDC  (Figure  13B),  whereas  mRNA 
levels  of  ID2,  the  functional  inhibitor  of  E2-2  [26]  were  significantly  lower 
(Figure  13C).  E2-2  regulates  the  synthesis  of  BDCA2  [97],  which  is 
specifically expressed by pDC and internalizes antigen for presentation to T Results      61 
cells. Mo-pDC expressed high BDCA2 similar to primary pDC, whereas mDC 
were BDCA2 low (Figure 13D). 
6.1.3  Functional validation of mo-pDC 
 
Plasmacytoid  DC  were  reported  to  be poor  inducers  of  T  cell  proliferation, 
since they do not capture, process and load antigen as effectively as mDC 
[98]. Thus,  we  checked  for  the  ability of  mo-pDC  to  induce  proliferation  of 
autologous CD3
+ lymphocytes.  
 
 
 
Figure 14. Functional validation of mo-pDC versus mDC. (A) Human peripheral blood CD3
+ 
lymphocytes were stained with 0.5 µM CFSE and then cocultured with mature mo-pDC or 
mDC  from  the  same  donor  for  5  days.  Supernatants  were  harvested  and  the  CFSE 
fluorescence was quantitated by FACS. The dotted line denotes CD3
+ lymphocytes alone, the 
black line  denotes  CD3
+  lymphocytes  cocultured  with  Mo-pDC  and  the  gray line  denotes 
CD3
+ lymphocytes cocultured with mDC. Representative FACS traces of three independent 
experiments from different donors are shown. (B) Jurkat cells were labeled with 0.5 µM CFSE 
and killed with staurosporine for 2.5 h. Apoptotic Jurkat cells were then cocultured with mo-
pDC or mDC for 3.5 h. The cocultures were harvested, stained with anti-CD11b-APC and 
analyzed  by  FACS.  Q4  denotes  CD11b
-  CFSE
+  apoptotic  Jurkat  cells;  Q1  denotes  non-
phagocytic CD11b
+ CFSE
- DC and Q2 denotes phagocytic CD11b
+ DC that have taken up 
CFSE
+  Jurkat  cells.  Representative  FACS  traces  of  four  independent  experiments  from 
different donors are shown. 
 
Therefore, autologous CD3
+ lymphocytes were labelled with CFSE, which can 
be used to monitor lymphocyte proliferation, due to the progressive halving of 
CFSE fluorescence within daughter cells following each cell division. CFSE 
labelled CD3
+ lymphocytes were cocultured with DC subsets for 5 days and 
CFSE  fluorescence  was  quantitated  using  FACS.  We  found  that  CD3
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lymphocytes  cocultured  with  mo-pDC  proliferated  less,  whereas  CD3
+ 
lymphocytes from a mDC coculture proliferated for many generations (Figure 
14A). CD3
+ lymphocytes without DC coculture served as a control.  
 
We also compared the capability of the DC subsets to phagocytose apoptotic 
cells. Jurkat T cells were labelled with CFSE and treated with staurosporine 
for 2.5 h to undergo apoptosis. Apoptotic CFSE-Jurkat were then cocultured 
with mo-pDC or mDC for 3.5 h at 37 °C to allow phagocytosis. Cocultures 
were harvested and costained with CD11b-APC to label the DC. Mo-pDC had 
a  50%  lower  phagocytic  capacity  compared  to  mDC,  when  analyzing 
percentages  in  Q1,  showing  non-phagoctic  DC  compared  to  Q2,  which 
defines DC that engulfed apoptotic Jurkat cells as shown by CD11b-CFSE 
double-staining (Figure 14B). The mo-pDC population expressed less CD11b 
compared to mDC, which corroborates literature data [99]. 
6.1.4  IFN-α production by mo-pDC 
 
Since  pDC  were  reported  to  be  primary  producers  of  IFN-α  [6]  and  E2-2 
deficient sources failed to produce type I interferons in response to the viral 
mimetic CpG [97], we checked the expression of IFN-α in TLR9-ligated mo-
pDC or PBMC as controls. Therefore, we analyzed intracellular IFN-α [100] 
and  surface  expression  of  CD45RA  by  FACS.  First,  IFN-α  production  of 
human PBMC, containing primary blood pDC (Figure 15A), was compared 
with basal IFN-α of mo-pDC (Figure 15B). CD45RA
+ cells of the TLR9-ligated 
PBMC fraction may comprise of monocytes, CD33
+ myeloid cells, CD56
+ NK 
cells, T cells, BDCA4
+ DC and CD19
+ B cells [101]. The occurrence of pDC in 
peripheral  blood  of  human  males  is  0.11%  ±  0.06%  and  that  of  human 
females is 0.11% ± 0.07% [17]. Thus, IFN-α producing cells in the CD45RA
+ 
fraction of PBMC (~2%) were likely pDC. Whereas human pDC produced high 
IFN-α  after  TLR9  ligation  [102],  only  few  mo-pDC  showed  weak  IFN-α 
intracellular  expression.  To  be  used  in  research  and  therapy  as  pDC 
equivalents, mo-pDC must produce high IFN-α. Since E2-2 is necessary for 
IFN-α production [25] and ID2 proteins are the major inhibitors E2-2 [26], we 
checked whether decreasing ID proteins would improve the IFN-α production Results      63 
of mo-pDC. Interestingly, some vitamins were reported to have a profound 
impact on ID protein expression. 1α, 25-Dihydroxyvitamin D3 decreased both 
ID1 and ID2 expression [103].  
 
 
 
Figure 15. IFN-α production by mo-pDC. (A) PBMC were isolated from human peripheral 
blood. 5 µg CpG ODN was added to PBMC for 2 h to induce IFN-α production followed by 
incubation with BFA for 2 h to stop anterograde protein transport. PBMC were then stained 
with anti-CD45RA antibody, fixed, permeabilized, co-stained with the anti-IFN-α antibody and 
analyzed  by  FACS.  Representative  FACS  traces  are  shown.  Experiments  were  repeated 
three times using different donors. Data are the mean ± SEM. (B) Mo-pDC were generated 
from monocytes using Flt3-L alone or in combination with 3 µM vitamin D3 or 3 nM ATRA for 
5  days.  Cells  were  incubated  with  5  µg  CpG  and  intracellular  IFN-α  was  analyzed  as 
described for PBMC. Representative FACS traces are shown. Experiments were repeated 
three times using monocytes from different donors. Data are the mean ± SEM. (C) TNF-α 
produced by immature mo-pDC and mDC was quantitated in supernatants using the CBA 
Human inflammation  kit  by FACS.  Data  are the mean  ±  SEM  of three  experiments from 
different  donors.  Asterisk  marks  statistically  significant  differences  (p  <  0.05).  (D)  IRF-7 
mRNA expression was quantitated by qPCR after TLR-9 agonism in mo-pDC without and with 
TNF-α pre-stimulation. qPCR data shown are normalized to 18s, with values for unstimulated 
mo-pDC set to 1. Data are mean ± SEM of at least three experiments. (E) Immature mo-pDC Results      64 
were pretreated overnight with 10 ng/ml TNF-α. TNF-α pretreated mo-pDC and immature 
mDC  were  incubated  with  CpG  ODN  and  IFN-α  intracellular  staining  was  performed. 
Representative  FACS  traces  are  shown.  Experiments  were  repeated  three  times  using 
monocytes from different donors. Data are the mean ± SEM. (F) IFN-α1, 2 and 16 mRNA 
expression was quantitated by qPCR after TLR-9 agonism in mo-pDC without and with TNF-α 
pre-stimulation and in monocytes. (G) Bioactivity of IFN-α in the supernatants of  CpG-treated 
monocytes, mDC, primary pDC and mo-pDC (without and with TNF-α pre-stimulation) was 
quantitated using bioassay. Experiments were repeated three times using monocytes from 
different donors. Data are the mean ± SEM expressed in IU for 10
5 cells. Asterisks mark 
statistically significant differences (p < 0.05). 
 
Also, all-trans retinoic acid (ATRA) decreased ID1 and ID2 expression [104]. 
Accordingly, we investigated the effects of vitamin D3 or ATRA on mo-pDC 
differentiation  from  monocytes,  by  adding  them  together  with  Flt3-L.  IFN-α 
production  increased  during  differentiation  of  mo-pDC  with  Flt3-L  in 
combination with Vitamin D3 or ATRA (Figure 15B). 
6.1.5  Augmenting IFN-α production by mo-pDC 
 
Additionally, we asked whether triggering IFN-α upstream pathways enhances 
IFN-α production in mo-pDC. IRF7 is the critical transcriptional regulator of 
IFN-α  [105]  and  TNF-α  stimulates  IRF7  expression  through  NFκB  [106]. 
Checking  basal  TNF-α  produced  we  noticed  that  mo-pDC  produced  only 
insignificant amounts of TNF-α, especially when compared to mDC (Figure 
15C). Therefore we checked the outcome of TNF-α pre-treatment on IRF-7 
expression  and  further  on  CpG-elicited  IFN-α  expression.  Indeed,  IRF-7 
mRNA  expression  in  mo-pDC  was  increased  after  TNF-α  prestimulation 
(Figure 15D).  
 
In line, IFN-α production was strongly enhanced by TNF-α-priming and TNF-
α-priming  further  increased  CD45RA  expression  in  mo-pDC  (Figure  15E). 
During differentiation along with vitamin D3 or ATRA followed by priming with 
TNF-α, the number of cells producing high levels of IFN-α could be further 
enhanced.  Here,  IFN-α  produced  by  TNF-α-pretreated  mo-pDC  was 
compared  with  TLR9 ligated  mDC  (Figure  15E).  It  was  reported that  pDC 
express CD45RA in comparison to mDC [94], which is also reflected by our Results      65 
observations showing that mo-pDC are more CD45RA
+ compared to mDC  or 
with respect to their respective isotypes (Figure  15E and Figure  15B).  
 
Primary  human  pDC  are  reported  to  show  a  certain  IFN-α  mRNA  subtype 
profile  compared  to  myeloid  cells  [107].  We  checked  the  differential 
expression of representative IFN-α mRNA subtypes in mo-pDC after TLR9 
agonism.  TNF-α  prestimulation increased  the  mRNA  levels  of  all  the  three 
IFN-α subtypes that were tested (IFN-α1, 2, 16) (Figure 15F). Interestingly, 
there  was  a  nice  correlation  regarding  the  increase  in  IFN-α2  expression 
between the intracellular staining that specifically detects IFN-α2 and IFN-α2 
expression  on  mRNA  levels  with  respect  to  TNF-α  pre-stimulated  and  un-
primed mo-pDC.  
 
To finally confirm IFN-α production by mo-pDC, we first used a conventional 
ELISA to quantitatively validate the amount of IFN-α produced after TLR-9 
agonism.  However,  the  outcome  was  not  satisfactory  when  compared  to 
primary  pDC  (data  not  shown).  Since  there  was  no  information  available 
regarding the specific subtype of IFN-α detected in the ELISA, we next used a 
cell-based  bioassay  to  detect  biologically  active  IFN-α  regardless  of  the 
subtype.  IFN-α  production  was  quantitated  after  TLR-9  agonism  in 
monocytes,  mDC,  primary  pDC,  mo-pDC  without  and  with  TNF-α 
prestimulation  (Figure  15G).  As  expected,  primary  pDC  produced  high 
amounts of biologically active IFN-α after CpG administration. Un-primed mo-
pDC produced around 10% biologically IFN-α after TLR9 agonism compared 
to primary pDC, whereas secretion of bioactive IFN-α was strongly increased 
when mo-pDC were pre-stimulated with TNF-α (Figure 15G). Pre-stimulated 
mo-pDC produced more than 50% of bioactive IFN-α when compared with 
primary pDC. Thus, the data obtained by intracellular staining as well as by 
evaluating mRNA expression were reflected satisfactorily by the amount of 
secreted bioactive IFN-α. 
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6.1.6  Phenotypical differences between normoxia and hypoxia differentiated 
mo-pDC  
 
Inflammation,  infection  [108]  and  cancer  [109]  share  the  occurrence  of 
hypoxic  episodes.  Interestingly,  pDC  became  non-functional  when  they 
infiltrated human head and neck carcinoma tissue [14]. 
 
 
 
Figure 16. Expression of E2-2, ID2 and E2-2-controlled BDCA2 in normoxia and hypoxia 
differentiated  mo-pDC.  (A)  Monocytes  were  differentiated  with  Flt3-L  for  2  days  under 
normoxia and hypoxia (1% O2, 5% CO2) and E2-2 expression  was analyzed by Western 
blotting.  Actin  served  as  the  loading  control.  A  representative  blot  of  three  independent 
experiments using different donors is shown. (B) Immature mo-pDC from two donors were 
generated  under  normoxia  and  hypoxia  for  5  days.  E2-2  expression  in  these  cells  and 
monocytes from the same donors was analyzed by Western blotting. A representative blot of 
three independent experiments using different donors is shown. (C) E2-2 and ID2 mRNA 
expression  of  mo-pDC  differentiated  under  normoxia  or  hypoxia  for  2  or  5  days  was 
quantitated by qPCR. Experiments were repeated three times using monocytes of different 
donors. Asterisk marks statistically significant differences (p < 0.05). (D) Surface expression 
of  BDCA2  was  measured  by  FACS  after  staining  mo-pDC  generated  under  normoxia  or 
hypoxia  for  2  or  5  days  with  an  anti-BDCA2  antibody  along  with  isotype  controls. 
Representative FACS traces are shown. Isotype – shaded, day 2 - solid line, day 5 – dotted 
line. Experiments were repeated four times using monocytes of different donors. Data are the 
mean flourescence intensity ± SEM.  
 
Besides,  E2-2  is  downregulated in  human  neuroblastoma  cells  exposed  to 
hypoxia  [110].  Therefore,  we  investigated  the  impact  of  hypoxia  on  E2-2 
expression during differentiation of monocytes to mo-pDC. E2-2 expression 
was  low  in  both  normoxia  and  hypoxia  differentiated  mo-pDC,  which  were 
differentiated for two days with Flt3-L (Figure 16A).  
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However,  at  day  5,  E2-2  protein  was  completely  absent  in  hypoxia 
differentiated  mo-pDC,  compared  to  the  expression  of  E2-2  in  normoxia 
differentiated mo-pDC. E2-2 expression was absent in monocytes of the same 
donor  (Figure  16B).  Interestingly,  we  observed  protein  bands  at  a  lower 
molecular  weight  in  hypoxia  treated  mo-pDC,  which  were  absent  in 
monocytes  or  normoxic  mo-pDC.  We  speculate  that  these  might  be  E2-2 
degradation products, although this phenomenon was not reported before. In 
order to substantiate the E2-2 Western data, we analyzed expression of E2-2 
as  well  as  its  inhibitor  ID2  on  mRNA  level.  Concomitant  with  protein 
expression, E2-2 mRNA was similar 2 days after differentiation under hypoxia 
as compared to normoxia, but significantly decreased after 5 days. Strikingly, 
ID2 mRNA expression was increased under hypoxia already on day 2, but 
was substantially higher on day 5 (Figure 16C). 
 
Table 2:  Surface marker expression at normoxia versus hypoxia’ 
Surface markers  Mo-pDC 
  Normoxia 
 day2   Hypoxia  day2   Normoxia  day 5  Hypoxia day5 
BDCA2  48±4  21±5  51±3.5  22±2 
CD86      56±3.4  44±5 
MHCI      74±3  67±4.5 
 
MFI ± S.D of surface marker expression displayed in Figure 16D and 17C 
 
Since BDCA2 expression on pDC is under the control of the E2-2 transcription 
factor  [97],  we  checked  the  expression  of  BDCA2  on  mo-pDC  generated 
under  normoxia  and  hypoxia.  The  expression  of  BDCA2  was  lower  on 
hypoxia-differentiated  mo-pDC  compared  to  normoxia-differentiated 
counterparts,  and  the  expression  remained  largely  unchanged  when 
differentiated until day 5 (Figure 16D). Quantification of the expression data is 
shown in Table 2.  
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Importantly, substantiating E2-2 expression data, hypoxia differentiated mo-
pDC produced less IFN-α without (Figure 17A) as well as with TNF-α pre-
treatment as determined by intracellular staining (Figure 17B). 
 
 
 
 
Figure  17.  Mo-pDC  generated  under  normoxia vs.  hypoxia  express  different  surface  and 
functional markers. (A-E) Mo-pDC were matured with 5 µg CpG ODN for 24 h under normoxia 
or  hypoxia.  The  expression  of  IFN-α  without  (A)  or  with  (B)  10  ng/ml  TFN-α  overnight 
pretreatment was quantitated by staining with respective antibodies and analysis in FACS. 
Representative  FACS  traces  are  shown.  Experiments  were  repeated  at  least  three  times 
using monocytes of different donors. Data are the mean ± SEM. (C) Surface expression of 
CD86 and MHCI was analyzed in FACS (shaded - isotype, solid - normoxia, dotted - hypoxia). 
(D, E) Supernatants from mo-pDC generated under normoxia or hypoxia were harvested and 
IL-10 and TNF-α (D) as well as IL-1β and IL-6 (E) levels were quantitated with CBA using 
FACS. Data are the mean ± SEM from three independent experiments using monocytes of 
different donors. Asterisks mark statistically significant differences (p < 0.05).  
          
Hypoxia had a profound impact on the phenotype of human mDC [111] and 
down-regulated antigen uptake [112]. We thus compared the expression of 
CD86 and MHCI between mo-pDC differentiated under normoxia vs. hypoxia. 
Indeed  mo-pDC  differentiated  under  hypoxia  showed  decreased  surface 
expression of CD86 and MHCI (Figure 17C). Quantification of the expression 
data is given in Table 2. DC do not only present antigens, but also produce a 
number  of  inflammatory  cytokines  in  response  to  primary  and  secondary 
maturation  signals.  These  cytokines  participate in  shaping  T  cell immunity. Results      69 
Whereas mDC produce rather a Th1 cytokine response, pDC produce Th2 
signatures  and  mediate  Th2  differentiation  [113].  Measuring  inflammatory 
cytokine production using CBA, mo-pDC showed rather a Th2 profile as seen 
by  low  TNF-α  but  high  IL-10  production.  However,  when  mo-pDC  were 
generated under hypoxia, they showed strong elevation of TNF-α production 
but similar IL-10 levels (Figure 17D). Remarkably, under hypoxia, mo-pDC 
produced higher IL-1ß and IL-6 levels (Figure 17E). Thus, hypoxia seemed to 
shift  mo-pDC  from  producing  primarily  type  I  interferon  and  IL-10  to  the 
production of high levels of Th1 cytokines 
 
6.2  Study of mice pDC development under the influence of HIF-1 and 
hypoxia 
 
Based  on  the  findings  outlined  above  indicating  defective  development  of 
human plasmacytoid dendritic cells (pDC) from monocytes under hypoxia in 
vitro, we wondered whether HIF-1 was involved in pDC differentiation using 
mouse bone marrow cultures.  
 
6.2.1  Increased pDC frequency in HIF-1
fl/fl LysM-Cre mice 
 
We  noticed  that  pDC  generation  from  human  monocytes  was  attenuated 
under  hypoxia  (1%  O2).  This  is  associated  with  up-regulation  of  the 
transcription  factor  ID2.  ID2  opposes  the  function  of  the  pDC  lineage-
determining  transcription  factor  E2-2  [114]  and  is  under  the  transcriptional 
control  of  HIF-1,  at  least  in  neuroblastoma  cells  [115].  Therefore,  we 
questioned whether depletion of HIF-1 in pDC progenitors would affect their 
development. To approach this question we used mice that lacked HIF-1 in 
cells expressing lysozyme 2 (LysM), i.e. HIF-1
fl/fl LysM-Cre mice (Figure 18). 
The suitability of this system for studying HIF-1 effects on pDC development 
might  be  surprising,  since  at  least  mature  pDC  do  not  express  LysM  as 
demonstrated in LysM-Cre reporter mice. However, MDP, which differentiate Results      70 
into CDP and can further develop to pDC, express LysM although at a lower 
frequency compared to granulocytes or monocytes [116].  
 
 
 
Figure  18:  Generation  of  HIF-1fl/fl  LysM-Cre  mice.  Mice  expressing  Cre  recombinase 
downstream of the LysM promoter were crossed with mice genetically engineered to express 
HIF-1α flanked by LoxP sites. In the resulting HIF-1
fl/fl LysM-Cre mice, in LysM expressing 
cells, HIF-1α will be deleted by Cre recombinase upon recognition of the LoxP sites. On the 
other hand, in cells that do not express LysM, HIF-1α persists. 
 
6.2.2  Hypoxia/HIF-1 represses pDC differentiation from whole bone marrow 
in vitro 
 
We  used  the  HIF-1
fl/fl  LysM-Cre  system  to  investigate  the  function  of 
hypoxia-induced  HIF-1  in  pDC  development  in  detail.  We  started  with 
differentiating whole bone marrow single cell suspensions derived from HIF-
1
fl/fl LysM-Cre or control mice to pDC using fms-related tyrosine kinase 3-
ligand (Flt3-L) as described before [117] at high or low O2 supply. 
 
We used SiglecH as the determining marker for bone marrow-derived pDC 
[118, 119]. Most cells derived from the Flt3-L cultures were CD11b
- CD19
- 
CD11c
+ SiglecH
+ pDC that also expressed B220 (CD45RA) and CD317, also 
known as bone marrow stromal antigen-2 or tetherin (not shown). Whereas 
B220 and CD317 are highly but not exclusively expressed by pDC, SiglecH Results      71 
appears to be pDC-restricted and is else only expressed by certain subsets of 
tissue-resident macrophages [120].  
 
 
Figure  19.  Hypoxia-induced  HIF-1  suppresses  pDC  differentiation  in  vitro.  Bone  marrow 
single  cell  suspensions  were  harvested  from  C57BL/6  wildtype  or  HIF-1
fl/fl  LysM-Cre 
animals. 2 x 10
6 cells per ml were seeded in ultra-low attachment plates and incubated with 
200 ng/ml murine recombinant Flt3-L at 20% or 5% O2 for 9 d. (A) Representative FACS 
traces indicating relative amounts of CD11c
+ SiglecH
+ pDC in the CD11b
- CD19
- population of 
individual groups as indicated are shown. (B) Quantification of relative pDC amounts in bone 
marrow cultures. Individual data points and the mean value indicated by bars are shown, n ≥ 
7. (C) Relative mRNA expression of E2-2 and ID2 quantitated via qPCR is displayed. Data 
are means ± SEM, n = 4. (D) Relative amount of IFN- (normalized to the 20% O2 group for 
each genotype) in 5 µg/ml CpG-stimulated bone marrow cultures was determined by ELISA. 
Data are means ± SEM, n = 4. 
 
 
When  we  compared  the  generation  of  pDC  within  this  population  to  cells 
differentiated under 20% O2, we nevertheless noticed a strong reduction in 
SiglecH
+ cells (Figure 19A, B). Thus, hypoxia, even at 5% O2 interfered with 
bone marrow cell differentiation into pDC in vitro. This was clearly HIF-1-
dependent  as  cells  from  HIF-1
fl/fl  LysM-Cre  bone  marrow  effectively 
differentiated  to  pDC  even  at 5%  O2    (Figure  19A,  B).  This  differentiation Results      72 
pattern was reflected at the transcription factor level. Wildtype bone marrow 
cells differentiated for 9 days under 5% O2 expressed significantly lower levels 
of E2-2 mRNA and higher levels of ID2 compared to cells differentiated at 
20%  O2.  In  contrast,  we  observed  neither  a  difference  in  E2-2  nor  in  ID2 
mRNA levels of differentiated HIF-1
fl/fl LysM-Cre bone marrow-derived cells 
(Figure 19C). Importantly, activation of in vitro-generated pDC using 5 µg/ml 
CpGA  resulted in  diminished  production of IFN-α  when  pDC  from  wildtype 
bone marrow were cultured under 5% O2  but not when pDC from HIF-1
fl/fl 
LysM-Cre bone marrow were generated under 5% O2  (Figure 19D). Thus, 
limited pDC development due to HIF-1 was also demonstrated on a functional 
level. These data indicate  that  differentiation  of  pDC in  vitro under  low  O2 
levels, which corresponds to in situ normoxia in the bone marrow [30], limits 
pDC generation in a HIF-1-dependent manner.  
 
6.2.3  Altered  immune  cell  populations  in  Flt3L-expanded  bone  marrow 
cultures dependent on O2 supply 
 
Next, we asked for the fate of cells that did not differentiate into pDC under 
5% O2 since we did not observe significant changes in overall cell numbers 
from 20% O2 compared to 5% O2 cultures (not shown). First, when analyzing 
the  total  single  cell  population,  we  observed  a  significant  increase  in  the 
CD11b
high  CD115
-  cell  population,  which  corresponds  to  cDC  or  their 
precursors  [20]  in  5%  O2  versus  20%  O2  cultures  (Figure  20A,  B). 
Furthermore,  CD11b
-  CD115
+  cells,  which  likely  are  pDC  precursors  (not 
shown)  were  expanded  under  5%  O2,  whereas  CD11b
-  CD115
-  pDC  were 
significantly  reduced  (Figure  20A,  B).  These  differences  were  strongly 
accentuated  when  analyzing  only  the  specific  Flt3-L  expanded  single  cell 
population (Figure 20A, C). Our data imply that differentiation of bone marrow 
cells using Flt3-L in vitro gives rise to pDC under high levels of O2, whereas 
their numbers are attenuated at low O2 tension. In the latter case, the majority 
of pDC remain in a premature state, as reflected by reduced E2-2 expression 
(Figure 19C), but some cells seem to differentiate along an alternative route 
to cDC corresponding to increased expression of ID2 (Figure 19C). 
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Figure  20.  Differentiation  of  bone  marrow  under  5%  O2  blocks  pDC  differentiation  and 
expands cDC. Bone marrow single cell suspensions were harvested from C57BL/6 wildtype. 
2 x 106 cells per ml were seeded in ultra-low attachment plates and incubated with 200 ng/ml 
murine  recombinant  Flt3-L  at  20%  or  5%  O2  for  9  d.  (A)  Representative  FACS  traces 
indicating expression of CD11b and CD115 in either total single cells (right density plots) or 
the specific Flt3-L-expanded population (left density plots) are shown. (B) Quantification of 
individual cell populations from total single cells based on CD11b and CD115 expression. (C) 
Quantification of individual cell populations from the Flt3-L-expanded single cell population 
based on CD11b and CD115 expression. Individual data points and the mean value indicated 
by bars are shown, n = 4. Asterisks indicate significant differences between groups, * = p < 
0.05, ** = p < 0.01, *** = p < 0.01. 
 
Taken together, our data indicate that HIF-1 limits murine pDC differentiation 
from precursors in vitro. Low oxygen levels in the bone marrow might be an 
environmental explanation why pDC numbers in the body are low compared 
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6.3  Generation of regulatory T cells by IL-27 secreting DC under the 
impact of apoptotic cell-derived factors 
 
We  aimed  to  investigate  how  priming  of  DC  by  factors/exosomes  shed  by 
dying  versus  living  tumour  cells  affects  their  ability  to  initiate  tumour  cell-
specific cytotoxic T cell responses. Conditioned media of apoptotic, necrotic, 
or  viable  MCF7  cells  (ACM,  NCM,  VCM)  were  incubated  with  primary 
monocyte-derived human DC at a ratio of one tumour cell/DC. Higher ratios of 
tumour  cells/DC  induced  cell  death  in  DC,  especially  when  using  NCM 
(Figure 21A). 
 
 
 
Figure 21. Basal DC phenotype upon activation with tumour cell supernatants. (A), Human 
monocyte-derived DC were incubated with supernatants of viable (VCM), apoptotic (ACM) or 
necrotic (NCM) MCF-7 cells at different ratios as indicated (1:1 = supernatant of 2 x 105 MCF-
7 cells added to 2 x 105 DC) for 16 h, followed by staining with Annexin-V and propidium 
iodide (PI). Representative density plots of at least five independent experiments indicate size 
(FSC) and granularity (SSC) of the individual populations as well as the amount of dying cells 
(Annexin V versus PI). (B) Human monocyte-derived DC  were controls or incubated  with 
supernatants of viable (VCM), apoptotic (ACM) or necrotic (NCM) MCF-7 cells at a ratio of 1:1 
for 16 h followed by FACS-analysis of CD86, HLA-DR, HLA-ABC, CD80, CD83 and CD40 
surface expression. Representative histograms of at least four independent experiments are 
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This might be a mechanism of suppressing DC-dependent immunity by highly 
abundant dying tumour cells occurring e.g. after chemo/radiotherapy. Tumour 
cell  supernatant-primed  or  unstimulated  DC  were  co-cultured  with  IL-2-
enriched autologous PBMC for 3 d (Figure 22).  
 
6.3.1  Priming  with  apoptotic  tumour  cell  supernatants  suppresses  DC-
dependent tumour cell killing 
 
IL-2  enriched  PBMCs  were  mainly  T  cells,  lacking  significant  amounts  of 
mononuclear  phagocytes,  B  cells  or  NK  cells  (<  1%)  (not  shown). 
Lymphocytes  derived  from  these  co-cultures  were  then  added  to  living 
CellTracker  Blue-stained  MCF-7  cells  for  4  h  at  different  ratios  and  MCF-
7/lymphocyte co-cultures were assessed for tumour cell death.  
 
 
 
Figure 22. Experimental outline. Human monocyte-derived DC were controls or incubated 
with supernatants of viable (VCM), apoptotic (ACM) or necrotic (NCM) MCF-7 cells at a ratio 
of  1:1  (Supernatants  of  2  x  105  MCF-7  added  to  2  x  105  DC)  for  16  h.  Subsequently, 
supernatants were removed by washing and autologous T cell-enriched PBMC were added at 
a ratio of 10:1 (Tcells/DC) and cultured for another 3 d. The resulting polarized T cells were 
then co-cultured with living tumour cells for 4 h to determine cytotoxicity as described under 
Materials and Methods. Experimental interventions as outlined in the manuscript are indicated 
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Specific cytotoxicity was not observed in any experimental group up to a ratio 
of 1:2 (tumour cells to T cells) and reached a plateau at and above a ratio of 
1:5 (Figure 23A).  
 
 
 
Figure 23. Viable cancer cell supernatants prime whereas  supernatants  of apoptotic cells 
suppress specific cytotoxicity. (A) CellTracker Blue-stained MCF-7 cells were incubated with 
T cells from individual co-cultures at effector to target (E:T) ratios of 0.1:1, 0,5:1, 1:1, 1:2, 1:5, 
1:10, 1:20 for 4h. Cytotoxicity calculated for the ACM, VCM, NCM groups was compared to 
the control group. Data are means ± SEM from five individual donors. (B) CellTracker Blue-
stained MCF-7 cells were incubated with T cells from individual co-cultures as well as control 
T cells at ratios of 1:5 for 4 h. Cytotoxicity was calculated compared to non co-cultured MCF-
7. Data are means ± SEM from five individual donors. (C) CellTracker Blue-stained MCF7 
(black bars) or T47D (white bars) breast carcinoma cells were incubated with T cells from 
individual  co-cultures  at  1:5  ratio  for  4  h  prior  to  cytotoxicity  measurements.  (D)  T  cells 
derived from  VCM co-cultures  were  pre-incubated  for  1h  with  anti-CD8  or  the  respective 
isotype control. These T cell were used to determine cytotoxicity against living MCF-7 cells 
compared to T cells from control co-cultures. Data are means ± SEM from four individual 
donors. Asterisks indicate significant differences between groups, * = p < 0.05. p-values were 
calculated using ANOVA with Bonferroni’s correction. 
 
At  a  ratio of  1:5,  the  VCM  group  unexpectedly  showed  significantly  higher 
cytotoxicity toward living MCF-7 cells compared to the control group, whereas 
T  cells  from  the  NCM  group  were  not  cytotoxic  (Figure  23A).  In  contrast, Results      77 
cytotoxicity towards living MCF-7 cells was reduced below controls when T 
cells  from  the  ACM  group  were  used.  Cytotoxicity  in  this  group  was 
comparable to the basal cytotoxicity exhibited by IL-2 activated T cells without 
DC co-culture (Figure 23B). Importantly, VCM-induced cytotoxicity was cell-
specific, since alterations in cytotoxicity were not observed when lymphocytes 
from MCF-7 supernatant-primed DC co-cultures where added to T47D cells 
(Figure 23C). In addition, CD8 depletion experiments suggested that CD8
+ T 
cells were required for VCM-induced cytotoxicity in our system (Figure 23D). 
 
6.3.2  Accumulation of CD39/CD69-expressing FoxP3
+ Treg in ACM-primed 
co-cultures  
 
 
 
Figure 24. Relative amounts of T cell subsets and FoxP3-expressing Tregs. A-C, The profile 
of human T cell subpopulations from 3 d co-cultures with unprimed ACM-, VCM- or NCM-
primed human monocyte-derived autologous DC  were quantified using polychromatic flow 
cytometry. (A) Representative FACS traces for each co-culture setting are displayed. CD3
+ T 
cells  were  sub-classed  depending  on  expression  of  CD4  and  CD8.  CD4
+  T  cells  were 
analyzed for expression CD25
+ versus FoxP3
+. CD4
+CD25
+FoxP3
+ cells were further sub-
divided based on expression of CD39 and CD69. (B) Graphs display statistical quantitation of 
relative CD4 versus CD8 expression by CD3
+ T cells. Data displayed as mean ± SEM from Results      78 
five individual donors. (C) Statistical quantification of FoxP3-expressing CD4
+CD25
+ T cells 
(Treg). Individual data points and the mean of seven individual donors are shown.  
 
Since ACM-priming of DC suppressed cytotoxicity compared to the VCM- or 
NCM-primed  groups,  we  determined  whether  alterations  in  the  T  cell 
populations  occurred  and  if  such  alterations  accounted  for  suppression  of 
tumour  cell  killing.  We  analyzed  the  T  cell  profile  in  the  co-cultures  using 
polychromatic flow cytometry (Figure 24A). Regarding whole T cell numbers 
or basal T cell subsets, CD3
+ T cell levels (not shown) and the ratio of CD4
+ 
versus  CD8
+  T  cells  (Figure  24B)  remained  unchanged  throughout  the 
experimental  groups.  Next,  we  checked  for  a  possible  expansion  of  Treg, 
which were detected by intracellular staining of FoxP3 in CD4
+CD25
+ T cells 
(Figure  24A).  The  relative  amount  of  FoxP3
+  cells  in  the  different 
experimental groups was unchanged (Figure 24C). 
 
However, a different picture emerged when we investigated markers of Treg 
function. We stained Treg for expression of CD39 and CD69 (Figure 24A). 
The ectonucleotidase CD39 is expressed on naturally occurring FoxP3
+ Treg 
[121],  while  the  lymphocyte  activation  marker  CD69  was  shown  to  be 
expressed by Treg of cervical cancer patients [122].  
 
 
 
 
Figure  25.  Apoptotic  cell  supernatants  induce  CD39  and  CD69-expressing  Treg.  (A-C) 
Statistical quantification of CD39
+ CD69- Treg (AD) CD39- CD69
+ Treg (B) CD39
+ CD69
+ 
Treg (C). Individual data points and the mean of six individual donors are shown. Asterisks 
indicate significant differences between groups, * = p < 0.05, ** =p < 0.01. p-values were 
calculated using ANOVA with Bonferroni’s correction. 
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Whereas  the  expression  of  CD39  by  Treg  was  not  significantly  different 
between  the  co-culture  set-ups  (Figure  25A),  there  were  significant 
differences with regard to CD69 expression. CD69 was upregulated on Treg 
selectively in the ACM group (Figure 25B), which was most significant in the 
population co-expressing CD39 (Figure 25C). 
 
This regulation pattern was Treg-specific, since neither CD39 nor CD69 were 
significantly  upregulated  in  the  total  CD4
+CD25
+  population.  CD39  was 
usually not expressed by CD8
+ T cells. However, in approximately 20% of all 
donors, a small subpopulation of CD8
+ T cells expressed CD39, which was 
selectively  elevated  in  the  ACM  group,  whereas  CD69  expression  was 
unaltered  (not  shown).  Conclusively,  ACM-primed,  but  not  VCM  or  NCM-
primed DC significantly induce surface CD69 expression in co-cultured CD39
+ 
Treg. 
 
Next,  we  asked  if  the  accumulation  of  CD69-expressing  Treg  in  the  ACM 
group (Figure 25B, 25C) contributed to reduced MCF-7 cell killing (Figure 
23A). In a first approach, we depleted Treg from unprimed, ACM-primed or 
VCM-primed  co-cultures  using  commercial  kits,  before  subjecting  the 
remaining cells to the cytotoxicity assay.  
 
 
 
Figure 26. Purity of isolated CD4+CD25+ Treg. Left panel shows representative FACS trace 
indicating Foxp3 expression by CD4
+CD25
+ cells isolated from T cell co-cultures by magnetic 
bead  sorting.  Right  panel  displays  co-expression  of  CD39  in  subpopulations  of  isolated 
CD4
+CD25
+ T cells. T cell isolation was routinely controlled. Representative histograms of at 
least 6 independent experiments are displayed. 
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Of  the  isolated  CD4
+  CD25
+  T  cells,  40%  expressed  intracellular  FoxP3, 
largely co-expressed CD39, and thus likely represent functional Treg (Figure 
26).  
 
 
 
Figure 27. Treg confer ACM-induced suppression of cytotoxicity. (A) Treg were isolated from 
2  d  co-cultures  of  ACM-  or  VCM-primed  human  monocyte-derived  autologous  DC  using 
automated magnetic bead-sorting. Residual T cells were added back to co-cultures for 24 h. 
MCF7 cells were then incubated with T cells from the ACM or VCM groups with or without 
(Dpl) Treg as well as controls and cytotoxicity was analyzed. Data are means ± SEM from five 
individual donors. (B) Treg were isolated from 2 d co-cultures of ACM- or VCM-primed human 
monocyte-derived autologous DC using automated magnetic bead-sorting. Treg from ACM 
groups were then mixed with Treg-depleted T cells from VCM groups and vice versa and 
added back to the co-cultures for 24 h. MCF-7 cells were subsequently incubated with T cells 
from the Treg exchange groups (Ex) compared to non-exchanged groups and the control. T 
cells alone cultured without DC are indicated as control T. Data are means ± SEM from six 
individual  donors.  Data  are  means  ±  SEM from four  individual  donors.  Asterisks  indicate 
significant differences between groups, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. p-values 
were calculated using ANOVA with Bonferroni’s correction. 
 
Interestingly,  Treg-depleted  lymphocytes  from  the  ACM  group  were 
significantly  more  cytotoxic  compared  to  the  complete  lymphocyte  fraction, 
whereas  Treg-depletion  from  the  VCM-primed  co-culture  did  not  affect  the 
enhanced cytotoxicity observed in the VCM group (Figure 27A). 
 
Next, we asked whether the Treg-dependent suppression of cytotoxicity in the 
ACM  group  might  be  transferable.  We  isolated  Treg  from  ACM-primed  or 
VCM-primed co-cultures on day 2 and added the Treg from the ACM group to 
the  Treg-depleted  lymphocytes  of  the  VCM  group  and  vice  versa.  After 
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in  the  cytotoxicity  assay.  Indeed,  Treg  from  the  ACM  group  significantly 
suppressed cytotoxicity of Treg-depleted lymphocytes from the VCM group. 
On  the  other  hand  Treg  from  the  VCM  group  were  unable  to  suppress 
cytotoxicity  in  the  ACM  group  (Figure  27B).  Thus,  ACM-priming  provided 
FoxP3
+ T cells with the ability to suppress cytotoxicity, which was correlated to 
expression of CD39 and CD69. Depletion of these cells restored cytotoxicity 
to a level comparable to the VCM-primed group. 
 
 
 
 
Figure 28. CD39 depletion restores ACM-induced suppression of cytotoxicity. (A, B) CD39
+ 
cells were depleted from IL-2 enriched PBMC using anti-FITC microbeads after labeling with 
CD39-FITC antibody by automated magnetic bead-sorting. CD39-depleted (CD39 Dpl) T cells 
were added to co-cultures in the same ratio as unmodified T cells. (A) Representative FACS 
traces displaying the relative amount of CD39
+CD69
+ cells in CD4
+CD25
+FoxP3
+ T cells in 
ACM co-cultures of CD39-depleted and unmodified T cells. (B) MCF7 cells were incubated 
with T cells from the VCM group, the ACM group with or without CD39
+ T cell depletion (Dpl) 
as well as controls and cytotoxicity was analyzed. Data are means ± SEM from four individual 
donors. Asterisks indicate significant differences between groups, * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001. p-values were calculated using ANOVA with Bonferroni’s correction. 
 
 
We  explored  the  relationship  of  CD39  and  CD69-expressing  Treg  with 
suppression of cytotoxicity by further depleting CD39
+ cells from IL-2-enriched 
lymphocytes before adding them to DC co-cultures. T cells from these co-
cultures  displayed  lower  levels  of  Treg  and  completely  lacked  the  CD39
+ 
subpopulation,  indicating  that  CD39
+  Treg  upregulate  CD69  expression  in Results      82 
ACM  co-cultures,  whereas  upregulation  of  CD39  by  CD69
+  cells  could  be 
ruled  out  (Figure  28A).  Importantly,  depletion  of  CD39
+  T  cells  restored 
cytotoxicity in the ACM group as observed when depleting total CD25
+ cells 
(Figure 28B).  
 
6.3.3  S1P in ACM confers suppression of cytotoxicity by activating S1PR4 on 
DC 
 
Next,  we  performed  experiments  to  interfere  with  the  immunosuppressive 
properties of ACM in order to determine whether CD69 expression on FoxP3
+ 
T cells accounted for reduced cytotoxicity.  
 
 
 
 
Figure 29. ACM-dependent suppression of cytotoxicity functions through S1P receptors. (A-D) 
T  cells  were  co-cultured  with  control  or  ACM-primed  autologous  DC  with  or  without  the 
S1PR2/4 antagonist JTE-013 or the S1PR1/3 antagonist VPC23019. (A) Cytotoxicity induced 
by T cells from individual co-cultures towards living MCF-7 cells. Data are means ± SEM from 
six individual donors. (B) Representative FACS traces of CD39 and CD69 expression by Treg 
from the individual co-cultures. C,D, Statistical evaluation of CD39
+ CD69
+ Treg (C) or CD39- 
CD69
+ Treg (D). Individual data points and the mean of six individual donors are shown. 
Asterisks indicate significant differences between groups, * = p < 0.05, **.= p < 0.01, *** = p < 
0.001. p-values were calculated using ANOVA with Bonferroni’s correction.  
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We  asked  for the  factor(s) in  ACM  inducing  DC-dependent  suppression of 
cytotoxicity. Among the immunomodulatory factors secreted by AC is the lipid 
mediator S1P [67]. which was present in ACM (~ 10 nM, determined routinely 
[123].  S1P  couples  to  five  specific  receptors  (S1PR),  with  human  DC 
expressing S1PR1-4. 
 
Pharmacological inhibition of S1PRs during ACM-priming of human DC was 
used to test an impact of AC-derived S1P on DC-dependent T cell activation. 
JTE-013, a partial inhibitor for S1PR2 (IC50 1.5 µM) and a full inhibitor of 
S1PR4 (IC50 4.5 µM)  [124] significantly prevented ACM-induced suppression 
of  cytotoxicity  when  used  at  high  concentrations  (15  µM),  whereas  the 
S1PR1/3 inhibitor VPC23019 (1µM) did not (Figure 29A).  
 
 
 
Figure 30. S1PR4 on DC conveys ACM-dependent suppression of cytotoxicity. (A-C) T cells 
were  co-cultured  with  control  or  ACM-primed  autologous  DC  with  or  without  the  S1PR4 
antagonists CYM74 or CYM58 (A) Cytotoxicity induced by T cells from individual co-cultures 
towards  living  MCF-7  cells.  Data  are  means  ±  SEM  from  four  individual  donors.  (B) 
Representative FACS traces of CD39 and CD69 expression by Treg from the individual co-
cultures. (C) Statistical evaluation of CD39
+ CD69
+ Treg from individual co-cultures. Individual 
data points and the mean of four individual donors are shown. Asterisks indicate significant 
differences between groups, * = p < 0.05, **.= p < 0.01, *** = p < 0.001. p-values were 
calculated using ANOVA with Bonferroni’s correction.  
 
Diminishing cytotoxicity by the S1PR2/4 inhibitor JTE-013 correlated with a 
significant reduction of the CD39
+CD69
+ Treg population, whereas the relative 
proportion of CD69
+CD39- Treg population was unchanged (Figure 29B-D). Results      84 
To substantiate these findings and to explicitly identify the S1PR subtype we 
used  the  recently  described  highly  specific  S1PR4  antagonists  CYM50374 
and CYM50358 (200 nM each) [84]. Both substances reversed suppression of 
cytotoxicity  induced  by  ACM  priming  (Figure  30A)  and  decreased  the 
expansion of CD39
+CD69
+ Treg (Figure 30B, 30C).  
 
 
 
Figure 31. Addition of S1P to VCM mimics ACM (A,B) T cells were co-cultured with control, 
ACM-  or  NCM-primed  autologous  DC  with  or  without  adding  1  µM  S1P  (A),  Cytotoxicity 
induced by T cells from individual co-cultures towards living MCF-7 cells. Data are means ± 
SEM  from  six  individual  donors.  (B),  Statistical  evaluation  of  CD39
+  CD69
+  Treg  from 
individual  co-cultures.  Individual  data  points  and  the  mean  of  four  individual  donors  are 
shown. Asterisks indicate significant differences between groups, * = p < 0.05, **.= p < 0.01, 
*** = p < 0.001. p-values were calculated using ANOVA with Bonferroni’s correction.  
 
Moreover, supplying S1P (1 µM) during VCM-priming of DC suppressed the 
VCM-induced  cytotoxicity  (Figure  31A)  and  increased  the  amount  of 
CD39
+CD69
+  Treg  (Figure  31B).  These  findings  indicate  that  S1PR4 
activation by S1P in ACM enabled DC to induce CD69 expression on Treg, 
correlating to suppressed cytotoxicity. 
 
6.3.4  ACM-primed DC secrete IL-27 to activate suppressive Treg 
 
Apparently  tumour-associated  DC  exist  in  different  functional  states 
depending on the microenvironment they are exposed to (i.e. tumour mass 
versus  TDLN)  [59].  We  asked  which  parameters  of  DC  functionality  were 
altered by  ACM.  For  maturation  markers,  each tumour  supernatant  slightly 
induced HLA-DR expression on DC as compared to the control group. CD80 Results      85 
expression remained unchanged. CD83 expression was induced slightly only 
in the ACM group. HLA-ABC expression remained largely unchanged, except 
for a reduction with NCM, whereas CD86 and CD40 expression were strongly 
induced  with  all  conditioned  media  (Figure  21B).  Conclusively, 
immunosuppression  by  ACM-priming  was  not  dependent  on  altered 
maturation.  
 
Apart from maturation, functional markers of tolerogenic DC include proteins 
such  as  IDO.  IDO  is  an  intracellular  enzyme  involved  in  tryptophan 
metabolism  along  the  kynurenine  pathway.  IDO  has  been  implicated  in 
tolerance induction mediated through depleting tryptophan, which halts T cell 
proliferation  and/or  by  accumulation  of  3-hydroxykynurenine  or  3-
hydoxyanthranilic acid, which is toxic to lymphocytes [125]. IDO is expressed 
by  DC  interacting  with  AC  [126].  We  saw  a  marked  upregulation  of  IDO 
protein expression in DC treated with ACM (Figure 32A). 
 
 
 
 
Figure 32. ACM-induced IDO expression and the effect of IDO inhibition on ACM-induced 
suppression  of  cytotoxicity.  (A)  IDO  protein  expression  in  untreated  DC  (C),  or  in  ACM-
stimulated DC (ACM) from the same donor was analyzed by Western blotting. Actin serves as 
a  loading  control.  Representative  blot  of  three  independent  experiments  using  different 
donors is shown. (B) DC were unprimed or treated with or treated with VCM, NCM or ACM 
with  or  without  pre-incubation  with  1mM  of  the  IDO  inhibitors  D-1MT  (dextro-1-methyl 
tryptophan) or L-1MT (levo-1-methyl tryptophan) for 2 h. These DC were co-cultured with 
autologous  T  cells  for  3  d.  Cytotoxicity  of  resulting  T  cells  towards  living  MCF-7  cells  is 
shown. Cytotoxicity was calculated compared to non co-cultured MCF-7. Data are means ± 
SEM, n = 5. Individual data points and the mean of five individual donors are shown. Asterisks Results      86 
indicate significant differences between groups, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. p-
values were calculated using ANOVA with Bonferroni’s correction. 
 
Thus,  we  asked  whether  this  enzyme  had  any  impact  on  the  observed 
immunosuppression in the ACM co-cultures. We found that neither inhibition 
of IDO1 using D-1MT nor IDO2 with L-1MT was able to significantly restore 
cytotoxicity  compared  to  the  VCM  group  (Figure  32B).  However,  in  some 
experiments L-1MT had minor efficiency in elevating cytotoxicity.  
 
 
 
Figure 33. Influence of ACM on cytokine induction. (A-C) Human monocyte-derived DC were 
controls or incubated with VCM, NCM or ACM with or without the addition of JTE-013 (15 µM) 
or  VPC23019  (1µ  M)  for  16  h.  (A)  Secreted  cytokines  were  quantified  using  Human 
inflammatory cytokine Cytometric Bead Arrays. Quantification of IL-6, TNF-α, IL-12 and IL-10 
in DC supernatants is shown. Individual data points and the mean of five individual donors are 
shown.  (B)  Relative  mRNA  expression  of  ebi3,  p28  and  p35  quantitated  via  qPCR  is 
displayed. Data are means ± SEM from four individual donors. (C) ELISA quantification of IL-
27 protein secretion by DC from the individual groups is shown. Individual data points and the 
mean of five individual donors are shown. Asterisks indicate significant differences between 
groups, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. p-values were calculated using ANOVA 
with Bonferroni’s correction.  
 
Next we measured the release of inflammatory cytokines by Cytometric Bead 
Arrays  using  flow  cytometry  16  h  after  stimulation  of  DC  with  tumour  cell Results      87 
supernatants, including ACM stimulation in the presence of S1PR antagonists 
to  detect  meaningful  regulation  patterns.  We  did  not  observe  release  of 
significant  amounts  of  IL-12,  although  there  was  a  tendency  towards 
enhanced  IL-12  secretion  by  VCM-primed  DC  versus  their  ACM-primed 
counterparts (Figure 33A). 
 
IL-6 showed a trend towards enhanced production in the VCM group, which 
was  significant  for  TNF-.  However,  compared  to  ACM,  secretion  of  these 
cytokines was enhanced when using VPC23019, but not JTE-013, which did 
not  correlate  with  changes in  cytotoxicity.  Release  of  the  anti-inflammatory 
cytokine IL-10 followed a meaningful regulation pattern, since it was enhanced 
with  ACM  treatment  as  compared  to  all  other  treatments  except  for  the 
ACM+VPC23019 group (Figure 33A). However, release of IL-10 was in the 
low pg/ml range, largely restricting its potential impact in the co-culture setting. 
 
Searching  for  other  candidates,  we  recognized  that  among  cytokines  that 
shape  T  cell-mediated  immunity  IL-12  family  members  play  a  central  role. 
Despite having structurally similar subunits or even sharing identical subunits, 
these cytokines may enhance generation of Th1, Th17 or Treg [127].  
 
For instance, the protein encoded by Epstein-Barr virus induced gene 3 (ebi3) 
is a common subunit of IL-35 and IL-27, both of which are recently emerging 
cytokines implicated in T cell biology. Analyzing mRNA expression in human 
DC  in  analogy  to  secreted  cytokines  as  mentioned above,  we  noticed  that 
ebi3 mRNA was upregulated upon incubation of DC with ACM after 16 h. This 
was  S1PR2/4-dependent  as  determined  by  using  JTE-013  or  VPC23019 
along  with  ACM  (Figure  33B).  Since  expression  of  p28  and  p35,  the 
complementary subunits for IL-27 or IL-35 respectively, were unchanged with 
ACM  treatment  (Figure  33B);  we  quantified  secretion  of  ebi3  subunit 
containing cytokines using commercial ELISA kits. While detecting IL-35 was 
unsuccessful,  IL-27  was  significantly  upregulated  in  ACM-treated  DC 
compared  to  controls  or  VCM-primed  DC.  This  effect  was  completely 
abolished when inhibiting the S1PR2/4 (Figure 33C).  Results      88 
 
 
Figure 34. ACM induces IL-27 in DC in a S1PR4-dependent manner to generate Treg. (A-C) 
T cells were co-cultured with control, VCM- or ACM-primed autologous DC with or without the 
addition of an IL-27-neutralizing antibody (-IL27) or the isotype control (IgG). (A) Cytotoxicity 
induced by T cells from individual co-cultures towards living MCF-7 cells. Data are means ± 
SEM from  seven  individual  donors.  (B)  Representative  FACS  traces  of  CD39  and  CD69 
expression  by  Treg  from the  individual  co-cultures.  (C)  Statistical  quantification  of  CD39
+ 
CD69
+ Treg. Individual data points and the mean of seven individual donors are shown, n = 7. 
Asterisks indicate significant differences between groups, * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. p-values were calculated using ANOVA with Bonferroni’s correction.  
 
To validate the role of IL-27 released by DC in generating suppressive Treg, 
we blocked its function by adding a specific IL-27-neutralizing antibody versus 
a non-specific isotype control (each 1 µg/ml) to DC before adding autologous 
T  cells.  Blocking  IL-27  potently  reduced  ACM-induced  suppression  of 
cytotoxicity  as  compared  to  the  isotype  control  (Figure  34A),  which  again 
correlated  with  attenuated  ACM-induced  CD69  expression  in  CD39
+  Treg 
(Figure 34B, 34C).  
 
We wondered whether induction of cell death using immunogenic drugs would 
deliver comparable results with regard to IL-27-dependent CD39
+ CD69
+ Treg 
expansion. When we compared effects of supernatants of oxaliplatin-treated 
MCF-7 cells (OXA-ACM) with staurosporine-treated cells (STS-ACM) on DC, 
we  noticed  significantly  lower  ebi-3  expression  in  OXA-ACM-treated  DC 
(Figure 35A). Correlating to that, we observed reduced CD69
+CD39
+ Treg in 
OXA-ACM co-cultures compared to STS-ACM co-cultures (Figure 35B). 
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Figure 35. OXA-ACM exhibits higher cytotoxicity compared to STS-ACM. (A-C) MCF-7 cells 
were subjected to 0.5 µg/ml staurosporine (STS) or 30 µM oxaliplatin (OXA) to induce cell 
death and supernatants were harvested. (A) Expression of ebi3 mRNA in DC treated with 
STS-ACM or OXA-ACM compared to control DC is displayed. Data are means ± SEM from 
four individual donors. (B) T cells were co-cultured with control, VCM-, or STS-ACM- or OXA-
ACM-primed autologous DC. Representative FACS traces of CD39 and CD69 expression by 
Treg  from  the  individual  co-cultures  are  shown.  (C)  Cytotoxicity  induced  by  T  cells  from 
individual co-cultures towards living MCF-7 cells. Data are means ± SEM from five individual 
donors. Asterisks indicate significant differences between groups, * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001. p-values were calculated using ANOVA with Bonferroni’s correction.  
 
This difference in the Treg population was  again reflected by the cytotoxic 
potential  of  co-cultured  T  cells  as  T  cells  from  the  OXA-ACM  group  were 
significantly  more  cytotoxic  compared  to  T  cells  from  the  STS-ACM  group 
(Figure 35C). Hence, also in our hands oxaliplatin induced immunogenic cell 
death, which correlated with reduced ebi-3 expression and thus, likely IL-27 
production, as well as reduced CD69 expression on CD39
+ Treg. 
 
6.3.5  Suppression of cytotoxicity is reduced by interference with adenosine 
generation  
 
We  went on  to identify  a  mechanism  of  how Treg  suppressed  cytotoxicity, 
which likely required functional CD8
+ T cells. Analyzing the contents of the T 
cell-derived cytokines IFN-γ, IL-10, IL-4, IL-17, IL-2 from co-cultures after day 
3, did not reveal any regulation patterns (not shown). Immunosupression by 
Treg can be mediated by various mechanisms including production of effector 
cytokines such as TGF-β and IL-10 [128]. 
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Figure 36. IL-10 and TGF-β are not involved in suppressing cytotoxicity. (A) Magnetic bead-
isolated Treg from the individual co-cultures at day 3 were analyzed for relative IL-10 mRNA 
expression  via  qPCR.  Data  are  means  ±  SEM  from  five  individual  donors.  (B)  TGF-β 
expression in CD4
+CD25
+FoxP3
+ Treg from whole individual co-cultures was determined via 
intracellular  staining  and  polychromatic  flow  cytometry.  Statistical  evaluation  TGF-β-
dependent mean fluorescence intensity (MFI) is displayed. Data are means ± SEM from four 
individual donors. (C) T cells were co-cultured with control, VCM- or ACM-primed autologous 
DC with or without the addition of a TGF-ß-neutralizing antibody (-TGF-ß) or the isotype 
control (IgG). Cytotoxicity induced by T cells from individual co-cultures towards living MCF-7 
cells was determined. Data are means ± SEM from five individual donors. Asterisks indicate 
significant differences between groups, * = p < 0.05, ** =p < 0.01. p-values were calculated 
using ANOVA with Bonferroni’s correction. 
 
We checked the expression of these cytokines specifically in Treg using two 
different approaches. IL-10 expression was determined on mRNA level after 
isolation  of  Treg  from  the  different  treatment  groups  as  mentioned  above, 
whereas TGF-β was quantified by intracellular staining using flow cytometry. 
Unexpectedly, neither IL-10 (Figure 36A) nor TGF-β expression (Figure 36B) 
was  significantly  altered  in  Treg  upon  ACM-stimulation.  In  addition, 
neutralizing TGF-ß in ACM co-cultures with a specific antibody did not restore 
cytotoxicity  (Figure  36C),  thus  ruling  out  TGF-ß  as  a  candidate  for 
immunosuppression in this set-up. 
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Figure 37. Relative expression of ectonucleotidases CD39 or CD73 by T cells. (A) Relative 
FACS traces indicating CD39
-expression by CD8
- T cells from control co
-cultures. Gating on 
these cells and evaluation of FoxP3 versus CD73 expression reveals that CD39 is selectively 
expressed by CD4
+ Treg. (B) Relative FACS traces indicating CD73
-expression by CD8
+ T 
cells from control co
-cultures. Gating on these cells and evaluation of FoxP3 versus CD39 
expression  reveals  that  CD73  is  selectively  expressed  by  CD8
+  FoxP3
-  T  cells.  (C) 
Quantification of CD73 expression by CD8
+ T cells from individual co-cultures as indicated 
analyzed  by  flow  cytometry  is  displayed.  Individual  data  points  and  the  mean  of  seven 
individual donors are shown. Asterisks indicate significant differences between groups, * = p < 
0.05, ** =p < 0.01. p-values were calculated using ANOVA with Bonferroni’s correction.  
 
Another  molecule  known  for  its  immunosuppressive  function  is  the  purine 
nucleotide adenosine. Extracellular adenosine inhibits various T cell functions 
among them proliferation and/or priming of CD8
+ T cells [129]. We saw the 
involvement  of  CD8  T  cells  in  VCM-induced  cytotoxicity  (Figure  23D). 
Adenosine  is  produced  by  the  sequential  breakdown  of  ATP  by  e.g.  the 
ectonucleotidases CD39 and CD73.  
 
Previous reports indicated that CD39 is expressed by human Treg, whereas 
CD73 might not be co-expressed by these cells [130], which we confirmed in 
our system. Whereas CD39 was mainly expressed by CD4
+ Treg, which did 
not express CD73 (Figure 37A), CD73 was expressed by CD8
+ cells (Figure 
37B). We did not observe alterations in CD73 expression by CD8
+ T cells 
upon priming with either ACM or VCM (Figure 37C).  
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Figure 38. Inhibition of ectonucleotidases and adenosine receptor A2a restores cytotoxicity 
(A) T cells were co-cultured with control, VCM- or ACM-primed autologous DC with or without 
addition of the CD39 inhibitor (ARL) (250 µM), the CD73 inhibitor (APCP) (100 µM) or the 
adenosine receptor A2a (CSC) (10 mM). Cytotoxicity induced by T cells from individual co-
cultures towards living MCF-7 cells is shown. Data are means ± SEM from six individual 
donors. Asterisks indicate significant differences between groups, * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001. p-values were calculated using ANOVA with Bonferroni’s correction.  
 
Adenosine  seemed  to  be  clearly involved in  ACM-  induced  suppression  of 
cytotoxicity in our system. Addition of the CD39 inhibitor ARL67156 as well as 
the CD73 inhibitor APCP [86] as well as the adenosine receptor A2a inhibitor 
CSC [87]  to the co-cultures on day 2 restored cytotoxicity brought about by 
ACM-priming (Figure 38A). These suggested a role for adenosine generation 
and  function in  our  system.  None  of  the  compounds  altered expression  of 
CD39  by  Treg  or  of  CD73  by  CD8
+  T  cells  except  for  the  CD73  inhibitor 
APCP,  which  diminished  surface  expression  of  CD73  on  CD8
+  T  cells,  an 
unrecognized mechanism of its action (Figure 38B). 
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Figure 39. Surface profiling of doublet T cell populations. (A) Representative FACS traces 
show analysis of the FSC-W gated CD3
+ doublet population of cells from control, ACM- or 
VCM-primed co-cultures. CD4
+CD8
+ events in the doublets, most likely aggregates of CD4
+ 
and  CD8
+  T  cells  were  analyzed  for  expression  of  CD25,  FoxP3,  CD39  and  CD69. 
Representative FACS traces are shown.  
 
So far, we observed accumulation of CD69-expressing CD39
+ Treg in ACM-
primed co-cultures, which directly correlated to suppression of cytotoxicity. We 
wondered  whether  CD69  expression  on  Treg  might  be  directly  involved  in 
suppressing CD8
+ T cell function.   
 
The  concerted  action  of  CD39  and  CD73  seemed  to  be  important  for 
suppression of cytotoxicity induced by ACM-priming although these molecules 
were  expressed  by  different  cells.  CD69  is  a  member  of  the  c-type  lectin 
family, proteins which regulate cell-cell contact. We hypothesize that CD69-
bearing  CD39
+  Treg  might  establish  direct  contact  with  CD73-expressing 
CD8
+  T  cells  to  ensure  efficient  adenosine  generation  and  subsequent 
immunosuppression. 
 
To  approach  this  question,  we  analyzed  CD4
+CD8
+  events  within  CD3
+ 
doublets from  control,  ACM  and  VCM  co-cultures  using  polychromatic  flow 
cytometry.  These  CD4
+CD8
+  doublets  were  generally  enriched  in Results      94 
CD25
+FoxP3
+ cells expressing CD69 (not shown). However this enrichment 
was strongly pronounced in the ACM group compared to the control or VCM 
groups (Figure 39A, 40A). 
 
 
 
Figure  40.  CD39/CD69-expressing  Treg  are  enriched  in  CD4+CD8+  doublet  events.  (A) 
Quantification of CD25
+FoxP3
+CD39
+CD69
+ events in the doublet CD4
+CD8
+ population is 
shown. Individual data points and the mean of seven individual donors are shown. (B) The 
amount of CD4
+ and CD8
+ positive events in the CD3
+ doublets was quantified. Individual 
data  points  and  the  mean  of  seven  individual  donors  are  shown.  (C)  The  ratio  of 
CD25
+FoxP3
+CD39
+CD69
+ events in doublets versus singlets in ACM-, VCM- or control co-
cultures is shown. Individual data points and the mean of seven individual donors are shown.  
Asterisks indicate significant differences between groups, * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. p-values were calculated using ANOVA with Bonferroni’s correction or paired Student’s 
t-test. 
 
Additionally,  there  was  a  significant  reduction  in  enrichment  of  CD4
+CD8
+ 
events  within  whole  CD3
+  doublets  in  the  ACM  group  as  compared  to  the 
control  or  VCM  co-cultures  (Figure  40B).  This  pattern  was  also  observed 
when  analyzing  whether  CD25
+CD39
+CD69
+  events  were  specifically 
enriched  in  doublets  as  compared  to  the  singlet  population  (Figure  40C). 
Interestingly,  though  Treg  numbers  were  generally  lower  in  doublets 
compared  to  singlets,  the  percentages  of  CD25
+CD39
+CD69
+  events  was 
higher in doublets compared to singlets.  
 
As  a  next  step,  we  wondered  whether  antibody-mediated  CD69  depletion 
would  reduce  CD4
+CD8
+  doublet  formation  as  well  as  enrichment  of 
CD25
+CD39
+CD69
+ events in doublets of the ACM group. 
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Figure 41. CD69 neutralization reduces the doublet T cell population (A) ACM co-cultures 
were treated with either anti-CD69 or the isotype control on day 2. Representative FACS 
traces show CD39 and CD69 expression in CD4
+ T cells on day 3. (B) The amount of CD4
+ 
and CD8
+ positive events in CD3
+ doublets in ACM-co-cultures with anti-CD69 (-CD69) or 
the isotype control (IgG) on day 3 is displayed. Individual data points and the mean of six 
individual donors are shown, n = 6. (C) The ratio of CD25
+FoxP3
+CD39
+ events in doublets 
versus singlets of ACM-co-cultures with anti-CD69 (-CD69) or the isotype control (IgG) on 
day 3 is shown. Individual data points and the mean of six individual donors are shown. 
Asterisks indicate significant differences between groups, * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. p-values were calculated using ANOVA with Bonferroni’s correction or paired Student’s 
t-test.  
 
CD69  depletion  was  efficiently  induced  in  ACM  co-cultures  using  CD69 
antibody compared to the isotype, without altering the total amount of CD39
+ 
cells (Figure 41A). Strikingly, CD4
+CD8
+ doublets (Figure 41B) as well as 
CD25
+CD39
+ events in the doublet population (Figure 41C) of the ACM group 
were decreased upon CD69 neutralization. These findings provide a first hint 
that  CD69-expressing  Treg  may  bind  to  an  unidentified  ligand  on  CD8
+  T 
cells,  which  might  aid  efficient  adenosine  production  and  subsequent 
suppression of cytotoxicity. 
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7  Discussion 
7.1  mo-pDC  generation  ex-vivo  brought  about  by  evoking  pDC 
developmental genes 
 
We  successfully  generated  donor-specific  plasmacytoid  DC  equivalents  ex 
vivo  from  monocytes,  which  can  be  further  manipulated  by  environmental 
stimuli such as hypoxia, vitamin D3 or ATRA. The availability of easy systems 
to generate mDC ex vivo made them attractive for cancer therapy with the 
advantage of manipulating DC during differentiation. Another subset of DC, 
the pDC are appreciated for their importance in therapy, to prevent allograft 
rejection, rheumatoid arthritis [15, 16] or cancer [12]. In mice, bone marrow 
cells have been used to generate pDC using Flt3-L [99], but in humans there 
is a need to generate pDC from easily available precursors instead of using 
cells  from  cumbersome  sources  such  as  bone  marrow-derived  cells. 
Peripheral  blood  monocytes  constitute  an  available  source  of  cells  from 
human  subjects  to  generate  mo-pDC  cells  as  demonstrated  in  this  study. 
Since monocytes produce basal levels of GM-CSF [101], we asked whether 
differentiating them with Flt3-L could generate pDC equivalents. Our method 
offers  the  possibility  to  manipulate  these  cells  during  differentiation  and  to 
study the impact of various stimuli on their differentiation and maturation.  
      
Flt3-L  is  a  pDC-determining  cytokine  [22].  The  expression  of  Flt3  on 
peripheral  human  monocytes  made  them  responsive  to  Flt3-L.  Mo-pDC 
obtained  after  differentiation  of  monocytes  with  Flt3-L  exhibited  surface 
marker profiles that characterize pDC such as high CD123 and BDCA4 but 
lower  CD11c,  CD86  and  TLR4  expression.  Whereas  pDC  do  not  express 
CD14 [131] the expression of CD14 seen in mo-pDC likely points to the partial 
retention of some monocyte phenotypical features, which was however lost 
upon long-term culture up to 10 days. Mo-pDC showed high TLR7 and TLR9 
expression, making them likely candidates for being responsive to viruses and 
produce IFN-α. Though also mDC express high TLR9 levels, they express 
less  IFN-α,  as  they  are  probably  deficient  in  expression  of  proteins  in  the Discusssion      97 
upstream IFN-α pathway that are under transcriptional control of E2-2. Mo-
pDC  also  expressed  CXCR3  like  their  primary  pDC  counterpart,  though in 
lower quantity. However, CXCR3 expression was higher compared to mDC. 
Thus, mo-pDC are likely to respond to CXCR3-dependent trafficking. 
 
 
 
 
Figure 42: Transcription factors (TF) profile during pDC development under normoxia and 
hypoxia. (Left)  In general, pDC express high levels of E2-2 but a low ID2. Under normoxia, 
the levels of these transcription factors are unaltered. In the absence of adequate levels of 
ID2, the E2-2 molecules are free to dimerize. The resulting, active E2-2 dimer binds to E-Box 
element in genes such as Irf-7/8, Spi-B and activates their transcription. (Right) However, 
under hypoxia, HIF induces ID2. In the presence of increased levels of E2-2 inhibiting TF ID2, 
E2-2 monomers are not able to dimerize. Since the E-Box is not occupied by the E2-2 dimer, 
the  gene  expression  can  not  be  initiated.  Hence,  the  expression  genes  involved  in  pDC 
development and function are switched off under hypoxia.  
 
 
E2-2 was identified as the critical pDC lineage determining marker, which is 
absent  in  conventional  myeloid  DC,  monocytes  and  macrophages  [25].  In 
humans it binds directly to the regulatory regions of multiple genes that are 
enriched in pDC such as ILT7, BDCA2, Spi-B, IRF7 and IRF8. A prominent 
E2-2 protein expression was observed in mo-pDC, whereas E2-2 expression 
was  absent  in  monocytes  of  the  same  donor.  Also,  mo-pDC  expressed 
significantly higher E2-2 and lower ID2 mRNA levels compared to mDC. Thus, 
mo-pDC might qualify as pDC equivalents, as they also differ in expression of 
pDC lineage markers compared to mDC generated from the same donor. Flt3-
L most likely prompted E2-2 induction. Mo-pDC differentiated under hypoxia 
(1% O2) for 2 days had similar levels of E2-2 like those differentiated under Discusssion      98 
normoxia, but with continuing differentiation under hypoxia, E2-2 expression 
was completely lost. It is interesting to note that E2a, another E protein like 
E2-2, was down-regulated after 1 to 3 days of exposure to hypoxia (1 % O2) 
[132].  Likely,  E2-2 as  well  as  E2a  was  decreased under  hypoxia  by  a  yet 
unknown  mechanism.  ID  proteins  are  the  naturally  occurring  dominant 
negative inhibitors for E proteins. ID2 is a functional inhibitor of E2-2 (Figure 
42) in human placenta [26]. On differentiation under hypoxia, we noticed that 
ID2 mRNA expression was progressively induced compared to normoxia. ID2 
and  ID3  inhibited  development  of  pDC  but  not  mDC  [133].  1α,  25-
Dihydroxyvitamin D3, an active form of vitamin D3 was reported to decrease 
both ID1 and ID2 expression [103]. Moreover, ATRA decreased ID1 and ID2 
expression [104]. Consequently, we investigated the effect of vitamins on mo-
pDC differentiation. As expected, mo-pDC differentiated with Flt3-L together 
with vitamin D3 or ATRA increased IFN-α production. Interestingly, vitamin D3 
is reported to be beneficial for cancer treatment [134] and ATRA has been 
used along with GM-CSF and chemotherapy for treatment of acute myeloid 
leukaemia [135]. Besides, retinoic acid inhibited measles virus through type I 
interferon production [136]. Therefore, the anti-tumour and anti-virus effects of 
vitamins may hint towards increased production of type I interferons by pDC. 
In  addition,  ID2  is  crucial  for  mDC  development  [27].  ID2  is  expressed  in 
human peripheral monocytes and its expression increases upon differentiation 
into terminal myeloid cells [137]. It is tempting to speculate that vitamins used 
in this study decreased ID proteins in monocytes. When ID levels are low, E2-
2 may be free to form homodimers and activate downstream transcriptional 
pathways (Figure 42).  
 
We checked the expression of markers in mo-pDC, which are reported to be 
under  the  control  of  E2-2.  BDCA2  expression  was  higher  in  mo-pDC 
compared to mDC, which was likely due to a lack of E2-2 in the latter [25]. 
Furthermore, we determined the levels of IFN-α in E2-2 expressing mo-pDC. 
TLR9-ligated PBMC served as a positive control. IFN-α produced by mo-pDC 
was marginal compared to the high levels of IFN-α, which were produced by 
blood  derived  pDC  [6].  Since  mo-pDC  expressed  TLR7  and  TLR9,  we 
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incomplete.  First  we  focussed  on  IRF-7,  since  the  IRF-7  gene  is 
transcriptionally  activated  by  E2-2  [97]  and  it  is  critical  to  induce  IFN-α 
production, which was impaired in pDC from E2-2 haplosufficient individuals 
[25].  IRF-7  gene  expression  could  be  stimulated  by  TNF-α  through  NFκB 
[106]. Therefore, we checked the basal expression of TNF-α in mo-pDC and 
mDC. Mo-pDC produced significantly lower basal TNF-α amounts compared 
to mDC. Although IFN-α expression by mDC was low despite the high basal 
expression of TNF-α by these cells, priming of mo-pDC with TNF-α strongly 
increased  their  IFN-α  expression  on  mRNA  and  protein  level  as  well  as 
secretion  of  bioactive  IFN-α.  Strikingly,  TNF-α-treated  mo-pDC  expressed 
higher levels of IRF7 compared to control mo-pDC. However, basal TNF-α 
production from cells such as mDC alone was not sufficient to induce IFN-α. 
Rather, the cells had to be equipped with both the IFN-α-producing upstream 
machinery as well as IRF-7 expression, which is determined among others by 
E2-2 and was enhanced by TNF-α. The IRF7 gene promoter is reported to be 
located in a GC-rich area of the chromosome, which could be condensed and 
inaccessible.  Thus,  chromosome  remodelling  must  take  place  in  order  to 
access the IRF7 promoter [106]. Whether E2-2 expression and TNF-α pre-
stimulation improve IRF7 gene accessibility might be investigated further on.  
 
Overall, mo-pDC generated by incubation of monocytes with Flt3-L were pDC-
like  cells,  which  still  retained  some  characteristics  of  monocytes  such  as 
CD14 expression or a low basal ID2 expression. However, differentiation with 
vitamins  or  priming  with  TNF-α  improved  their  function.  Our  method  now 
provides  an  easily  accessible  system  to  study  pDC  differentiation  and 
maturation using human cells.  
 
7.2  Under  hypoxia  mo-pDC  development  is  halted  to  produce  non-
functional cells 
 
Hypoxia  has  a  strong  influence  on  the  phenotype  and  functions  of  mDC. 
Immature  DC  undergo  differentiation  under  hypoxia  and  further  induce 
proliferation  of T  cells [111,  112].  In  contrast,  mo-pDC  differentiated  under Discusssion      100 
hypoxia  became  non-functional,  based  on  decreased  BDCA2  expression, 
attenuated IFN-α production, and a decreased CD86 as well as MHCI surface 
exposure.  During  differentiation  under  hypoxia,  followed  by  maturation  with 
CpG,  mo-pDC  also  produced  higher  levels  of  TNF-α,  IL-1β  and  IL-6,  but 
constant  levels  of  IL-10  as  compared  to  normoxia-differentiated  mo-pDC. 
Induction  of  IL-6  by  hypoxia  is  reported  to  result  from  activation  of  MAP 
kinase,  HIF-1  and  the  NF-κB  pathway  [138],  which  also  might  account  for 
induction of TNF-α and IL-1β. Overall, judging from cytokine data, hypoxia 
might strengthen NF-κB-dependent transcription downstream of TLR9 ligation 
[139].  
 
Decreased  expression  of  BDCA2  and  production  of  IFN-α  might  be  a 
consequence  of  the  lower  E2-2  and  higher  ID2  levels  at  later  stages  of 
differentiation  under  hypoxia.  Hypoxia  might  cause  dedifferentiation  of  mo-
pDC  by  decreasing  E2-2  especially  later  during  differentiation,  since  E2-2 
expression was observed during early stages of differentiation under hypoxia 
as well as normoxia. The impact of hypoxia on E2-2 expression in later stages 
of  mo-pDC  development  might  have  physiological  implications  e.g.  in 
tumours,  as  it  is  reported  that  E2-2  predominantly  regulates  terminal 
development  of  pDC  functions  [97].  Therefore,  properties  of  pDC  under 
physiological hypoxia such as in tumours should be investigated. Interestingly, 
HIF-1  was  described  to  induce  ID2  in  neuroblastoma  cells  during  hypoxia 
[115].  Therefore,  hypoxia  and  HIF-1-mediated  ID2  induction  may  further 
contribute to the non-functionality or dedifferentiation of mo-pDC by inhibiting 
E2-2. To further evaluate this hypothesis, we went on to study the influence of 
hypoxia on pDC generation and function in the mouse system by using bone 
marrow progenitors that were deficient in expression of HIF-1α.  
 
7.3  Mouse pDC differentiation in vitro is inhibited by hypoxia-induced 
HIF-1 
 
Indeed, on culturing mouse bone marrow cells with Flt3-L, a CD19
- CD11c
+ 
SiglecH
+ pDC population was expanded that also expressed the mouse pDC Discusssion      101 
markers  B220  (CD45R)  and  CD317  as  described  earlier  [117].  But,  when 
culturing these bone marrow cells under 5% O2, differentiation to pDC was 
inhibited.  This  inhibition  of  differentiation  was  HIF-1α-dependent  as  we 
observed an increase in pDC generation from progenitors lacking HIF-1 in 
HIF-1
fl/fl LysM-Cre mice under 5% O2 compared to cells from wildtype mice. 
Besides, this absence differentiation was directly related to changes in the 
relative transcription factor levels and it was reflected on the diminished IFN-a 
production by these cells. 
 
 
 
 
 
 
Figure 43: pDC development under normoxia and hypoxia: The differentiation of DC subsets 
may follow the hematopoietic stem cell (HSC)-multipotent progenitor (MPP)-common myeloid 
precursor  (CMP)/common  lymphoid  precursor  (CLP)  path  (HSC-MPP-CMP/CLP  path) 
(depicted in pink) or the HSC-common DC progenitor (CDP)-cDC precursor/pDC precursor 
path  (depicted  in  blue)  (Left)  (Left)  Under  normoxia,  mDC  develop  from  the  CMP/cDC 
precursors and pDC develop from the CLP or pDC precursor. (Right) Under hypoxia mDC 
development is not affected, whereas pDC development is inhibited. Either the precursors are 
1) developed into putative cDC or 2) arrested from differentiating to pDC.  
 
 
It seems well-established that pDC in the bone marrow develop from common 
dendritic  cell  progenitors  (CDP)  that  themselves  arise  from  monocyte/DC 
progenitors (MDP) [20]. CDP in the bone marrow can give rise to either pDC Discusssion      102 
or progenitors of conventional DC (cDC) that leave the bone marrow to further 
differentiate  along  the  DC  lineage.  Under  hypoxia,  pDC  generation  was 
inhibited whereas, the progenitors were retained as undifferentiated CD11b
- 
CD115
+ cells [140] or the development was forked to generate a CD11b
high 
CD115
- cDC cell population. Thus, our data support the current view [21] that 
pDC mainly develop along a common pathway with cDC, which in the bone 
marrow might be the CDP (Figure 43). 
 
 
Our  data  give  first  experimental  evidence  that  one  of  the  yet  unidentified 
signals that encourage CDP differentiation to cDC might be the low oxygen 
level in the bone marrow, thereby limiting pDC generation [114, 140]. Indeed, 
the hypoxic milieu in the bone marrow might be a reason why pDCs constitute 
only a very small cell population in humans and mice. Since they are highly 
potent producers of type I interferons and are major drivers of autoimmune 
reactions  [120],  the  identified  mechanism  might  have  evolved  to  limit  their 
numbers and thus limit the magnitude of autoimmunity. To further elucidate 
the DC developmental program in vitro under the influence of hypoxia and 
HIF-1,  detailed  analysis  for  detecting  progenitor  populations  could  be 
performed 
  
Recently, cancer immunotherapy using mDC along with pDC-activating CpG 
mimetic  has  proven  successful  against  cancer [11,  12].  This is  due  to  the 
capacity of pDC to produce type I interferon, which is crucial in preventing 
tumour growth by directly acting on tumour cells and on host hematopoietic 
cells [141]. We observed that there is a decrease in pDC differentiation under 
hypoxia. Furthermore, pDC function depends on continuous E2-2 expression 
[142], which might be decreased under hypoxia even in mature pDC, thereby 
limiting  their  functional  properties.  Thus  tumour  microenvironmental  factors 
such  as  hypoxia  may  contribute  to  thwarting  beneficial  effects  of  such 
combinational immunotherapy which aims at pDC activation to check tumour 
growth.   
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7.4  Apoptotic cell priming in reducing cytotoxicity and inducing Tregs 
in DC dependent priming  
 
A  growing  tumour  or  a  tumour  subjected  to  conventional  therapy  sheds 
tumour-derived  factors/exosomes  [143].  These  factors  released  from  dying 
tumour  cells  may  be  another  crucial  microenvironmental  factor  that  may 
contribute to suppressing anti-tumour immunity. Over the last years it became 
apparent that the immune status of tumour-infiltrating lymphocytes is a crucial 
determinant for patient prognosis. In human colorectal cancer the presence of 
FoxP3
+ Treg correlated positively with the presence of immunosuppressive 
DC  and  the  absence  of  antigen-specific  effector  T  cells  [144].  In  addition, 
accumulation  of  Treg  can  hinder  beneficial  effects  of  immunotherapy. 
Depletion  of  Treg  using  anti-CD25  or  anti-CTLA4  along  with  T  cell  or  DC 
immunotherapy  was  shown  to  successfully  restore  anti-tumour  immunity 
[145]. Thus targeting Treg is  a  promising  strategy to  reduce tumour-driven 
immune suppression [146].We analyzed the impact of factors released from 
dying tumour on the T cell-associated cytotoxicity mediated through DC. DC 
have been shown to internalize membrane material from living cells to mount 
CD8
+ T cell immune responses [147]. Indeed we observed that factors shed 
from apoptotic tumour cells (ACM) reduced cytotoxicity; whereas priming with 
viable cell derived factors (VCM) increased cytotoxicity against living tumour 
cells.  We  propose  that  antigens  contained  in  VCM  exosomes  might  be 
responsible to induce cytotoxicity via CD8
+ T cells, whereas Treg induced by 
immunosuppressive  factors  contained  in  ACM  prevent  cytotoxicity.  Despite 
tumour cell-specific Tc might still be generated by ACM as indicated by the 
Treg  depletion  experiments,  which  restored  cytotoxicity.  Interestingly,  the 
suppressive potential of ACM-induced Treg was transferable to VCM-primed 
lymphocytes. Hence apoptotic debris resulting from cytotoxic cancer therapy, 
which is known to induce immune paralysis [57], when shed, e.g., to the TDLN 
might culminate in generation of Treg that block potent endogenous tumour-
killing CTL activity or CTL from an T cell adoptive-transfer immunotherapy.  
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Tumour-released  factors  modify  functions  of  DC  at  the  tumour  site  or  in 
draining  lymph  nodes  thereby,  exploiting  their  tolerogenic  function  [148]. 
Generation of suppressive Treg required activation of S1PR4 on DC, likely 
due to S1P that is secreted by AC [149-151]. S1P is a potent lipid mediator 
that  signals  via  specific  G  protein  coupled  receptors  to  control  aspects  of 
phagocyte biology [152]. We previously demonstrated that S1P is involved in 
activating  macrophages  to  a  potentially  tumour-supportive  phenotype  [153, 
154]. Furthermore, during LPS-induced maturation of DC, S1P inhibits Th1 
responses by suppressing IL-12 release and instead promotes Th2 responses 
by increasing IL-4 and IL-10 production [152]. We observed that inhibition of 
S1PR1/3 upon treatment with ACM indeed marginally increased secretion of 
the  pro-inflammatory  cytokines  IL-12,  TNF-  and  IL-6,  while  moderately 
increasing  IL-10.  This  suggests  that  S1P  acting  on  S1PR1/3  might  be  an 
intrinsic  attenuating  signal  in  AC-induced  inflammation.  However,  for 
suppression of cytotoxicity these changes seemed irrelevant. Rather, S1P in 
ACM induced expression of ebi3 and the release of IL-27 through S1PR4. 
Whether  IL-35,  which  was  implicated  in  human  Treg  function  [155],  was 
upregulated by ACM could not be confirmed due to lack of a suitable IL-35 
detection method. Although we cannot exclude a role for IL-35 in our system, 
IL-27  moderates  suppressive  Treg  function,  as  demonstrated  by  antibody 
neutralization.  
 
Generally, the function of IL-27 in T cell biology is ambiguous between pro-
inflammatory (induction of Th1) and anti-inflammatory (immunosuppression) 
[156]. IL-27 induces expression of the Th1 transcription factor T-bet [157] and 
was recently shown to promote CD8
+ T cell proliferation by activating STAT1 
[158],  which  argues  for  IL-27  being  pro-inflammatory.  However,  Treg  also 
have been shown to express T-bet together with CXCR3. These specialized 
Treg  migrate  to  areas  of  Th1  inflammation  and  contribute  to 
immunosuppression  [159],  which  might  be  a  mechanism  to  dampen  over-
activation of immunity. This mechanism may be employed by ACM-primed DC 
expressing IL-27 to induce Treg that can in turn cause immunosuppression 
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IL-27 potently reduces expression of the Th17 cell-determining transcription 
factor (TF) RORC as well as the Th2-determining TF GATA3, but not Foxp3 
[160].  In  our  hands,  interfering  with  IL-27  also  had  no  effect  on  FoxP3 
expression. Instead, IL-27 inhibition in the ACM group decreased the CD39
+ 
CD69
+  Treg  population.  This  might  be  facilitated  by  a  yet  unknown 
mechanism  similar  to  the  one  employed  by  IL-35,  which  shares  the  ebi3 
subunit with IL-27, to induce CD39 expression on CD4
+Foxp3
+ Treg [161]. A 
mechanism how IL-27 upregulates CD69 remains to be discovered.  
 
7.5  The  Adenosine  pathway  is  utilized  by  Treg  to  cause 
immunosuppression 
 
The  exact  mechanism  employed  by  Treg  to  suppress  of  anti-tumour 
responses in our system has yet to be defined. CD4
+ Treg can be divided 
among others into CD4
+ CD25
+ Foxp3
+ Treg and T regulatory type 1 (Tr1) 
FoxP3
- cells. IL-27 was shown to enhance the generation of IL-10 expressing 
Tr1  cells in  mice  [162]  and  to induce  regulatory  activity  to  NK  cells  which 
inturn, suppresses T cells [163]. In our system, using human cells, IL-27 did 
not upregulate IL-10 expression in the ACM group. The defining characteristic 
of  the  suppressive  Treg  subpopulation  expanded  by  ACM-primed  DC  was 
expression of the ectonucleotidase CD39 and the activation marker CD69. It 
is reported that CD39 was nearly exclusively expressed by FoxP3
+ cells [121]. 
CD39  metabolizes  ATP  and  ADP  to  AMP,  the  former  being  produced  by 
activated T cells that have undergone TCR engagement and calcium influx 
[164]. Since DC treated with ACM do not show deficiencies in maturation or 
activation, they might well engage the TCR of T effector cells to stimulate ATP 
release, which can be metabolized to AMP by CD39 present on the surface of 
Treg. Further on, AMP can be degraded to adenosine by CD73 present on 
CD8
+ T cells in the co-culture. Extracellular adenosine was shown to inhibit 
many aspects of T cell functionality such as effector differentiation, activation 
(by  increasing  cAMP  levels),  cytokine  production,  metabolic  activity  and 
proliferation [129]. Interestingly ectonucleotidase expression and activity was 
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to  their  immunosuppressive  function  [86].  A  similar  mechanism  of 
immunosuppression  is  employed  by  ectonucleotidase-expressing  ovarian 
carcinoma cells, which generate adenosine to inhibit CD4
+ T cell proliferation 
as well as NK cell cytotoxicity through activation of ADORA2A on these cells 
[165].  Hence  adenosine generated  through CD39  and  CD73  expressed  by 
Treg and CD8
+ T cells respectively might suppress the function of CTL in our 
system acting via ADORA2A, whose inhibition indeed restored cytotoxicity in 
the ACM group. 
 
 
 
Figure 44: Pathway leading to suppression of anti-tumour immunity by apoptotic tumour cell 
priming of DC: Priming of DC with factors derived from apoptotic tumour cells (AC) induces 
expression of regulatory enzyme IDO and also expression of cytokine subunit ebi3. The ACM-
polarized DC release cytokines such as IL-27 or IL-10, mediated through the S1PR4. IL-27 is 
responsible for up-regulation of CD69 on a Treg subpopulation that expresses FoxP3 and the 
ectonucleotidase  CD39.  The  expression  of  CD39  on  Treg  along  with  an  expression  of 
ectonucleotidase  CD73  on  the  surface  CD8
+  T  cells  generates  adenosine  to  mediate 
immunosuppression.  This  is  likely  transmitted  through  adenosine  acting  on  adenosine 
receptors expressed on CD8
+ T cells. The CD69 molecule expressed by Treg might interact 
with a so far unidentified receptor on CD8
+ T cells forming a scaffold that supports adenosine 
generation to suppress the cytotoxic activity of CD8
+ T cells towards living tumour cells.  
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The  most  defining  aspect  of  Treg  from  the  ACM  group  was  expression  of 
CD69. CD69 expression on T cells inhibits S1P1 expression [166], which may 
act to maintain Treg in a suppressive state, since S1P has been shown to 
overcome FoxP3
+ Treg-mediated suppression [167]. Besides, we hypothesize 
that  CD69  on  Treg  might  directly  suppress  the  activity  of  effector  T  cells. 
CD69  is  a  C-type  lectin,  which  can  trigger  e.g.  TGF-β  production  [168]. 
Although TGF-β was connected with suppression of cytotoxic CD8
+ T cells 
before [169], we did not observe significant up-regulation of TGF-β in Treg of 
the ACM group and TGF-β neutralizing did not restore cytotoxicity in our set-
up.  An  alternative  option  might  be  binding  of  CD69  to  a  putative 
‘ligand/receptor’ on the surface of CD8
+ T cells, which is a common pattern for 
C-type lectins. This is true e.g. for interactions between cytotoxic lymphocytes 
and their targets [170]. However, a binding partner for CD69 is not known. If 
this putative molecule is expressed on CD8
+ T cells, CD69-expressing Treg 
might  bind  to  these  cells  to  create  a  functional  platform  for  adenosine 
production by bringing CD39 and CD73 in close proximity. Our analysis of 
CD4
+CD8
+  doublets  is  a  first  hint  to  support  this  hypothesis.  Future 
experiments  addressing  the  function  and  the  putative  ligand  for  CD69  are 
needed. 
 
Ex-vivo priming of DC with tumour lysates and in vivo DC activation strategies 
have  been  employed  in  cancer  immunotherapy  [171].  Therefore,  our  data 
might add to the understanding how priming with viable or killed tumour cells 
might  impact  final  anti-tumour  activity  and  thus  might  aid  in  improving 
strategies for ex vivo DC activation. Conventional therapy will probably benefit 
from inhibition of intrinsic immunosuppressive pathways. Our results suggest 
that interfering with S1PR4 and/or IL-27 might prove beneficial. In the future, 
new  findings  regarding  the  putative  CD69L  could  help  to  understand  the 
significance of CD69 expression on Treg in modulating CTL responses. 
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8  Concluding remarks 
 
Immune cells have evolved the capacity to act as a rheostat to control the 
amplitude of an immune response. DC are no exception to this rule and have 
a capacity to mount an inflammation or tolerance depending on the factors 
that  they  were  primed  with.  Interestingly,  pDC  are  immunoregulators  that 
despite  being  present  only  in  lesser  numbers  in  the  body  participate  in 
mounting  an  anti-viral  immunity  or  induce  tolerance.  A  protocol  to  easily 
differentiate pDC equivalents from human monocytes was attempted. The mo-
pDC thus generated expressed some typical pDC surface markers. Besides, 
they  also  expressed  pDC-determining  transcription  factor  E2-2  whose 
expression was downregulated upon differentiation under hypoxia. pDC are 
principal IFN-α producers in the body. The capacity of mo-pDC to produce 
IFN-α was upregulated with TNF-α pretreatment. When differentiated under 
hypoxia,  the  IFN-α  production  by  these  mo-pDC  was  restricted,  likely 
mediated through the increased ID2 production by the mo-pDC. ID2 inhibits 
E2-2 that controls the transcription of pDC differentiation genes. In addition, in 
vitro  differentiation  of  bone  marrow  precursors  from  mice  lacking  HIF-1α 
enhances pDC generation compared to culturing the precursors from wildtype 
mice under hypoxia, which limits pDC generation. The precursors are shunted 
to generate along the myeloid pathway to generate cDC or get arrested in an 
undifferentiated state. The lack of HIF-1 in progenitors of HIF-1
fl/fl LysM-Cre 
mice represses ID2 upregulation and encourages E2-2 function such as IFN-α 
production. 
 
Hypoxia is one of the stress factors that encourages tumour growth. Another 
of such a stress factor is the presence of dying tumour cells, which maintains 
immune cells and tumour stromal cells in a state of alternative activation that 
ensures  tumour  cell  survival.  The  influence  of  apoptotic  or  necrotic  cell-
derived  factors  on  DC  functions  and  phenotype  could  further  help  to 
understand their interactions with effector cells and tumour stroma in detail. 
Cancer  immunosuppression  brought  about  by  apoptotic  cells  has  lately 
become a topic of intense research [172]. Myeloid DC can be activated ex Concluding remarks      109 
vivo and used for tumour therapy. But the presence of tumour-derived factors 
has  been  known  to  offset  benefits  of  tumour  therapy.  Chemotherapy  and 
radiation  therapy  discharges  large  amounts  of  dying  cell-released  factors. 
However  the  exact  mechanism  of  how  the  dying  cell-discharged  factors 
induce  tolerance,  in  order  to  disrupt  tumour  cell  killing,  is  not  clear.  We 
discovered that upon priming with the apoptotic cell-generated lipid S1P, DC 
undergo biochemical polarization via the S1P4 receptor. The resulting release 
of  the  T  cell-modulating  cytokine  IL-27  can  direct  a  shift  in  T  cell 
differentiation/activation and functions towards tolerance. In this study, the IL-
27  released  by  DC  upregulated  a  specific  Treg  subset.  These  CD39  and 
CD69 co-expressing FoxP3
+ Treg suppressed the cytotoxic capability of CD8
+ 
T cells through the adenosine pathway. This message as we speculate could 
be transmitted by the physical interaction of Treg with CD8
+ T cells. Thus, the 
message of anti-tumour defence is relayed from 1) antigen presenting DC to 
2) the T cells. Apoptotic cell-released factors; especially lipid messages can 
impact biochemical pathways at these two checkpoints. The role that IL-27, a 
newly  discovered  cytokine  plays  in  Treg  expansion  under  apoptotic  cell 
priming is an interesting revelation. It will be of future interest to investigate 
the  pathways  activated  downstream  of  IL-27R  ligation  in  Treg  and  their 
contribution to Treg functions.  
 
A fully functional immune system is essential for mounting an inflammatory 
response in the presence of a tumour. This is exemplified by the prevention of 
breast  tumour  destruction  in  individuals  with  a  mutation  in  TLR4  [173]. 
Therefore, the efficacy of chemotherapeutics administered to cancer patients 
may also depend on their impact on the immune system. Chemotherapeutics 
may either kill tumour cells without immune involvement, which may or may 
not be immunogenic, may cause tumour cell death by activating immune cells 
or  cause  immunosuppression  by  also  killing  immune  cells  [174].  The 
immunological outcome depends on surface alterations of dying cells or, as 
seen in our system, on the apoptotic cell secretome, which depends on the 
cell death-inducing agent. In our studies, the immunogenic cell death inducer 
oxaliplatin did not induce immune suppression as opposed to staurosporine. 
One might speculate that this was due to the absence of S1P production by Concluding remarks      110 
oxaliplatin-treated  MCF-7  cells.  Finally,  understanding  how  tumour 
microenvironmental  factors  cause  altered  phagocyte  and  effector  function 
may  greatly  contribute  to  designing  better  immunotherapeutic  approaches 
against tumours.  
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